|
|
||||||||
Physiological Reviews, Vol. 81, No. 2, April 2001, pp. 871-927
Copyright ©2001 by the American Physiological Society
Institut National de la Santé et de la Recherche Médicale U. 495, Biology of Neuron-Glia Interactions, Salpêtrière Hospital, and Neurogenetic Laboratory, Neuroscience Institute, Unité Mixte de Recherche 7624 Centre National de la Recherche Scientifique, University Paris, Paris, France
I. INTRODUCTION
II. OLIGODENDROCYTES
A. Morphology of Oligodendrocytes
B. Specific Components of Oligodendrocytes
C. Origin and Differentiation of Oligodendrocytes
D. The Glial Network
E. Functions of Oligodendrocytes
III. MYELIN
A. Phylogeny
B. Morphological Structure of the Myelin Sheath and of the Node of Ranvier
C. Myelin Isolation and General Composition
D. Myelination
E. Biochemical Aspects of Myelin Assembly and of the Node of Ranvier
F. Factors Influencing Glial Cell Maturation Leading to Myelin Formation
G. Roles of Myelin
H. Plasticity of the Oligodendrocyte Lineage: Demyelination and Remyelination
IV. EXPERIMENTAL AND HUMAN DISEASES OF MYELIN
A. Genetic Diseases of Myelin
B. Inflammatory Demyelinating Diseases
C. Tumors: Oligodendrogliomas
V. CONCLUSIONS
| |
ABSTRACT |
|---|
|
|
|---|
Baumann, Nicole and
Danielle Pham-Dinh.
Biology of Oligodendrocyte and Myelin in the Mammalian Central
Nervous System. Physiol. Rev. 81: 871-927, 2001.
Oligodendrocytes, the
myelin-forming cells of the central nervous system (CNS), and
astrocytes constitute macroglia. This review deals with the recent
progress related to the origin and differentiation of the
oligodendrocytes, their relationships to other neural cells, and
functional neuroglial interactions under physiological conditions and
in demyelinating diseases. One of the problems in studies of the CNS is
to find components, i.e., markers, for the identification of the
different cells, in intact tissues or cultures. In recent years,
specific biochemical, immunological, and molecular markers have been
identified. Many components specific to differentiating
oligodendrocytes and to myelin are now available to aid their study.
Transgenic mice and spontaneous mutants have led to a better
understanding of the targets of specific dys- or demyelinating
diseases. The best examples are the studies concerning the effects of
the mutations affecting the most abundant protein in the central
nervous myelin, the proteolipid protein, which lead to dysmyelinating
diseases in animals and human (jimpy mutation and
Pelizaeus-Merzbacher disease or spastic paraplegia, respectively). Oligodendrocytes, as astrocytes, are able to respond to changes in the
cellular and extracellular environment, possibly in relation to a glial
network. There is also a remarkable plasticity of the oligodendrocyte
lineage, even in the adult with a certain potentiality for myelin
repair after experimental demyelination or human diseases.
| |
I. INTRODUCTION |
|---|
|
|
|---|
Glial cells constitute the large majority of cells in the nervous system. Despite their number and their role during development, their active participation in the physiology of the brain and the consequences of their dysfunction on the pathology of the nervous system have only been emphasized in the recent years.
Virchow (639) first described that there were cells other than neurons. He thought that it was the connective tissue of the brain, which he called "nervenkitt" (nerve glue), i.e., neuroglia. The name survived, although the original concept radically changed.
The characterization of the major glial cell types was the result of microscopic studies, and especially the techniques of metallic impregnation developed by Ramon y Cajal and Rio Hortega. Using gold impregnation, Ramon y Cajal (495) identified the astrocyte among neuronal cells, as well as a third element which was not impregnated by this technique. A few years later, using silver carbonate impregnation, Rio Hortega found two other cell types, the oligodendrocyte (514), first called interfascicular glia, and another cell type that he distinguished from the two macroglial cells (i.e., macroglia), and that he called microglia (513).
The morphological characteristics of macroglia have been reviewed (453). The progress of morphological techniques and the discovery of cellular markers by immunocytochemical techniques indicate the notion of multiple functional macroglial subclasses. Our understanding of the role of glia in central nervous system (CNS) function has made important progress during recent years. Glial cells are necessary for correct neuronal development and for the functions of mature neurons. The ability of glial cells to respond to changes in the cellular and extracellular environment is essential to the function of the nervous system. Furthermore, there is now growing recognition that glia, possibly through a glial network, may have communication skills that complement those of the neurons themselves (Fig. 1). There are currently expanding discoveries of specialization of both neurons and glial cells and their persistent interactions that gives also a new insight to the understanding of pathological outcomes. The association of neuronal and glial expression for some neurotransmitters, their transporters, and receptors contributes to the understanding of their functional cooperation. It now seems likely that oligodendrocytes have functions other than those related to myelin formation and maintenance.
|
As an overview, the number of glial cells increases during evolution; glial cells constitute 25% of total cells in the Drosophila, 65% in rodents, and 90% in the human brain (456). The very few morphological studies do not take into account the different glial cell types. Brain white matter tracts are deprived of neuronal cell bodies but contain glial cells; because brain white matter constitutes as big a volume as the cortex gray matter, the overall glia-to-neuron ratio is considerably increased (456).
| |
II. OLIGODENDROCYTES |
|---|
|
|
|---|
A. Morphology of Oligodendrocytes
The term oligodendroglia was introduced by Rio Hortega (513) to describe those neuroglial cells that show few processes in material stained by metallic impregnation techniques. The oligodendrocyte is mainly a myelin-forming cell, but there are also satellite oligodendrocytes (449) that may not be directly connected to the myelin sheath. Satellite oligodendrocytes are perineuronal and may serve to regulate the microenvironment around neurons (349). A number of features consistently distinguish oligodendrocytes from astrocytes (reviewed in Ref. 453), in particular their smaller size, the greater density of both the cytoplasm and nucleus (with dense chromatin), the absence of intermediate filaments (fibrils) and of glycogen in the cytoplasm, and the presence of a large number of microtubules (25 nm) in their processes that may be involved in their stability (350). An oligodendrocyte extends many processes, each of which contacts and repeatedly envelopes a stretch of axon with subsequent condensation of this multispiral membrane-forming myelin (82, 84) (Fig. 2). On the same axon, adjacent myelin segments belong to different oligodendrocytes. The number of processes that form myelin sheaths from a single oligodendrocyte varies according to the area of the CNS and possibly the species, from 40 in the optic nerve of the rat (453) to 1 in the spinal cord of the cat (83). Rio Hortega (514) classified oligodendrocytes in four categories, in relation to the number of their processes (also described in Ref. 83). According to their morphology and the size or thickness of the myelin sheath they form, Butt et al. (89) also distinguish four types of myelinating oligodendrocytes, from small cells supporting the short, thin myelin sheaths of 15-30 small diameter axons (type I), through intermediate types (II and III), to the largest cells forming the long, thick myelin sheaths of one 1-3 large diameter axons. Morphological heterogeneity is, in fact, a recurrent theme in the study of interfascicular oligodendrocytes (84). At the electron microscopic level, oligodendrocytes have a spectrum of morphological variations involving their cytoplasmic densities and the clumping of nuclear chromatin. Mori and Leblond (406) distinguish three types of oligodendrocytes: light, medium, and dark. The dark type has the most dense cytoplasm. On the basis of labeling with tritiated thymidine of the corpus callosum of young rats, they suggest that light oligodendrocytes are the most actively dividing cells and that oligodendrocytes become progressively dark as they mature.
|
Before their final maturation involving myelin formation, oligodendrocytes go through many stages of development. Their characterization is often insufficient by morphological criteria alone both in vivo and in vitro. A number of distinct phenotypic stages have been identified both in vivo and in vitro based on the expression of various specific components (antigenic markers) and the mitotic and migratory status of these cells. They are described in section II, B and C.
B. Specific Components of Oligodendrocytes
Characterization of a number of specific biochemical markers has increased our knowledge on the stages of oligodendrocyte maturation, both in vivo and in vitro. These components, although they may be present in other cell types or other tissues, or in specific cells only at certain stages, must be viewed as modular elements that generate, with other elements, complex and unique surface patterns (502). All the biochemical and molecular characteristics of oligodendrocytes are not described here. We limit ourselves to those that have given insights into our understanding of this cell type. Although some markers are very useful in culture to determine the sequences of maturation, and ultimately their mechanism, they may be more difficult to use in situ, because some of them are present on other cell types in vivo.
Oligodendrocytes originate from migratory and mitotic precursors, then progenitors, and mature progressively into postmitotic myelin-producing cells (see sect. IIC5). The sequential expression of developmental markers, identified by a panel of cell specific antibodies, divide the lineage into distinct phenotypic stages (249, 455; reviewed in Ref. 344) characterized by proliferative capacities, migratory abilities, and dramatic changes in morphology (Fig. 3). Many of these markers have been at first identified in tissue cultures. Some of them are characteristic myelin components (see sect. IIIC). Myelination requires a number of sequential steps in the maturation of the oligodendroglial cell lineage (249, 455) accompanied by a coordinated change in the expression of cell surface antigens often recognized by monoclonal antibodies. Differentiation involves the loss of certain surface or intracellular antigens and the acquisition of new ones. Some of the surface antigens are lineage markers; discrete phases in these lineages are marked by differential expression of additional antigens or phase markers (502).
|
1. Markers of maturation of the oligodendrocyte lineage
A) NESTIN.
Nestin is a protein recognized by the rat-401 monoclonal antibody
(257), whose expression specifically distinguishes
neuroepithelial stem cells (from which the name nestin is originated)
from other more differentiated cells in the neural tube
(327). Nestin defines a distinct sixth class of
intermediate filament protein, closely related to neurofilaments.
Nestin is also expressed by glial precursors (327), such
as radial glia (257), and in the cerebellum by immature Bergmann fibers, and also by adult Bergmann fibers recapitulating developmental stages when placed in the presence of embryonic neurons
(573). Using cortical- or CG-4-derived oligodendrocyte lineage cells, culture experiments have shown that high levels of
nestin protein are also expressed in proliferating oligodendrocyte progenitors, but the protein is downregulated in differentiated oligodendrocytes (206). B) PROTEOLIPID PROTEIN.
A special note should be made concerning the proteolipid protein (PLP)
gene expression, as a marker of developmental maturation of myelinating
glial cells, in the CNS as in the peripheral nervous system
(PNS). By RT-PCR and in situ hybridization, the mRNA of DM-20, coding for an isoform of PLP, can be detected in the
developing CNS at a very early stage of development, before the onset
of myelination (272, 454, 610,
611). With the use of PLP-Lac Z transgenic mice,
expression of the splicing variant DM-20 of the PLP gene is detected in
the mouse embryo within very discrete regions of the CNS and rather
extensively throughout the PNS (576, 666).
The DM-20 protein is detected precociously in different regions of the
nervous system, in oligodendrocyte precursors from the spinal cord
(144), or in ensheathing cells from the olfactory bulb
(145). C) PLATELET-DERIVED GROWTH FACTOR
D) PSA-NCAM.
The embryonic polysialylated form of neural cell adhesion molecule
(NCAM), PSA-NCAM, defines in the absence of expression of GD3, the
precursor stage (239, 248), from which
oligodendrocyte progenitors arise. E) GANGLIOSIDE GD3.
The ganglioside GD3 has been identified by the use of two monoclonal
antibodies: R24 (483) and LB1 (127). In fact,
R24 recognizes also minor gangliosides. In vitro, there is a high
expression of GD3 on oligodendrocyte progenitors in culture
(248); thus it is a good marker for oligodendrocyte cell
culture; GD3 expression disappears as the cell matures. Nevertheless,
in vivo it is also expressed in other glial cell types such as immature
neuroectodermal cells, subpopulations of neurons and astrocytes during
development, resting ameboid microglia (174,
671), reactive microglia, and astrocytes
(223). Thus particular caution should be used when extrapolating from in vitro investigations to the CNS in situ (223). F) THE MONOCLONAL ANTIBODY A2B5.
The monoclonal antibody A2B5 (172) recognizes several
gangliosides (198) that remain as yet uncharacterized. It
is expressed both on neurons and glial cells in vivo; it is used
essentially in oligodendrocyte cultures to follow the maturation of
oligodendrocyte progenitors. In culture, ganglioside GT3 and its
O-acetylated derivative are the principal A2B5-reactive
gangliosides (153, 181). Both antigens are
downregulated as the cell differentiates into the mature
oligodendrocyte. This corresponds to the disappearance of cell surface
immunostaining by A2B5. Like GD3 monoclonal antibodies, A2B5 binding in
vivo is not cell specific. G) THE RAT NG2 PROTEOGLYCAN.
The rat NG2 proteoglycan is an integral membrane chondroitin sulfate
proteoglycan with a core protein of 260 kDa. In the mature CNS, cells
express this antigen together with PDGFR- H) THE MONOCLONAL ANTIBODY O4.
The monoclonal antibody O4 (571) marks a specific
preoligodendrocyte stage of oligodendrocyte maturation. It reacts also with sulfatides and still unidentified glycolipids
(23). 2. Oligodendrocyte/myelin markers
A) GLYCOLIPIDS.
There are specific glycolipids in oligodendrocytes and myelin, such as
galactosylceramides (GalC) (galactocerebrosides) and sulfogalactosylceramides (sulfatides). Galactosylceramides and sulfogalactosylceramides are early markers that remain present on the
surface of mature oligodendrocytes in culture (455,
488) and in vivo (693). It appears often
difficult to characterize them on the cell surface of the
oligodendrocyte during development with precision, because many of the
reagents, i.e., the monoclonal antibodies used, are less specific than
thought at first. The main antibody used to identify some of these
developmental stages is O1 (571), which recognizes
galactocerebrosides, but also monogalactosyldiglycerides and an
unidentified antigen present during oligodendrocyte development. This
is also the case for the R-MAb (497), which has been
mainly used for galactocerebroside identification, but recognizes also sulfatides, monogalactosyldiglycerides, seminolipids, and another unidentified antigen (23). Some polyclonal IgG antibodies
to galactocerebrosides alter the organization of oligodendroglial membrane sheets (164). B) RIP ANTIGEN.
RIP antigen has been identified through the use of a monoclonal
antibody that was generated against oligodendroglia from rat olfactory
bulb (199). It recognizes an unknown cytosolic epitope on
oligodendrocytes and labels both oligodendrocyte processes and the
myelin sheath (44, 199). Two bands of 23 and
160 kDa have been found by Western Blot, the nature of which have not been elucidated. Interestingly, this marker may serve to determine biochemical subtypes of oligodendrocytes together with carbonic anhydrase II (89). C) CARBONIC ANHYDRASE II.
Among the seven isozymes that are products of different genes, carbonic
anhydrase II (CAII) is the only one that is located in the nervous
system, in oligodendrocytes. CAII covers all stages of the lineage and
is also a marker of adult oligodendrocytes (217); it is a
more diffuse marker of glial cells in the developing animal
(95). In the anterior medullary velum of the rat,
RIP+ CAII+ oligodendrocytes support numerous
myelin sheaths for small diameter axons, whereas RIP+
CAII D) NI-35/250 PROTEINS.
NI-35/250 proteins are transmembrane proteins enriched in mammalian
myelin CNS and oligodendrocytes (105). NI-35/250 have been
found to be potent inhibitors of axonal regrowth in pathological conditions (see sect. IIIG3C). The
bovine NI-220 cDNA has been recently characterized (578).
These proteins are recognized by the monoclonal antibody IN-1. The gene
has recently been cloned (114). There are three isoforms
of the proteins; one of them, NOGO A, is the one with the inhibitory
properties and which is mainly expressed on CNS oligodendrocytes and
myelin (see sect. IIIG3) (reviewed in Refs. 20,
222, 232). E) SPECIFIC MYELIN PROTEINS.
Genes encoding the specific myelin proteins are expressed at different
stages of the oligodendrocyte differentiation and maturation. 2',3'-Cyclic nucleotide-3'-phosphohydrolase (CNP), myelin basic protein
(MBP), PLP/DM-20, myelin- associated glycoprotein (MAG), and
myelin/oligodendrocyte glycoprotein (MOG) genes as well as other minor
myelin proteins are described in section IIIC2. 3. Other oligodendrocyte protein markers
A) TRANSFERRIN.
Transferrin, the iron mobilization protein, is expressed in
oligodendrocytes (62) and choroid plexus epithelial cells.
Before the establishment of the blood-brain barrier, neural cells
are dependent on serum transferrin biosynthesized in the liver. As the
blood-brain barrier gets established during development, neural cells become dependent on transferrin produced by oligodendrocytes and
choroid plexus epithelial cells. In addition, transferrin acts as a
trophic and survival factor for neurons and astrocytes, suggesting an
important function for oligodendrocytes besides myelination
(176). B) S100 PROTEINS.
S100 proteins are Ca2+ and Zn2+ binding
proteins; they are at high concentration in the mammalian brain. It is
now known that the S100 family of calcium-binding proteins contains
~16 members, each of which exhibits a unique pattern of tissue/cell
type specific expression. Whereas the most abundant isoform, S100
C) GLUTAMINE SYNTHETASE.
Glutamine synthetase catalyzes the conversion of glutamate to glutamine
in the presence of ATP and ammonia. By immunocytochemical methods, its
presence has been demonstrated in the cytoplasm of astrocytes. It is
also found in a discrete population of oligodendrocytes (129). C. Origin and Differentiation of Oligodendrocytes
For many years, one has mainly inferred lineage relationships by
examining patterns of antigen expression and morphological changes in
developing glia. Lineage can now more securely be traced with gene
transfer techniques using retroviral vectors (109, 352, 476) and transgenic constructs
(191, 224, 666). In the former
kind of analysis, a replication-deficient retrovirus bearing a
reporter gene such as LacZ coding for the bacterial Mammalian species acquire their full complement of cortical neurons
during the first half of gestation. Radial glia are established early
in development at the time of neurogenesis, during the early gestational period, and support neurons during their migration to the
cortex (reviewed in Ref. 493). The subventricular zone (SVZ), which is
present in late gestational and early postnatal mammalian brain, is a
major source of astrocytes and oligodendrocytes, although astrocytes
may also develop from radial glia. Maturation of oligodendrocytes and
astrocytes takes place in the mammalian CNS largely in early postnatal life. 1. Common precursors for neurons and glia: pluripotentiality
of stem cells
In the Drosophila CNS, during neurogenesis, there is a
binary genetic switch between neuronal and glial determination
(261, 285). The mutation of a gene encoding a
nuclear protein, glial cells missing (gcm), causes
presumptive glial cells to differentiate into neurons, whereas its
ectopic expression using transgenic constructs forces virtually all CNS
cells to become glial cells. Thus, in the presence of gcm
protein, presumptive neurons become glia, whereas in its absence,
presumptive glia become neurons. However, a gene with an identical
function has not as yet been identified in the vertebrate nervous system. In the mammalian cortex, both neurons and glia arise from the
proliferating neuroepithelial cells of the telencephalic ventricular and SVZ (149). The SVZ is a mosaic of multipotential and
lineage restricted precursors (329), where environmental
cues influence both fate, choice, and all surviving cells
(279). A number of trophic factors (see sects.
IIC8 and IIIF) influence
the actual developmental fate of a progenitor or a multipotent stem
cell from the SVZ, which can differ from its developmental potential (91, 241, 281, 484,
682). As a consequence of this growth factor dependency,
neurons are not formed postnatally because of the lack of trophic
factors necessary for their survival, resulting in their death; this
has been shown by a recent clonal analysis of the progeny of single rat
SVZ cells using replication deficient retroviral vectors
(329). Because environmental conditions can be provided in vitro when adding
specific trophic factors to the culture medium (18, 281, 415, 484,
503), glial cells differentiating in cultures may exhibit
a considerable plasticity in the extent of lineage switching, not
observed in vivo (565) (see sect.
IIC6). On the other hand, it has been hypothesized that even after development
is completed, the Notch pathway may help maintain some mammalian stem
cells and precursor cells in adult tissues by preventing them from
differentiating, thus allowing for the possibility of new cell
generation in renewing or damaged tissues (14). The identity of neural stem cells in the adult CNS is presently debated
and could be either ependymal cells (280) or SVZ astrocytes (149, 323a). For a critical review
of these data, see Reference 27. 2. Oligodendrocyte precursors in the ventricular zone
Oligodendrocyte precursors originate from neuroepithelial cells of
the ventricular zones, at very early stages during embryonic life. This
was first suggested by following the expression of specific markers of
oligodendrocytes (127, 248, 249,
328, 455), some of which are transcripts of
future protein components of myelin (CNP, MBP, PLP) (272,
454, 478, 610, 611,
690). In spinal cord, oligodendrocytes initially arise in ventral regions of
the neural tube. Miller and co-workers (652) have shown, using a special dye (DiI) associated with specific markers of
the oligodendrocyte lineage, that oligodendrocyte precursors arise in
the ventral spinal cord and then migrate dorsally during development.
During subsequent development, the dorsal regions acquire the capacity
for oligodendrogenesis, probably both intrinsically (94)
and through the ventral to dorsal migration of oligodendrocyte precursors. This has been confirmed using cultures of the
thoraco-lumbar area of the rat spinal cord, which showed that the
ability to give rise to oligodendrocytes is restricted to the ventral
region of this area of the spinal cord until E14 (652).
Signals from the notochord/floor plate, involving the morphogenetic
protein sonic hedgehog, are necessary to induce the development of
ventrally derived oligodendroglia (392, 441,
442, 467, 479). In situ hybridization for mRNAs of proteins involved in oligodendrocyte
maturation has been used to characterize early oligodendrocyte precursors. Ventral ventricular cells express mRNA for PDGFR- The initial restricted localization of oligodendrocyte precursors in
the ventral plate of the neural tube appears not to be limited to the
spinal cord (690) but is also observed in mid- and
forebrain (576, 610). In addition, a similar
restricted localization of the sites of oligodendrogliogenesis has been
described in other vertebrate species, such as human
(244), chick (440), and Xenopus
(688). The population of oligodendrocytes derived from the
restricted loci of cells appears to be regionally distributed in the
brain. For instance, in the chick embryo, some of the oligodendrocytes of the optic nerve generate suprachiasmatic foci of precursors located
in the medio-ventral epithelium of the third ventricle (440). The developing cerebral cortex of murine embryos
could be populated by oligodendrocytes originating from precursor cells located in the laterobasal plate of the diencephalon and probably also
in the telencephalon (475). For comprehensive reviews of the different hypotheses concerning origin
and development of cells of the oligodendrocyte lineage, see References
245, 510, 577. 3. Oligodendrocyte progenitors in the SVZ
The SVZ is a germinal matrix of the forebrain that first appears
during the later third of murine embryonic development
(149). It enlarges during the peak of gliogenesis, between
P5 and P20, and then shrinks but persists into adulthood. Lineage
tracing studies of perinatal SVZ cells using stereotactically injected retrovirus support the view that the majority of progenitors within this germinal matrix are glial precursors that generate astrocytes on
the one hand and oligodendrocytes on the other hand (352, 476). Although the majority of cells give rise to
homogeneous progeny, some SVZ cells give rise to both oligodendrocytes
and astrocytes, and a rare cell will develop into both neurons and glia
(329). The assumption that each cluster is a clone, i.e., the complete progeny of a single precursor, was based on the thought that the dispersion of cells in structures like embryonic cortex was
purely radial. However, other retroviral studies, together with other
techniques, have shown that cells disperse considerably and also
tangentially during postnatal corticogenesis and embryonic development
(475). Thus two clones could occupy an overlapping space.
Therefore, this is not yet a completely settled issue. Nevertheless, it
does seem from tritiated thymidine, immunocytochemistry, and retroviral
studies that the majority and possibly all oligodendrocytes originate
from different cells in the SVZ than those that give rise to
astrocytes. In the neonatal rat cerebrum, oligodendrocytes arise
postnatally from the SVZ of the lateral ventricles (329, 695). Similarly, immunocytochemical studies have indicated
that oligodendrocytes of the cerebellum arise postnatally from the SVZ
of the fourth ventricle (505). Oligodendrocyte progenitors then migrate long distances away from these zones and populate the
developing brain to form white matter throughout the brain, as shown by
developmental (200, 329) and transplantation
studies (177, 321). Because mature
oligodendrocytes cannot migrate, preventing premature differentiation
of progenitors is crucial for ensuring that they successfully make it
to their final destination. Premature oligodendrocyte differentiation
is effectively prevented by an inhibition mechanism recently shown to
occur in gliogenesis, the Notch pathway (651) (see sect.
IIID2). Oligodendrocytes, first found in the optic nerve around birth, continue
to increase in number for six postnatal weeks in rodents (31, 567). Indirect evidence suggests that
optic nerve oligodendrocytes are derived from precursor cells that
migrate into the nerve from the brain rather than from neuroepithelial
cells of the original optic stalk. For example, during late embryonic
development in the rat (at about E15), cultures from the chiasma but
not from the retinal end of the nerve contain significant numbers of
oligodendrocyte progenitor cells (568). 4. Oligodendrocyte migration: mechanisms and molecules
involved
Oligodendrocyte progenitors migrate extensively throughout the CNS
before their final differentiation into myelin-forming oligodendrocytes (568). Moreover, as in other
developmental systems, oligodendrocytes have to extend processes in a
similar fashion to the extension of neurites from neuronal cell bodies.
As for neurons, a number of extracellular matrix (ECM) molecules play an instructive role in the control of migrating oligodendrocytes. For
example, tenascin-C is expressed at high levels at the rat retina-optic nerve junction, an area through which oligodendrocytes do not migrate, so preventing access of myelin-forming cells to the
retina (187). Therefore, it has been proposed that
tenascin-C might provide a barrier to oligodendrocyte migration at
the retinal end of the optic nerve (37). The inhibitory
effect of tenascin-C is dependent on the substrate: tenascin-C
inhibits migration in response to fibronectin but not in response to
merosin (200). Moreover, to find their way and to regulate
the extension of their processes along the astrocyte-produced ECM,
oligodendrocytes use metalloproteinases (MMP). In vivo, elevation of
MMP protein expression in tissues rich in oligodendrocytes and myelin
coincides with the temporal increase in myelination that occurs
postnatally. Process formation is retarded significantly in
oligodendrocytes cultured from MMP-9 null mice, as compared with
controls, providing genetic evidence that MMP-9 is necessary for
process outgrowth (434). On the contrary, MMP inhibitors
decrease process extension of oligodendrocytes, supporting the key role
of MMPs (623). With the use of explant cultures of newborn rat neurohypophysis, it was
shown that migrating oligodendrocyte progenitors express a
polysialylated (PSA) form of NCAM (649). Removal of
PSA-NCAM from the surface of progenitors by an endoneuraminidase
treatment results in a complete blockade of the dispersion of the
oligodendrocyte progenitor population from the explant. As shown for
neurons and astrocytes, the expression of PSA-NCAM does not itself
provide a specific signal for migration, but its expression appears to open a permissive gate (528) that allows cells to respond
to external cues at the appropriate time and space. In contrast, in the
chick, the migration of oligodendrocyte precursors along the optic
nerve axons appears unaffected by removal of PSA-NCAM (440). Thus migrating oligodendrocyte progenitors may use
distinct and discrete mechanisms to navigate specific migrational pathways. Oligodendrocyte progenitors express a distinctive array of integrin
receptors (394) that may mediate specific interactions with ECM components, such as thrombospondin-1, which could also be
involved in the regulation of migration (553). 5. Stages of maturation of oligodendrocytes
As described in section II, A and
B, oligodendrocyte progenitors have been characterized in
rodent species by their bipolar morphology and by the presence of
specific markers: 1) glycolipids:GD3 (248)
recognized by the monoclonal antibodies (MAbs) R24 and LB1; other
glycolipids, not as yet fully characterized (198) recognized by the MAb A2B5; and 2) a chondroitin sulfate
proteoglycan called NG2 (427). In vitro studies
(127, 455) as well as in vivo experiments
through transplantation techniques (26, 177, 226, 321) show that these cells are actively
proliferating and possess migratory properties. They proliferate in
vitro, in response to growth factors such as fibroblast growth factor
(FGF) and PDGF (211, 249, 393,
489, 509) (see sect.
IIC8). After their migration in the mammalian CNS, progenitors settle along
fiber tracts of the future white matter and then transform into
preoligodendrocytes (Fig. 4),
multiprocessed cells which keep the property of cell division and
acquire the marker O4 (571). At this stage, they are less
motile (442), or even postmigratory (455),
and lose their mitogenic response to PDGF (208,
250, 478).
The preoligodendrocyte becomes an immature oligodendrocyte,
characterized in the rat by the appearance of the marker GalC, and the
loss of expression of GD3 and A2B5 antigens on the cell surface. CNP is
the earliest known myelin-specific protein to be synthesized by
developing oligodendrocytes (505, 506,
579, 642). Other markers appear at this
stage, such as RIP (199), CAII, and MBP (89)
(see sect. IIB). In vivo there seems to be a
GD3/GalC intermediate stage (127). In rat cerebellum, CNP
is expressed at the same time as GalC (505) and MBP is
expressed 2-3 days later along with PLP, immediately before myelin
formation. The same sequence occurs also in vitro; CNP is expressed at
the same time as GalC in cultured oligodendrocytes (455).
MBP, MAG, and PLP appear sequentially both in vivo and in vitro
(154, 249, 399,
455) and signify a mature oligodendrocyte. In vitro analyses suggest that maturation of oligodendrocytes from the
precursor stage to the mature cell is identical in culture, even
without neurons, as in intact tissue. Thus the capacity of
oligodendrocyte progenitors to differentiate into oligodendrocytes is
intrinsic to the lineage (605). In the absence of neurons, oligodendrocytes can clearly make a myelin-like membrane
(533); nevertheless, coculture with neurons increases
myelin gene expression, such as PLP, MBP, and MAG (358,
366). The presence of MOG correlates with late stages of
maturation of the oligodendrocyte (570) (see sect.
IIIC2). A similar myelin-gene induction by neuronal contact with
oligodendrocytes is also observed in vivo (295); the
switch to PLP isoform expression in DM20-expressing premyelinating
oligodendrocytes indicates the beginning of the process of myelination
in individual myelinating processes (620). This
myelin-gene induction parallels morphological modifications, i.e.,
in vivo, when axonal contact occurs, there is a dramatic modification
of oligodendrocyte morphology with loss of oligodendrocyte processes
that have not contacted axons (246). 6. Oligodendrocyte-type 2 astrocyte (O-2A phenotype)
From the early 1980s glial research was centered around an
oligodendrocyte-type 2 astrocyte progenitor (O-2A) first
discovered in culture of the optic nerve (reviewed in Ref. 475). O-2A
progenitors in culture generate oligodendrocytes constitutively but can
give rise to process-bearing astrocytes (so-called type 2 astrocytes) when treated with 10% fetal calf serum. Attempts to find
cells in vivo with the type 2 astrocyte phenotype during normal
development have failed (248, 505), even
after grafting O-2A cells into brain during development
(177). Combination of tritiated thymidine and specific
cell type immunocytochemistry indicate that most astrocytes are
generated prenatally and during the first postnatal week, before
oligodendrocyte formation (565), suggesting that there is
not a second wave of type 2 astrocytes in vivo as suggested by the
previous in vitro studies. "The apparent discrepancies between the
data obtained in vitro and in vivo highlights an important aspect of
the approach in vitro; when a progenitor cell is grown in tissue
culture, the environments to which it can be exposed are restricted
only by the imagination of the experimenter. By exposing the cell to a
variety of signals, the full differentiation potentiality of the cell
can be explored. In contrast, during development, a progenitor cell is
exposed to a restricted sequence of signals that are spatially and
temporally programmed" (196). 7. The number of mature oligodendrocytes is regulated by
apoptosis
The final number of mature myelinating oligodendrocytes is
determined by the proliferative rate of their progenitors and by the
process of programmed cell death that occurs during development (reviewed in Ref. 29). As oligodendrocytes differentiate late in the
CNS, their development may be influenced by signals derived from other
neural cell types, such as astrocytes and neurons (249, 510). Axon-to-oligodendrocyte signaling results in the
generation of the precise numbers necessary to myelinate entirely a
given population of axons (reviewed in Ref. 32). Confocal microscopy analysis of rat brain tissue has clearly
demonstrated that premyelinating oligodendrocytes that express DM-20
have two fates, programmed cell death (PCD) or myelination. PCD occurs
during a process of axon matching to eliminate surplus cells. The cells
that make contact with axons survive and begin myelination
(620), as hypothesized earlier (28). The
appearance of MOG (see sect. IIIC2E)
in oligodendrocytes (119, 368,
455, 552), as in the CG4 oligodendrocyte cell
line (570), is a reliable marker for fully differentiated
myelin-forming oligodendrocytes. 8. Factors necessary for oligodendrocyte maturation and
survival
A) GROWTH FACTORS.
Many growth factors have been found to be involved in the
proliferation, differentiation, and maturation of the oligodendrocyte lineage (29, 99, 100,
248, 249, 377, 378,
455, 489, 509,
684). Most of these studies have been performed in vitro. It is extremely difficult to extrapolate to in vivo conditions, as
multiple factors may act in concert to achieve the exquisitely fine
regulation of the complex process of oligodendrocyte development and
myelination. Combinations of factors often produce effects that are
significantly different from those seen with any one factor alone
(379). Furthermore, these factors have multiple effects
during development. In contrast to experiments on rodent cells, growth
factors that act on human cells have not as yet been fully determined.
-RECEPTOR.
The platelet-derived growth factor
-receptor (PDGFR-
)
transcripts are also detected at very early stages of the developmental maturation of myelinating glial cells. Although PDGF R-
and
PLP/DM-20 cells are usually found in a close vicinity, either in the
same or in adjacent territories, they are rarely coexpressed by the same cells, raising the question of single or multiple oligodendrocyte lineage (reviewed in Refs. 510, 577).
(426,
427, 504). These cells have extensive
arborizations of their cell processes and are found ubiquitously long
after oligodendrocytes are generated. They do not express antigens
specific to mature oligodendrocytes, astrocytes, microglia, and
neurons, suggesting that they are a novel population of glial cells
which undergoes proliferation with morphological changes in response to
stimuli such as inflammation or demyelination (reviewed in Ref.
136a, 426).
oligodendrocytes support fewer myelin sheaths for
large-diameter axons (89). This immunocytochemical
classification overlaps the morphological classification of Bunge
(84). However, CAII is also reported to be expressed by
microglia (671).
-protein, is expressed predominantly by astrocytes, it is also
present in adult rat brain in a minor subpopulation of oligodendrocytes
(511).
-galactosidase, is introduced into a dividing cell population. After the virus enters a
cell, DNA copies of viral RNA are synthesized, and a proportion of
cells undergoing DNA replication will integrate viral DNA into genomic
DNA. From that point on, viral genes will be passed to all the progeny
(633). Moreover, the promotor sequences of genes
specifically activated in glial precursors induce the expression of the
LacZ reporter gene in the glial lineages. In the transgenic mice
bearing this type of transgene, LacZ expression characterizes the
subpopulation that expresses the transgene during its differentiation.
(478). Similarly, a discrete population of cells
expressing mRNA for the myelin protein CNP (690) and DM20
(PLP gene) (610) has been localized to the ventral
ventricular zone of the developing mammalian spinal cord. A group of
cells in the ventricular and mantle zone of the ventral diencephalon of
the E13 rat express mRNA for the PDGFR-
(478). A
similar distribution of cells expressing DM-20 mRNA has also been
described in the mouse (610). Nevertheless, this issue
still remains unclear as both markers are not expressed by the same
population of oligodendrocyte precursors, indicating a diversity in
this population already at this stage. DM-20 protein is also expressed
on embryonic cells that may become oligodendrocyte progenitors as shown
by Dickinson et al. (144) in the spinal cord.

View larger version (57K):
[in a new window]
Fig. 4.
A: migration and differentiation of cells of astrocyte
and oligodendrocyte lineages, and multifocal pattern of development of
glial rows in the fimbria between embryonic day 15 (E15) and postnatal
day 60 (P60). (Lower surface, ependyma; upper surface, pia.) There is a
relatively small increase in the thickness of the fimbria. The
multicellular ventricular layer (small open circles at lower surface at
E15 and P0) becomes reduced to a unicellular adult ependyma (triangles
on ependymal surface). Cells migrating into the body of the fimbria,
and supplemented by division of precursors there, become arranged in
progressively longer interfascicular glial rows. The astrocytes (large,
pale circles) change from predominantly radial processes to
predominantly longitudinal. Oligodendrocytes are represented by small,
black, filled contiguous circles. Myelination (not represented) largely
occurs between P10 and P60. Axons (not represented) are present from
the earliest developmental stage. [From Suzuki and Raisman
(596). Copyright 1992, reprinted by permission of
Wiley-Liss, Inc., a subsidiary of John Wiley & Sons, Inc.]
B: organization of the glial framework of central white
matter tracts. Arrangement of radial and longitudinal processes of
oligodendrocytes (Og) and astrocytes (As) forming a continuous meshwork
of processes intermingled within the axonal tracts in the fimbria.
Astrocytes are linked with each other by gap junctions, and also form
gap junctions with oligodendrocytes, thus providing an indication for a
functional as well as an anatomical functional syncytium. Myelination
occurs on an asynchronous mode, with individual oligodendrocytes
maturing independently within a cluster of adjacent oligodendrocytes,
suggesting an interaction between axon maturation and oligodendrocyte
differentiation. [From Raisman (492).]
from the
surface of oligodendrocyte progenitor cells but is due to the blockade of the intracellular signaling pathways from the PDGF receptor to the
nucleus (250). The PDGF-
receptors disappear at the O4+ stage of oligodendrocyte maturation (173,
427). PDGF is also a survival factor for oligodendrocyte
progenitors (28, 489), as recently
demonstrated by the impaired oligodendrocyte development in the
PDGF-A deficient mice (201). In these mice, there are profound reductions in the numbers of PDGFR-
progenitors and oligodendrocytes in the spinal cord and cerebellum, but less severe reductions of both cell types in the medulla. Infusion of PDGF into the
developing optic nerve in vivo greatly reduces apoptotic cell death
(33). PDGF also stimulates motility of oligodendrocyte progenitors in vitro and is chemoattractive.
and therefore increases the
developmental period during which oligodendrocyte progenitors or
preoligodendrocytes are able to respond to PDGF (377).
Preoligodendrocytes can even revert to the oligodendrocyte progenitor
stage when cultured with both PDGF and bFGF (65). This
inhibition of oligodendrocyte differentiation can be overridden by the
presence of astrocytes (65, 371). bFGF is
present in the developing nervous system in vivo (175).
The levels of expression of mRNA for the high-affinity bFGF
receptors-1, -2, and -3 are differentially regulated during lineage
progression (22); this pattern of expression could provide a molecular basis for the varying response of cells to a common ligand
that is seen during development.
inhibits PDGF-driven proliferation and promotes
differentiation of oligodendrocyte progenitors (379).
IL-2. IL-2 directly affects the function of both neurons and
glia in the nervous system, inducing proliferation and differentiation or inducing oligodendrocyte cell death (444).
Hormones act also on myelinating cells and are described in section
IIIF.
B) NEUROTRANSMITTERS AND OLIGODENDROCYTE DEVELOPMENT. Oligodendrocyte progenitors are equipped with a variety of ligand- and voltage-gated ionic channels that are expressed in vitro as in vivo (572, 586). They are not detailed here.
Recent data suggest that glutamate, the most abundant excitatory neurotransmitter in the mammalian brain, acting on its ionotropic receptors, is involved in the shaping of the oligodendrocyte population. The main ionotropic glutamate receptors expressed by oligodendrocytes belong to the dl-
-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) and
kainate classes (369). It has been shown that non-NMDA
glutamate receptor agonists are able to inhibit oligodendrocytes progenitor proliferation in cell cultures (207). In
cerebellar slice cultures, glutamate is an antimitotic signal at all
proliferative stages of the oligodendrocyte lineage, i.e., for both
oligodendrocyte progenitors and precursors. Interestingly, the
glutamate effects are receptor and cell specific, because they are
selectively mediated through AMPA receptors, whereas in the same
context, astrocyte proliferation and number are not affected
(691).
The dopamine D3 receptor (D3R) has been found to be expressed by
precursors and immature oligodendrocytes, but absent from mature
oligodendrocytes (68). By confocal microscopic analysis, it was shown that D3R was associated with cell bodies and cell membranes, but not with the processes emanating from cell soma. Immunohistochemistry revealed the presence of D3R in some
oligodendrocytes located mainly within parts of the corpus callosum
during myelinogenesis and was shown to modulate the timing of
oligodendrocytes maturation and elaboration of myelin sheath. Treatment
of glial cultures with a dopamine agonist altered the normal pattern of
oligodendrocyte differentiation. Another dopamine receptor, D2R, is
also present in a subset of mature interfascicular oligodendrocytes in
the rat corpus callosum (262).
GABAA receptors have also been reported in oligodendrocytes
(45).
Oligodendrocytes express opioid receptors, µ-receptors are apparent
at the earliest stages of oligodendrocyte development, while
-receptors are detected later at the time that MBP is expressed (306). There is a proliferative response to µ-receptor stimulation.
These data indicate that these neurotransmitter receptors are involved
in processes other than nerve conduction and may have additional,
perhaps trophic functions in glial and neuronal differentiation.
D. The Glial Network
In a review of cell junctions among the supporting cells of the CNS, E. Mugnaini wrote in 1986 (413): "Cell junctions require careful analysis because they reflect not only the biology of individual cells, but also their sociology; that is, the cooperativity with other cells, and the relation to the environment." In situ, morphological studies have shown that astrocyte gap junctions are localized between cell bodies, between processes and cell bodies, and between astrocytic end-feet that surround brain blood vessels (679). In vitro, junctional coupling between astrocytes has also been observed (189, 635). Although less frequently observed than junctions between astrocytes, gap junctions also occur between oligodendrocytes, as observed in situ (90, 519, 574) and in vitro (634). Moreover, astrocyte-to-oligodendrocyte gap junctions have been identified between cell bodies, cell bodies and processes, and between astrocyte processes and the outer myelin sheath (654; reviewed in Ref. 218). Thus the astrocytic syncytium extends to oligodendrocytes, allowing glial cells to form a generalized glial syncytium (413), also called "panglial syncytium," a large glial network that extends radially from the spinal canal and brain ventricles, across gray and white matter regions, to the glia limitans and to the capillary epithelium (498) (Fig. 1).
Gap junctions are channels that link the cytoplasm of adjacent cells and permit the intercellular exchange of small molecules with a molecular mass <1-1.4 kDa, including ions, metabolites, and second messengers (reviewed in Refs. 81, 218). In addition to homologous coupling between cells of the same general class, heterologous coupling has been observed not only between astrocytes and oligodendrocytes, but also between ependymal cells and retinal Muller glia. Homologous coupling could serve to synchronize the activities of neighboring cells that serve the same functions. Such coupling would extend the size of a functional compartment from a single cell to a multicellular syncytium, acting as a functional network (reviewed in Ref. 218).
Gap junctions are now recognized as a diverse group of channels that vary in their permeability, voltage sensitivities, and potential for modulation by intracellular factors; thus heterotypic coupling may also serve to coordinate the activities of the coupled cells by providing a pathway for the selective exchange of molecules below a certain size. In addition, some gap junctions are chemically rectifying, favoring the transfer of certain molecules in one direction versus the opposite direction. The main gap junction protein of astrocytes is connexin (Cx) 43 (review in Ref. 218), whereas Cx32 is expressed in oligodendrocytes in the CNS (539) as well as another type of connexin, Cx45 (140, 141, 318, 332, 419). Heterologous astro-oligodendrocyte gap junctions may be composed of Cx43/Cx32, if these connexins form functional junctions. Heterocoupling between astrocytes and oligodendrocytes has been proposed to serve K+ buffering around myelinated axons (332; reviewed in Ref. 692).
E. Functions of Oligodendrocytes
The main and evident function of oligodendrocytes is the formation of a myelin sheath around most of axons in the CNS. The function of myelin is studied in section III, including roles newly ascribed to myelin itself, such as clustering of sodium channels at the node of Ranvier during axogenesis, participation to development and regulation of axonal caliber (sect. IIIG2), and maintenance of axons, but also inhibition of axonal growth and regeneration (sect. IIIG3). Myelin morphology, composition, and specific roles are treated in specific sections (sect. III, B, C, and G), as well as experimental and human diseases involving oligodendrocyte/myelin (sect. IV).
| |
III. MYELIN |
|---|
|
|
|---|
The myelin sheath around most axons constitutes the most abundant membrane structure in the vertebrate nervous system. Its unique composition (richness in lipids and low water content allowing the electrical insulation of axons) and its unique segmental structure responsible for the saltatory conduction of nerve impulses allow the myelin sheath to support the fast nerve conduction in the thin fibers in the vertebrate system. High-speed conduction, fidelity of transfer signaling on long distances, and space economy are the three major advantages conferred to the vertebrate nervous system by the myelin sheath, in contrast to the invertebrate nervous system where rapid conduction is accompanied by increased axonal calibers.
The importance of myelin in human development is highlighted by its involvement in an array of different neurological diseases such as leukodystrophies and multiple sclerosis (MS) in the CNS and peripheral neuropathies in the PNS.
A. Phylogeny
In terms of evolution of the nervous system, the myelin sheath is the most recent of nature's structural inventions. Myelin is found in all vertebrate classes except the evolutionarily oldest agnathan cyclostomata, i.e., the jawless fish (hagfish and lampreys) in which axons, however, are surrounded by glial cells. All other vertebrates, including cartilaginous fish, bony fish, and tetrapods as well as lungfish and coelacanth manifest extensive myelination in both the CNS and PNS. So, the first myelin-like ensheathed axons may have appeared about 400 million years ago. Although compact myelin is a uniquely vertebrate feature, a form of glial ensheathment of axons exists in invertebrates (such as annelids, crustaceans, mollusks, and arthropods), forming a superficially resembling vertebrate myelin sheath (reviewed in Refs. 122, 645). Ontogenetically, PNS myelin appears before CNS myelin; however, it has not been demonstrated to occur phylogenetically.
B. Morphological Structure of the Myelin Sheath and of the
Node of Ranvier
1. Myelin
Myelin, named so by Virchow (640), is a spiral
structure constituted of extensions of the plasma membrane of the
myelinating glial cells, the oligodendrocytes in the CNS
(82, 452). These cells send out sail-like
extensions of their cytoplasmic membrane (Figs. 2 and 3), each of which
forms a segment of sheathing around an axon, the myelin sheath
(reviewed in Refs. 41, 404, 453, 457). Several structural features
characterize myelin. Its periodic structure, with alternating
concentric electron-dense and light layers, was already shown in
1949, in the optic nerve myelin of guinea pig (563). The
major dense line (dark layer) forms as the cytoplasmic surfaces of the
expanding myelinating processes of the oligodendrocyte are brought into
close apposition. The fused two outer leaflets (extracellular
apposition) form the intraperiodic lines (or minor dense lines) (Figs.
2 and 5). The periodicity of the lamellae
is 12 nm. Each myelin sheath segment or internode appears to be
150-200 µm in length (90); internodes are separated by
spaces where myelin is lacking, the nodes of Ranvier (84). It does seem that oligodendrocytes form thicker myelin around larger
axons (657).

View larger version (43K):
[in a new window]
Fig. 5.
Myelinating glial cells, myelin structure, and composition in
the peripheral nervous system (PNS) and in the CNS. In the PNS, the
myelinating Schwann cell myelinates only one segment of axon (top left
corner), whereas in the CNS (top right corner), the oligodendrocyte is
able to myelinate several axons. The compact myelin is formed by the
apposition of the external faces of the membrane of the myelinating
cell, forming the "double intraperiodic line"; the apposition of
the internal faces followed by the extrusion of the cytoplasm, form the
"major dense line." The myelin proteins are schematically
described; they differ between PNS and CNS. [Adapted from
Pham-Dinh (457).]
A) THE SCHMIDT-LANTERMAN CLEFTS. The Schmidt-Lanterman clefts (also called Schmidt-Lanterman incisures) correspond to cytoplasmic faces of the myelin sheath that have not compacted to form the major dense line; thus they constitute pockets of uncompacted glial cell cytoplasm within the compact internode myelin. They are oblique, funnel-like clefts that extend across the entire thickness of the sheath, providing a pathway through which cytoplasm on the outside of the sheath is confluent with that of the inside part. Schmidt-Lanterman clefts are common in the PNS, but rare in the CNS (Fig. 5). The myelin sheath is separated from the axonal membrane by a narrow extracellular cleft, the periaxonal space.
B) THE PARANODAL LOOPS. Myelin is less compacted at the inner and outer end of the spiral, forming inner and outer loops that retain small amounts of oligodendrocyte cytoplasm. The myelin lamellae end near the node of Ranvier in little expanded loops containing cytoplasm. The loops are arranged on a roughly regular and symmetric pattern on each side of the node. This sequence of loops is named the paranodal region or paranode. Each paranodal loop makes contact with the axon. Freeze-fracture studies have shown distinct membrane morphologies in the axolemma (reviewed in Ref. 655), corresponding to the different domains of the myelinated fibers: the internode, the paranodal region, and the node of Ranvier. These anatomically different regions of the axolemma are formed by specific interactions between the axon and the myelinating glial cell. The interface between the lateral loops and the axon membrane exhibits a row of 15 nm regularly spaced densities, the transverse band (256). The transverse bands, which comprise rows of regularly spaced particles in glial and axonal membranes, are associated with cytoskeletal filaments and appear to tighten the axonal-paranodal apposition (270). Molecular structure and organization of the axolemma at the paranode and node of Ranvier have recently come to light (135, 171, 293, 382; reviewed in Refs. 530, 653) (see below and sect. IIIE).
2. The node of Ranvier
Along myelinated fibers, adjacent internodes are separated by the nodes of Ranvier where the axolemma is exposed to the extracellular milieu (84) (Fig. 2). The nodes of Ranvier play a major role in nerve impulse conduction. They allow the fast saltatory conduction, the impulse jumping from node to node, rather than progressing slowly along the axon as in unmyelinated or demyelinated fibers. Thin axons appear to possess tiny node gaps, and thick axons exhibit spacious node gaps, as observed at nodes of Ranvier in rat white matter (56). Astrocytic processes may be seen in close proximity to the axon membrane at the node of Ranvier (58) (see sect. IIIE for the molecular organization of the node). Another cell type characterized by the NG2 antigen has recently been shown to contact the node of Ranvier in adult CNS white matter (88), and this cell is thought to be a glial precursor.
C. Myelin Isolation and General Composition
Myelin is the essential constituent of white matter in the CNS which contains ~40-50% myelin on a dry weight basis. The composition of myelin was widely studied more than 20 years ago, when methods of myelin isolation became available (431, 432); its low density allows its easy preparation as a fraction after sucrose gradient centrifugation. Although developed for fresh rat brain, it has been widely used for human specimens and gives a well-defined fraction, even from frozen myelin (39). Contaminants may increase when myelin is in low quantities, such as during development, and in pathological conditions such as hypomyelination and demyelination (689). Most biochemical analyses refer to the work of the group of Norton (reviewed in Ref. 404). Myelin is a poorly hydrated structure containing 40% water in contrast to gray matter (80%). Myelin dry weight consists of 70% lipids and 30% proteins. This lipid-to-protein ratio is very peculiar to the myelin membrane. It is generally the reverse in other cellular membranes. The insulating properties of the myelin sheath, which favor rapid nerve conduction velocity, are largely due to its structure, its thickness, its low water content, and its richness in lipids.
The specific constituents of myelin, glycolipids, and proteins are formed in the oligodendrocyte.
1. Myelin lipids
Lipids found in oligodendrocytes and myelin are also present in other cellular membranes, but in a different proportion. In every mammalian species, myelin contains cholesterol, phospholipids, and glycolipids in molar ratios ranging from 4:3:2 to 4:4:2 (reviewed in Ref. 404). Therefore, the molar ratio of cholesterol is greater than that of any other lipid. Cholesterol esters are not present in normal myelin. There are no major peculiarities in myelin phospholipids that represent 40% of total lipids, except for the high proportion of ethanolamine phosphoglycerides in the plasmalogen form which account for about one-third of the phospholipids. Diphosphoinositides and triphosphoinositides are nonnegligible components, respectively, 1-1.5 and 4-6% of myelin phosphorus.
One of the major characteristics of oligodendrocyte and myelin lipids
is their richness in glycosphingolipids, in particular galactocerebrosides, i.e., galactosylceramides (GalC) and their sulfated derivatives, sulfatides, i.e., sulfogalactosylceramides. These
lipids have been immunolocalized in oligodendrocytes and tissue
sections of myelin (490, 693). Even though
there are no "myelin lipids," GalC are the most typical lipids of
myelin in which they are specifically enriched (reviewed in Ref. 404) and represent 20% lipid dry weight in mature myelin. These
glycosphingolipids represent a family of components, as there is a
great variability in the ceramide moiety, both in its sphingosine
content (18-20 carbon atoms) and in its long-chain fatty acids
content. The ceramide core of these glycosphingolipids is particularly
rich in very-long-chain fatty acids, 22-26 carbon atoms, saturated,
mono-unsaturated, and
-hydroxylated. During development, the
concentration of galactocerebrosides in brain is proportional to the
amount of myelin present (432). This is also the case for
the very-long-chain fatty acids (276). The biosynthesis
for myelin very-long-chain fatty acids occurs in the microsomal
compartment and not in mitochondria (72). Abnormalities of
lysosomal enzymes related to degradation of sulfatides or
galactocerebrosides, or proteins involved in the transport of these
fatty acids to the peroxisomes, give rise to leukodystrophies (see
sect. IVA2).
There are also several minor galactolipids (3% of total galactose) in myelin such as fatty esters of cerebroside, i.e., acylgalactosylceramides (608) and galactosyldiglycerides (463). Monogalactosyl diglyceride appears also to be a marker for myelination (541). This may be also the case for acylgalactosylceramides (608).
A sialylated derivative of galactocerebroside (sialosylgalactosylceramide), the ganglioside GM4, is present mainly in murine and primate myelin, including human, but not, for instance in bovine brain (117). Ganglioside GM1, although a minor component of myelin, is greatly enriched in myelin, compared with polysialogangliosides. It has been localized in myelin and some glial cells using specific monoclonal antibodies (313).
Furthermore, a number of major CNS myelin proteins, such as PLP, MAG, CNP (see below) are also covalently acylated (3, 448) (see sect. IIIC2), which gives them hydrophobic properties.
2. Myelin proteins
Myelin proteins, which comprise 30% dry weight of myelin, are for most of the known ones, specific components of myelin and oligodendrocytes (97). The major CNS myelin proteins MBP and PLP (and isoform DM-20) are low-molecular-weight proteins and constitute 80% of the total proteins. Another group of myelin proteins, insoluble after solubilization of purified myelin in chloroform-methanol 2:1, have been designated as the Wolfgram proteins, since their existence was suspected already in 1966 by Wolfgram (670). These proteins comprise the CNP and other proteins.
Several glycoproteins are present in myelin (reviewed in Ref. 486), among which are MAG and MOG. Other proteins have also been identified, some of which have enzyme activities.
A) MBP. MBP (296) is one of the major proteins of CNS myelin and constitutes as much as 30% of protein. In fact, it is a family of proteins, as there are many isoforms of different molecular masses. The amino acid composition of the major MBPs was determined by Eylar et al. (178) from bovine brain, and by Carnegie (104) in humans. The major protein isoforms can be separated by SDS-PAGE. The molecular masses of the major forms are 21.5, 18.5, 17, and 14 kDa in the mouse and 21.5, 20.2, 18.5, and 17.2 kDa in humans (for review, see Ref. 97). In the adult, the major isoforms are 18.5- and 17.2-kDa isoforms in humans and 18.5 and 14 kDa in the mouse, constituting ~95% of the MBPs (582). The MBP isoforms are coded by alternative transcripts from the MBP gene which consists of seven exons (516). The MBP gene is distributed over a 32-kb stretch in the mouse on chromosome 18. In the human, the MBP gene has been assigned to 18q22-qter (535, 575) and is distributed over a length of 45 kb (291). In the mouse, at least seven transcripts are expressed from this gene through alternative splicing of exons 2, 5A, 5B, and 6 (15, 137, 424, 600). A number of other mRNA splicing variants of the mouse MBP gene predominantly expressed in embryonic stage have also been characterized (365, 421). One of these variants is expressed at the protein level in embryonic nervous system at a time when other MBP isoforms are not detected. By in situ hybridization, the expression of the MBP gene has been observed as early as E14.5 in the spinal cord in the mouse (454).
The MBP gene is contained within a larger transcription unit (98, 238, 474) that contains three unique exons spanning a region 73 kb upstream of the classic MBP transcription start site in the mouse (98). This transcription unit, called the Golli-MBP gene, is 195 kb in mice and 179 kb in humans (98, 474) and produces a number of alternative transcripts. The Golli-MBP gene consists of 10 exons, 7 of which constitute the MBP gene. The acronym Golli has been chosen for "gene expressed in the oligodendrocyte lineage." In fact, transcripts are also found in cells of the immune system (237, 473, 474, 694) and in some neurons (472). Corresponding Golli-MBP proteins have been found in the same tissues (290). Both Golli and MBP families of transcripts are under independent developmental regulations. Regulatory elements responsible for the specific expression of the MBP gene in the CNS (versus the PNS) have been identified using transgenic mice (227). A MBP promoter region of 256 bp that has been shown to contain regulatory elements for efficient transcription in glial cells is sufficient to direct oligodendrocyte-specific expression (224). It is of note that the 17- and 21.5-kDa isoforms, which contain exon 2, appear earlier during development in the mouse. In the human, the exon 2-containing isoforms of 20.2 and 21.5 kDa are also mainly expressed during myelinogenesis. They are reexpressed in chronic lesions of MS, and their reexpression correlates with remyelination (101) (see sect. IIIH). The active transport of exon 2-containing MBPs from the cytoplasm to the nucleus suggests a regulatory role in myelination for these karyophilic MBPs (447) (details on immunolocalization of MBP are reported further, see sect. IIIE1). Posttranslational modifications including NH2-terminal acetylation, phosphorylation, and methylation can occur on the MBPs; indirect evidence suggests that methylation of MBP may be important for compaction of the membrane during myelin maturation (97). Citrullination can also occur (673). Direct evidence that MBPs play a major role in myelin compaction in the CNS was provided from studies of the shiverer mutant mouse (see sect. IVA), which presents a large deletion of the MBP gene (517) and in which the major dense line is absent from myelin (480).B) PROTEOLIPID PROTEINS (PLP AND DM-20). In 1951, Folch and Lees (190) discovered that a substantial amount of protein from brain white matter could be extracted by organic solvent mixtures. Because these proteins were apparently lipid-protein complexes, they were given the generic name of proteolipids to distinguish them from water-soluble lipoproteins. They are mainly myelin constituents. Although other myelin proteins can be solubilized this way, the name has been given to a major component of myelin, named PLP. This protein corresponds to 50% of myelin proteins. The predominant isoform commonly named PLP has an apparent molecular mass on SDS-PAGE of 25 kDa; a second isoform DM-20 (10-20% PLP in the adult) migrates as a 20-kDa band on electrophoresis. The authentic molecular masses appear to be slightly higher as PLP and DM-20 are both acylated by covalent linkage of mainly palmitic, oleic, and stearic acids (3, 606) on numerous cysteine residues localized on the cytoplasmic side of the myelin membrane (659). There is also a nonenzymatic glycosylation of extracytoplasmic domains (660). The complete amino acid sequence of bovine PLP has been elucidated by Stoffel et al. (592) and Lees et al. (326).
The gene coding for PLP is located on the X chromosome, in humans (667) at position Xq22 (367) and in mice in the H2C area (131). Its size is 15 kb, and it is organized in seven exons. PLP and DM-20 are coded by the same gene (405), and the two isoforms are formed by alternative splicing (423). The mRNA coding for PLP comprises all 7 exons, while a sequence corresponding to the 5'-part of exon 3 (exon 3B) is spliced out of the mRNA coding for DM-20, leading to a 35-amino acid deletion in the protein sequence. There is a 100% sequence identity between murine and human PLP proteins (146, 356). PLP comprises four hydrophobic
-helices spanning
the whole thickness of the lipid bilayer, two extracytoplasmic and
three cytoplasmic domains (including the NH2 and COOH
termini) localized, respectively, at the intraperiodic and major dense
lines of myelin. The theoretical tridimensional topographical model
developed by Popot et al. (470) has been confirmed
experimentally by Weimbs and Stoffel (659). The respective distribution of PLP and DM-20 isoforms during development has been
mentioned in section IIB1.
Spontaneous mutations involving the PLP gene occur, among which are the
jimpy (jp) mouse (see sect. IVA1) and
a number of other animal models, as well as human dysmyelinating
diseases (sect. IVA2). PLP null alleles have
been recently engineered in mice by an antisense transgenic approach
(67), or by a knock-out strategy (305).
Without PLP/DM-20 expression, oligodendrocytes are still competent to
myelinate axons and to assemble compacted myelin sheaths. However, the
ultrastructure of myelin showed condensation of the intraperiodic lines
(as also observed in natural PLP mutants), correlating with a reduced
physical stability; these observations suggest that PLP forms a
stabilizing membrane junction after myelin compaction
(66), similar to a "zipper" (305). On the
other hand, the unexpected consequence of the absence of PLP/DM-20 is an early occurrence of widespread focal axonal swellings, followed later by axonal degeneration associated with impairment of motor performance in 16-mo-old mice (235) (see sect.
IVA1A).
Two mammalian proteins of unknown functions (M6a and M6b) show 56 and
46% sequence identity with DM-20 protein (680),
suggesting the existence of a family of DM-20 genes. M6a is a
neuronal-specific protein, and M6b is a neuronal and
myelin-associated protein (681). Several other members
of this gene family have been characterized in sharks and rays. The
"DM" proteins not only are highly homologous to each other, but
also contain regions bearing similarities with segments of
channel-forming regions of the nicotinic acetylcholine receptor and
the glutamate receptor (122, 303).
C) CNP. CNP represents 4% of total myelin proteins. This protein hydrolyzes artificial substrates, 2',3'-cyclic nucleotides into their 2'-derivatives. However, the biological role of this enzyme activity is obscure since 2',3'-nucleotides have not been detected in the brain (642). The association of CNP with one of the major Wolfgram proteins has been known for a long time (580). CNP appears on SDS-PAGE as a doublet of two peptides of molecular masses varying from 48 to 55 kDa, according to species. In general, there are two closely spaced protein bands at 48 and 46 kDa referred to CNP2 and CNP1, respectively (579).
The structure for the mouse and human CNP genes have been determined. The gene is located on chromosome 11 in the mouse (49) and on chromosome17q21 in the human (152). The gene consists of four exons spanning 7 kb. The two CNP isoforms are produced by alternative splicing from two transcription start sites; the 5'-exon (exon 0) contains an upstream initiation codon; a splice site is present on exon 1 (319). Interestingly, two translational start sites can be used on the mRNA encoding the CNP 2 isoform, giving rise to CNP1 and CNP2 protein isoforms (439). CNP is at high concentration not only in myelin, but also in photoreceptor cells in the retina (642). CNP mRNAs are detected in mouse spinal cord during embryonic stages (454, 690). CNP, although isolated with the myelin fraction, is not found immunocytochemically localized in compact myelin; it is present in the cytoplasm of noncompacted oligodendroglial ensheathment of axons and in the paranodal loops (618). The protein is posttranslationally modified, acylated, and phosphorylated, especially the larger isoform (642). CNP is associated with the cytoplasmic plasma membrane of the oligodendrocyte by isoprenylation (74), mainly CNP1. CNP possesses two of the three binding domains for GTP (75). In addition, a COOH-terminal domain is analogous to the GTP-binding proteins of the Ras family. These properties are not related to the catalytic site of the enzyme. Thus CNP may function in a way unrelated to this enzyme activity for which no physiological substrate has been found. Overexpression of CNP in transgenic mice perturbs myelin formation and creates aberrant oligodendrocyte membrane expansion (233).D) MAG. MAG (487) is quantitatively a minor constituent, representing 1% of the total protein found in myelin isolated from the CNS and 0.1% in the PNS. The MAG gene spans 16 kb in length and includes 13 exons; it is located on chromosome 7 in mouse and 19 in human (35, 142). MAG has an apparent molecular mass of 100 kDa on SDS-PAGE, of which 30% is carbohydrate. Two MAG proteins have been identified (194, 531), large MAG (L-MAG) and small MAG (S-MAG). These proteins correspond to polypeptides of 72 and 67 kDa in the absence of glycosylation. MAG proteins have both a membrane-spanning domain and an extracellular region that contains five segments of internal homology that resemble immunoglobulin domains (531) and are strikingly homologous to similar domains of the NCAM and other members of the immunoglobulin gene superfamily. Both share identical extracellular and transmembrane domains but differ in their cytoplasmic domains, corresponding to the alternative splicing of exon 12 from a single RNA transcript. The deduced amino acid sequence of the human S-MAG COOH terminus shows conservative substitutions of 4 of the 10 residues compared with the rodent peptide (387).
MAG is also glycosylated and bears the L2/HNK1 epitope (374, 466). The 72-kDa L-MAG can be phosphorylated and acylated (169). It was shown in the mouse that L-MAG is involved in the activation of Fyn, a protein tyrosine kinase of the src family, which suggested that the tyrosine phosphorylation cascade might be implicated in signal transduction for myelinogenesis, as evidenced by the impaired myelination observed in fyn-deficient mice (625). Moreover, it has recently been demonstrated that morphological differentiation of oligodendrocytes is dependent on fyn tyrosine kinase activation (443). In the adult rat CNS, MAG is confined to the periaxonal collar of the myelin sheath (617), contrasting with a larger distribution across the different regions of PNS myelin (see sect. IIIC3). A differential intracellular sorting of MAG isoforms has been characterized, suggesting that L-MAG contains a basolateral sorting signal, whereas the sorting of S-MAG is dependent on extrinsic factors, such as coexpression by adjacent cells; altogether, these features indicate that the isoforms perform different functions (395). MAG function has been studied by generating MAG gene knock-out mice (331, 400, 686). Surprisingly, CNS myelin forms almost normally in MAG-deficient mice; however, a prominent defect of the mutant myelin sheaths is an abnormal formation of the periaxonal cytoplasmic collar that is lacking in most of the internodes; myelin sheaths contain cytoplasmic organelles between lamellae, indicating a delay or block of myelin compaction; ~10% of axons, versus 3% in wild-type mice, received two to four sheaths around a single axon, suggesting that MAG may have a role in helping oligodendrocyte processes to distinguish between myelinated and unmyelinated axons in the CNS (331, 400). Moreover, a "dying-back oligodendrogliopathy" was further observed (323), which seems to be a toxic death of oligodendrocytes induced by an abnormality at the inner mesaxon, i.e., far from the cellular body of the cell. The differential role of S-MAG and L-MAG was further studied by generating mutant mice that express a truncated form of the L-MAG isoform, eliminating the unique portion of its cytoplasmic domain, but that continue to express S-MAG (203). CNS myelin of the L-MAG mutant mice displays most of the pathological abnormalities reported for the total MAG null allele mice, whereas PNS axons and myelin of older L-MAG mutant animals do not degenerate, in contrast to the peripheral neuropathy observed in full null MAG mutants (103, 202). These data indicate that S-MAG is sufficient to maintain PNS integrity, whereas L-MAG is the critical MAG isoform in the CNS (203). It is of note that during CNS myelination in rodent, L-MAG is expressed earlier than S-MAG, which is the predominant form in adult CNS myelin, whereas S-MAG is always prominent in PNS myelin (194, 531). These differential developmental patterns of expression may explain the different phenotypes presented by the full- and the L-MAG-mutant deficient mice, demonstrating that the cytoplasmic domain of the large MAG isoform is needed for proper CNS but not PNS myelination (203). In contrast to rodents, the L-MAG predominates in adult human brain while, like in rodents, S-MAG is most abundant in peripheral nerves (387). Moreover, in the MAG-deficient mice, axonal caliber is significantly decreased in the PNS (686). For a long time MAG has been considered as a potential receptor for an axonal ligand important for the initiation and progression of myelination (reviewed in Refs. 188, 384). Indeed, MAG is expressed exclusively by myelinating cells where it is enriched in the periaxonal membranes of the myelin internodes, thus in direct contact with the axon (622). Moreover, in vitro studies of transfected Schwann cells correlated MAG overexpression with accelerated myelination, whereas MAG underexpression was associated with hypomyelination (see reviews in Refs. 188, 384). The fact that MAG belongs to a family of glycoproteins sharing a common L2/HNK1 carbohydrate epitope led to the suggestion that MAG could be involved in cell surface recognition (466). Indeed, in vitro experiments with anti-MAG antibodies showed that MAG is involved in neuron-oligodendrocyte interactions (466). Recently, the discovery that MAG belongs to the family of sialic acid binding lectins, the sialoadhesins, as shown by the binding of MAG to neurons in a sialic acid-dependent manner, has led to the study of gangliosides, prominent neural cell surface sialoglycolipids, as MAG ligands (683). The sialic acid-dependent binding of MAG to neurons is trypsin sensitive, indicating that MAG binds to a neuronal sialo-glycoprotein rather than to a sialo-glycolipid and that the sialic acid binding site of MAG with the axon has been shown to be located at Arg-118 in the MAG amino acid sequence (601). Another proposed function of MAG is to inhibit neurite outgrowth, i.e., axon regeneration in the CNS after lesion (reviewed in Refs. 188, 485) (see sect. IIIG3D). On the other hand, it has recently been shown that, in the CNS, MAG can be proteolyzed near its transmembrane domain by a calcium-activated protease and that the soluble proteolytic product can be found in the cerebrospinal fluid (583). The conversion of 100-kDa MAG to its soluble derivative dMAG of 90 kDa occurs more rapidly in myelin from human and other primates than in myelin from rat brain. Soluble dMAG may be involved in the molecular mechanism of demyelination, as the rate of formation of dMAG is increased even more in myelin from white matter of patients with MS (398).E) MOG. MOG was first identified by a polyclonal antibody directed against an antigen called M2 that induces autoimmune encephalomyelitis in the guinea pig. MOG was first identified as the antigen responsible for the demyelination observed in animals injected with whole CNS homogenate; it was later identified as a minor glycoprotein specific for CNS myelin (324, 325). MOG was further characterized by immunological methods, immunohistochemistry, and Western blot, using a mouse monoclonal antibody against glycoproteins of rat cerebellum (337). Both M2 and MOG migrate at the 52- to 54-kDa and 26- to 28-kDa levels on SDS gels. The purified protein is a minor protein of myelin of 25 kDa with some glycosylation resulting in molecular mass 26-28 kDa that can form dimers of 52-54 kDa (9, 54). MOG is only present in mammalian species (54) and is highly conserved between species. In humans, MOG expresses the L2/HNK1 epitope (86). The NH2-terminal, extracellular domain of MOG has characteristics of an immunoglobulin variable domain and is 46% identical to the NH2 terminus of bovine butyrophilin (BT) expressed in the mammary gland, and chick histocompatibility BG antigens (212, 461). These proteins form a subset of the immunoglobulin superfamily. They colocalize to the human major histocompatibility complex (MHC) locus, on chromosome 6 (6p21.3-p22) in the human, and on chromosome 17 in the mouse (461). In both species, the MOG gene is localized at the distal end of the MHC class Ib region (460). The mouse and human MOG genes have been cloned and sequenced (130, 255, 459, 525). The mouse and the human MOG gene are 12.5 and 19 kb long, respectively. There are eight exons and at least six transcripts generated by alternative splicing in the human (459). MOG protein is mostly located on the outermost lamellae of compact myelin sheaths in the CNS (79). The topology of MOG indicates that there may be only one transmembrane domain (138, 316) as other members of the immunoglobulin superfamily. MOG is located on the plasma membrane of the oligodendrocyte, especially on oligodendrocyte processes, and on the outermost lamellae of myelin sheaths (79). It is a surface marker of oligodendrocyte maturation (54, 119, 461, 552). Its presence correlates with late stages of maturation, possibly restricted to the myelinating oligodendrocytes, as shown using the CG4 cell line (570). At present, MOG is the only CNS protein that can induce both a T cell-mediated inflammatory immune reaction and a demyelinating antibody-mediated response in an animal model of demyelinating diseases, the experimental autoimmune encephalomyelitis (EAE) (see sect. IVB2).
F) OTHER PROTEINS OF MYELIN. I) Small basic proteins. Myelin-associated oligodendrocyte basic protein. Myelin-associated/oligodendrocyte basic protein (MOBP) is a small highly basic protein that has been recently isolated (678). Three isoforms are generated by alternative splicing. The three corresponding polypeptides are of 8.2, 9.7, and 11.7 kDa. MOBPs are located in the major dense line of myelin (259, 678) where they could play a similar role to MBP in myelin compaction. MOBP has also been described in the mouse, where the abundance of MOBP transcripts is less than PLP but greater than that of the CNP gene (401). The MOBP mRNA is located initially in the cell bodies of the oligodendrocytes and moves distally into the processes when myelination proceeds, as does the MBP mRNA (401). The gene has been mapped to chromosome 9 in the mouse (372), at a region syntenic with the human chromosome 3 (3p22) (258).
P2. P2, a basic protein of 13.5 kDa, has also been found in the CNS (619), although it is mainly a PNS myelin protein. In the CNS, it is present essentially in the spinal cord of the rabbit and the human, but not in the rat and the mouse. The reason for this regional and species variation has not been determined. II) Members of the tetraspan-protein family. Besides PLP in the CNS, PMP22 and Cx32 in the PNS, an increasing number of four-
-helix transmembrane proteins have been found to be associated
with myelin.
Rat myelin and lymphocyte protein. rMAL (r for rat, MAL for
myelin and lymphocyte protein), an homolog of human MAL, a protein expressed in various T cell lines in human, was identified in myelin by
Schaeren-Wiemers et al. (536); it was further
characterized in the mouse (362). On the other hand, the
biochemical properties of a purified protein-lipid complex were
used by Pfeiffer and co-workers (298) to identify
MVP17 ("myelin vesicular protein" of 17 kDa), homologous to rMAL.
Plasmolipin, also a myelin-oligodendrocyte proteolipid protein, was
cloned by Gillen and coll. (220).
Oligodendrocyte-specific protein.
Oligodendrocyte-specific protein (OSP) is a single 22-kDa protein
present in CNS myelin and oligodendrocytes; it is structurally related
to other tetraspan proteins and particularly to PMP-22 found in PNS
myelin, with which it presents 48% amino acid similarity and 21%
identity. The gene for OSP has been localized in the mouse and in
humans on the 3q26.2-26.3 region of chromosome 3. It has recently been shown that OSP is the third most abundant protein in CNS myelin, after
PLP/DM20 and MBP, accounting for ~7% of the protein content (76). The analysis of the OSP-deficient mice indicated
that OSP is a tight junction protein, claudin-11 (408),
which is the mediator of parallel-array tight junction strands in
CNS myelin as in testis (231).
Cx32. Cx32 has recently been found on some areas of CNS
myelin and corresponding myelinating oligodendrocytes
(140, 141, 318,
332, 539). These data suggest a specialized
role of gap junctions composed of Cx32 along myelinated fibers
belonging to subpopulations of neurons.
Tetraspan-2. Tetraspan-2, a novel rat tetraspan protein in
cells of the oligodendrocyte lineage has recently been identified (55).
III) Other minor proteins. Oligodendrocyte-myelin
glycoprotein. Oligodendrocyte-myelin glycoprotein (OMgp)
is a glycosylated protein first isolated from human myelin. It is
bound to myelin through a glycosyl phosphatidylinositol. Its apparent
molecular mass is 120 kDa. Its oligosaccharidic moiety bears also the
HNK-1 epitope (388). The gene contains only two exons and
is located in the human on chromosome 17 q11-12 band. Interestingly,
the OMgp gene is located in the intronic site of the gene of type 1 neurofibromatosis (641). The gene has also been identified in the mouse and is highly conserved. OMgp location in myelin is
limited to the paranodal areas. Recently, it has been shown in the
mouse CNS that OMgp is not confined to oligodendrocytes and myelin but
is also expressed on the plasma membrane of the neuronal perikarya and
processes (243).
Myelin/oligodendrocyte specific protein.
Myelin/oligodendrocyte specific protein (MOSP) is a 48-kDa protein
identified with a monoclonal antibody (165). It is located
on the extracellular surface of oligodendrocytes and myelin.
RIP antigen. RIP antigen (see sect.
IIB) labels both oligodendrocyte processes and
myelin sheath (44, 199). Two bands of 23 and
160 kDa have been found by Western blot, the nature of which have not
been elucidated.
NI-35/250 proteins. NI-35/250 proteins are
membrane-bound proteins highly enriched in mammalian CNS myelin and
oligodendrocytes, but minor in PNS myelin (105) (see sect.
IIB2). Their role in axonal growth inhibition
conditions has been well documented (see sect.
IIIG3C). The cDNA encoding the
bovine NI-220 inhibitor has been recently characterized
(578); this will allow an accurate analysis of the
specific functions of this myelin inhibitory molecule during
neurogenesis as well as in pathophysiological conditions.
Nevertheless, as pointed out by Colman et al. (123), there
are still today a great number of unidentified myelin proteins.
G) OLIGODENDROCYTE/MYELIN ENZYMES. UDP-galactose:ceramide galactosyltransferase (CGT), which catalyzes the transfer of galactose to ceramide to form galactosylceramide, has been found in the myelin fraction. The human gene encoding CGT has five exons distributed over >40 kb; it has been cloned and assigned to human chromosome 4, band q26 (69), and is highly conserved during evolution (70). Expression of CGT transcripts in brain is time regulated and parallels that of MBP (544). In situ hybridization has shown that in cerebrum and cerebellum, CGT is restricted to the oligodendrocyte-containing cell layers that also express MBP (544). However, CGT is also weakly expressed in some subtypes of neurons in the adult CNS (537).
Surprisingly, in CGT-knock-out (KO) mice (71, 118), ultrastructure of myelin is apparently normal, except for slightly thinner sheaths in some regions of the CNS. Glucocerebroside, previously not identified in myelin, is present in these galactocerebroside- and sulfogalactosylceramide-deficient mice. However, the apparent normal structure is associated with impaired insulator function, as shown by a block of saltatory conduction, especially in the CNS; severe generalized tremor and ataxia develop with age with extensive vacuolization of the ventral region of the spinal cord, indicating that galactosylceramide and sulfatides play an indispensable role in the insulator function of myelin and its stability. The CGT-KO mice generally die at the end of the myelination period. Recently, using electron microscopic techniques, specific ultrastructural myelin abnormalities in the CNS that are consistent with the electrophysiological deficits were demonstrated (163). These abnormalities include altered nodal lengths, an abundance of heminodes, an absence of transverse bands, and the presence of reversed lateral loops. In contrast to the CNS, no ultrastructural abnormalities and only modest electrophysiological deficits were observed in the PNS. Taken together, these data indicate that GalC and sulfatide are essential in proper CNS node and paranode formation and that these lipids are important in ensuring proper axon-oligodendrocyte interactions (163; reviewed in Ref. 468). Many enzyme activities have been found when myelin is isolated by ultracentrifugation (reviewed in Ref. 425): neuraminidase, cholesterol ester hydrolase, phospholipid synthesizing enzymes and catabolizing enzymes, phosphoinositide metabolizing enzymes, proteases, protein kinases, and phosphatases. Recently, neutral sphingomyelinase activity has also been found in myelin, which is stimulated by tumor necrosis factor-
(110).
3. Differences in lipid and protein composition between CNS and PNS
Except for ganglioside GM4, the specific galactolipids of CNS myelin are present in peripheral nerve. Thus leukodystrophies involving the degradation of these sphingolipids such as Krabbe disease, adrenoleukodystrophy, and metachromatic leukodystrophy affect also the peripheral nerve. On the other hand, some glycolipids such as sulfated glucuronyl paragloboside and its derivatives are specific of peripheral nerve myelin (116).
Several major CNS myelin proteins are also present in the peripheral nerve (Fig. 5), generally in smaller quantities, although their function may not be identical.
MBP is present in peripheral nerve myelin, but probably does not play a major role in myelin compaction, as the major dense line of PNS myelin is not affected in the shiverer mutant mouse which is devoid of MBP (302). Moreover, P0 and MBP can play interchangeable roles during the process of myelin formation as shown from the work on P0 knock-out and P0/MBP double knock-outs (363).
The PLP mRNA and protein have been identified in Schwann cells (482). In the sciatic nerve, DM-20 (messengers as well as protein) is present at a much higher level than PLP (458), and both are present in the myelin membrane (2). In the same context, it has recently been shown in humans that PLP/DM-20 protein is necessary in peripheral as well as central myelin, since patients with Pelizaeus-Merzbacher disease caused by absence of PLP gene expression (due to a premature stop codon) also present an associated peripheral neuropathy (209). In contrast, PLP null mice do not present any peripheral defect (235).
MAG is a very minor component of PNS myelin, in which it represents 0.1% total proteins. In rodents, L-MAG is the major isoform during development and declines in the adult CNS myelin, whereas S-MAG is the predominant isoform during development as in the adult PNS myelin (448). In contrast to rodents, the L-MAG splice variant predominates in adult human brain while, like in rodents, S-MAG transcripts are most abundant in peripheral nerve. In contrast to the CNS where MAG is confined to the periaxonal region of the myelin sheath (622), in the adult rat PNS, MAG present a large distribution in myelin internodes and is enriched in paranodal loops, Schmidt-Lanterman incisures, and inner as outer mesaxon membranes (622; see for review Ref. 384).
PMP 22, a peripheral nerve myelin protein, plays an important role in Schwann cell metabolism and PNS myelin compaction (reviewed in Ref. 418); its mRNA are also found in some categories of motoneurons in the CNS (446), even at embryonic stages (445).
Cx32 is not a typical PNS myelin component since it is widely expressed in the organism. Nevertheless, it seems to have a special role in relation to myelin formation and/or maintenance in PNS, as recently shown by the deleterious effect of mutations of Cx32 leading to Charcot-Marie-Tooth neuropathies (46). Recently, Cx32 has also been found in oligodendrocytes of rat brain together with Cx45 (318). Expression in oligodendrocytes of another type of connexin may prevent dysmyelinating effects of Cx32 mutations in the CNS of Charcot-Marie-Tooth X type patients.
P2 protein is a myelin-specific protein of peripheral nerve, although it is found in some areas of the CNS (see sect. IIIC2). It has a molecular mass of 13.5 kDa and contains a high percentage of basic amino acids. P2 is a true fatty acid-binding protein isoform (543).
4. Relations between oligodendrocyte/myelin proteins and the immune system
Recent works have shown that several oligodendrocyte/myelin protein genes are expressed in the immune system.
In humans, Northern blot analysis reveal that Golli-MBP transcripts are also expressed in fetal thymus, spleen, and human B-cell and macrophage cell lines, clearly linking the expressions of genes coding for an encephalitogenic protein to cells and tissues of the immune system (98, 237, 694). Some Golli-MBP proteins have been found expressed in the embryo (365, 421) and have also been found expressed in the thymus (473), in the thymic macrophages. Recently, Kalwy et al. (290) have found that a 25-kDa band, composed at least of four proteins, is present in brain, thymus, and spleen and not in the tissues that do not express the novel MBP transcripts.
PLP transcripts are also expressed in peripheral blood lymphocytes (102), probably by a process of illegitimate transcription, very useful for genetic diagnostic purposes. On the other hand, PLP/DM-20 proteins have also been found in macrophages of the human thymus (473). Thus PLP/DM-20 proteins are expressed in antigen-presenting cells in the human immune system and are not shielded from the immune system behind the blood-brain barrier. These observations have to be interpreted in the context of acquisition of tolerance against encephalitogenic antigens such as PLP and MBP, which may not simply be related to their sequestration from a "naive" immune system (473).
In the rat, an mRNA for CNP has been demonstrated in thymus and in lymphocytes (48). CNP has recently been implicated in the humoral response in MS; indeed, anti-CNP antibodies have been found in large amount in serum and CSF from MS patients, the antibody response being exclusively restricted to CNP1. Both CNP1 and CNP2 isoforms bind the C3 complement fraction, providing a plausible mechanism for opsonization of myelin membrane in the MS brain (647).
There is an amino acid sequence homology between MAG and immunoglobulin-like molecules, especially NCAM (531). The immunoglobulin gene family is a family of proteins that shares a common extracellular subunit termed the immunoglobulin homology unit. Among the members of this superfamily expressed in the nervous system are L1, NCAM, P0, MOG, and CD22. MAG most closely resembles the leukocyte adhesion molecule CD22, which is a sialic acid binding protein (557).
The antibody HNK1 has been used to identify a subpopulation of human lymphocytes with natural killer function. Thirty percent of all MAG molecules isolated from mouse brain carry the L2/HNK1 epitope, which is also expressed in a group of NCAM and L1 molecules (466), on glycolipids (paraglobosides) with sulfated glucuronic acid (116), and on other myelin proteins from CNS, such as MOG, OMgp (see sect. IIIC2), or PNS, such as P0 (643) and PMP-22 (569). Thus several myelin proteins share an epitope with cells of the immune system.
The recently shown association of myelin proteins, MOG and CNP, with different elements of the complement cascade (282, 647), may be relevant to connections between the immune system and the nervous system and may have some physiopathological implications in demyelinating disease (587). Also the MOG gene is located in the MHC locus (460, 461) (see sect. IIIC2E).
D. Myelination
Myelination consists of the formation of a membrane with a fixed composition and specific lipid-protein interactions allowing membrane compaction and the formation of the dense and intraperiodic lines of myelin. Therefore, myelination also needs activation of numerous enzymes of lipid metabolism necessary for the synthesis of myelin lipids, of synthesis and transport of specific protein components of myelin or their mRNAs to the oligodendrocyte processes.
1. Steps and timing of myelination
Little is known about the mechanism of myelination or the signals that regulate this complex process. There are sequential steps involving the following: 1) the migration of oligodendrocytes to axons that are to be myelinated, and the fact that axons and not dendrites are recognized; 2) the adhesion of the oligodendrocyte process to the axon; and 3) the spiraling of the process around the axon, with a predetermined number of myelin sheaths and the recognition of the space not to be myelinated, i.e., the nodes of Ranvier.
In the first step, the preoligodendroglial multiprocessed cells settle along the fiber tracts of the future white matter, maintaining the ability to divide. Indeed, mitoses are present in the interfascicular longitudinal glial rows (507). Second, these preoligodendrocytes become immature oligodendrocytes, characterized by the acquisition of specific markers (see sect. IIIC) and ready for myelination.
Myelination occurs caudorostrally in the brain and rostrocaudally in the spinal cord. The sequence of myelination is a strictly reproducible process for a given species. In the mouse, it starts at birth in the spinal cord. In brain, myelination is achieved in almost all regions around 45-60 days postnatally. In humans, the peak of myelin formation occurs during the first year postnatally, although it starts during the second half of fetal life in the spinal cord. It can continue until 20 years of age in some cortical fibers, especially associative areas (677) (Fig. 6). More precise data on the topographical sequence of myelination in the human have been recently obtained using magnetic resonance imaging (MRI) (630).
|
Myelination requires an extraordinary capacity for oligodendrocytes to synthesize membranes at a given time, specific for a species and a region of the CNS, and concerns only certain nerve fibers and tracts (547). The timing of CNS myelination pathways is so precise and characteristic that the age of human fetuses can be determined accurately simply by assessing which pathways have myelinated. These data suggest that a highly localized signaling mechanism regulates the timing of oligodendrocyte differentiation and myelination.
2. Oligodendrocyte and axon interactions related to myelin formation
In vivo, Barres and Raff (30) have shown that proliferation of oligodendrocyte precursor cells depends on electrical activity in ganglion retinal cells. Oligodendrocyte number is also dependent on the number of axons, as has been shown in transgenic mice expressing Bcl2 under the control of a neuron-specific enolase promoter (87). In these mutant mice, the oligodendrocyte cell population is increased due both to the decrease of oligodendrocyte apoptosis and to the increase in the number of axons. Interestingly, it was shown in an early work that sectioning the optic nerve postnatally, a few days after the appearance of mature oligodendrocytes, induces apoptosis in these cells, although astrocytes remain intact (205).
It is well known in vivo that oligodendrocytes myelinate solely axons, although oligodendrocytes are able to form uncompacted myelin or myelin-like figures in the absence of neurons (533, 674). Lubetzki et al. (343) have established long-term dissociated cultures of neurons and oligodendrocytes from mouse embryos that myelinate in culture solely axons after 13-14 days, as shown by the use of specific monoclonal antibodies recognizing differently the somatodendritic domain and axonal neurofilament epitopes.
The signal indicating which axon should be myelinated remains unclear. Studies in the CNS support the idea of a critical diameter for myelination, but individual axons are not myelinated along their entire length simultaneously, indicating that other factors are involved (597) (Fig. 4B). On the other hand, using intracellular dye injections, Butt and Ransom (90) showed that, during the markedly asynchronous development of the whole population, individual oligodendrocytes matured all their processes simultaneously to an equal length. Using MBP immunolabeling, Suzuki and Raisman (596, 597) studied the rat fimbria and found, first, patches of cells of the oligodendrocyte lineage along the axonal tract that finally form unicellular rows. Differentiation of immature oligodendrocytes into myelinating cells occurs in a multifocal mode. Within each cell cluster, a single oligodendrocyte gives rise simultaneously to a complement of varicose myelinating processes. This quantal mode of differentiation of the oligodendrocyte population suggests that over adjacent areas of the fimbria, all the clusters are responding simultaneously to the same overall stimulus but that there exists an internal regulation within each cluster so that only one cell is triggered. Such a highly localized "mosaic-like" pattern of differentiation, and the subsequent asynchronous myelination, could be generated by an interaction between axon maturation and oligodendrocyte differentiation (596, 597) (Fig. 4B). Recently, indirect evidence suggests that, in the rat optic nerve, the timing of oligodendrocytes differentiation and myelination is controlled by the Notch pathway. Whereas the Notch pathway was thought to specifically regulate neuronal development (14), it was also shown that Notch receptors are present on oligodendrocytes and their precursors. Retinal ganglion cells express Jagged 1, a ligand of Notch1 receptor, along their axons (651). Jagged1 is developmentally downregulated in axons of retinal ganglion cells with a time course that parallels myelination, suggesting that Jagged1 signals to Notch1 on surfaces of oligodendrocyte precursors to inhibit their differentiation into oligodendrocytes. The downregulation of Jagged1 expression by retinal ganglion cells correlates well with the onset of myelination in the optic nerve, as well as with the maturation of immature astrocytes. Myelination of axons in a given pathway generally occurs a few days after they reach their target (547), raising the question of whether downregulation of Jagged1 in axons occurs in response to target innervation, subsequently triggering the signal to begin myelination.
The proliferation of oligodendrocyte precursor cells depends in vivo on
electrical activity, as shown in ganglion retinal cells by Barres and
Raff (30). The role of electrical activity in the
myelination process has been suggested by the fact that animals
maintained without light since birth have a retardation in myelination
(242); conversely, premature opening of the eyelids accelerates myelination in optic nerve (603). Demerens et
al. (139) have shown in an in vitro myelination system
using dissociated cultures from embryonic brain, that tetrodotoxin
(TTX) blocks the initiation of myelination.
-Scorpion toxin, which
induces repetitive electrical activity by slowing Na+
channel inactivation, has an opposite effect. This group has shown also
in vivo in the developing optic nerve of mice that the intraocular
injection of TTX inhibits myelination. Different results, possibly
under slightly different experimental conditions, have been observed by
Colello et al. (120) and by Shrager and Novakovic
(561).
One of the important steps for triggering myelination is the oligodendrocyte process extension that favors axonal contacts. Recently, it has been shown that astrocytes induce oligodendrocyte process to align with and adhere to axons, providing a novel role for astrocytes in controlling the onset of myelination (385).
Interestingly, cells of the oligodendrocyte lineage exclusively express a novel form of microtubule-associated proteins (MAP) called MAP 2c localized in the cell body of preoligodendrocyte that may assist in the initiation of process extension (644). There is a developmental pattern of several other MAPs suggesting that during myelination, there is a reorganization of the cytoskeleton of the oligodendrocyte that may interact with the growing myelin membrane. An isoform of neurofascin, comprising the third fibronectin type 3 (FNIII) repeat but lacking the mucinlike domain, is specifically expressed by oligodendrocytes at the onset of myelinogenesis and decreases rapidly once oligodendrocytes have engaged their targeted axons (121). Given its unique transient pattern of expression in oligodendrocytes at the early stages of myelination, this cell adhesion molecule protein may have a role in mediating axon recognition but also signals axonal contact through its links with the actin cytoskeleton. It is of note that later on a different neurofascin isoform (lacking FNIII but comprising the mucinlike domain) is specifically expressed in the axolemma at the node of Ranvier (135). On the other hand, in MAG-null mutant transgenic mice (400), axons may be myelinated several times, indicating that MAG may be involved in the recognition of myelinated axons from the nonmyelinated ones by the oligodendrocyte processes (330).
3. Axon regulation of myelin thickness
The axon probably participates in the regulation of myelin thickness as single oligodendrocytes can myelinate several axons with different diameters; they form thicker myelin along the larger axons (657). This suggests that the axon specifies, in a localized way, the number of myelin lamellae formed by a single oligodendrocyte process. Studies of the female carrier of the jimpy mutation (see sect. IVA1A) exemplify well the plasticity of neuroglial cells and the mechanisms of quantitative production of oligodendrocytes and myelin. Oligodendrocytes have considerable flexibility in the amount of myelin they can make, and a reduction in the number of oligodendrocytes does not necessarily involve a reduction in the amount of myelin (566).
4. Astrocytes and myelination
Outside of providing trophic factors to oligodendrocytes, astrocytes may be important in relation to myelination. Suzuki and Raisman (596, 597) have studied the rat fimbria and found, first, patches of cells of the oligodendrocyte lineage along the axonal tract which finally form unicellular rows in which astrocytes are interspersed singly between stretches of 5-10 continuous oligodendrocytes. Mitosis is present in the interfascicular longitudinal glial rows (507). Radial and longitudinal processes of the oligodendrocytes and the astrocytes are interwoven to form a rectilinear meshwork along which the tract axons run (Fig. 4B). The presence of junctional coupling (see sect. IID) between the glial cells suggest that this glial array constitutes a functional as well as an anatomical unit (597).
An increase in glial fibrillary acidic protein (GFAP) level has
been found in the mouse CNS during the early stages of myelinogenesis (277); whether it is functionally related to
myelinogenesis could not be determined. Recently, mice carrying a null
mutation for GFAP were generated (334). These mice display
abnormal myelination; nonmyelinated axons are numerous in the optic
nerve and spinal cord anterior column; the altered white matter
vascularization, possibly linked to abnormal astrocytic processes, may
be related to the dysmyelination observed. It is of note that the
vimentin-GFAP transition in the rat neuroglia cytoskeleton occurs
at the time of myelination (128). Moreover, transgenic
mice carrying several copies of the human GFAP gene die by the second
postnatal day by a fatal encephalopathy with astrocyte inclusion bodies
similar to the Rosenthal fibers found in Alexander's disease
(75a). Astrocytes in these mice are hypertrophic and
upregulate small heat shock proteins (383). These studies
suggest major links between astrocyte function, myelination, and its
maintenance. Interestingly, these hypotheses are supported by data
obtained in several human demyelinating conditions; e.g., in
Alexander's leukodystrophy, the primary target cell is the astrocyte
whose dysfunctions are characterized by high levels of expression of
the heat shock protein,
-B-crystallin (251,
275). In adrenoleukodystrophy (ALD), the mutated protein, adrenoleukodystrophy protein (ALDP), is expressed in white matter oligodendrocytes, but also in astrocytes and microglial cells everywhere in the brain, suggesting that dysfunction of these cells may
indirectly affect oligodendrocytes early in the disease (16).
5. Difference between PNS and CNS myelinating glial cells and process of myelination
Oligodendrocytes embrace an array of axons while Schwann cells myelinate single axons. In contrast to the CNS node, where there is contact of the axon with the extracellular space (84), the myelinating Schwann cell processes interdigitate over the node. Moreover, the Schwann cell soma is circumferentially covered by a basement membrane. This basal lamina is continuous with that of the adjacent internode; thus the Schwann cell processes and basal lamina cover the PNS node. In fact, whether the Schwann cells myelinate or not, they share a common basal lamina that forms a glial channel along the nerve fiber. PNS myelinated fibers are separated from each other by an extracellular compartment, the endoneurium, whereas the CNS myelinated fibers are in close contact. Interestingly, electron microscopy and immunohistochemistry have shown that rat CNS fibers do not exhibit a strict relation between nodal complexity and fiber size, as in the PNS (56). Furthermore, some of the components of PNS myelin, lipids, and proteins are different (see sect. IIIC3) (Fig. 5).
6. Formation of the node of Ranvier
The internodes are separated along myelinated axons by intervals where the axolemmal membrane is exposed, the node of Ranvier (Figs. 2, 3, 5, and 8). Nodes of Ranvier comprise a membrane specialization (see sect. IIIE) of the axon (Fig. 6) (reviewed in Refs. 253, 655). Premyelinated axons exhibit a low density of sodium channels that appear to be distributed uniformly along the length of the fiber, whereas during maturation of myelinated tracts, sodium channels become segregated into regularly spaced gaps in myelin, i.e., at the nodes of Ranvier, thereby allowing saltatory conduction in myelinated fibers. Moreover, potassium channels are enriched in the paranodal regions where they may contribute to the repolarization and ionic homeostasis. This molecular specialization enables the regeneration of the action potential at the node of Ranvier and is responsible for its unique function. The clustering of sodium channels was first ascribed to the presence of astrocytic processes at the node of Ranvier, since previous studies have demonstrated a close spatial and temporal correlation between astrocyte-axon contact and the appearance of a high density of intramembrane particles (reviewed in Ref. 655). However, it was recently demonstrated, first in the PNS, that the contact with Schwann cells induces clustering of sodium channels along axons of peripheral nerves, in vivo as in vitro (155). In a same way, the remarkable enrichment, i.e., clustering, of voltage-gated sodium channels in the nodal axolemma of myelinated CNS tracts has been shown to be due to signals from the oligodendrocyte, as shown in the optic nerve (293). Ultrastructural studies indicated that the axon begins to differentiate and displays foci of membranes with nodal properties before the onset of myelin compaction (656). Indeed, Kaplan et al. (293) found that clustering of the sodium channel occurs concomitantly as oligodendrocytes wrap axons with insulating myelin sheaths. The induction but not the maintenance of sodium channel clustering along the axons was demonstrated to depend on a protein secreted by oligodendrocytes in coculture with rat retinal ganglion cells. Furthermore, in vivo, mutant md rats (see sect. IVA1A), deficient in oligodendrocytes but not in neurons or astrocytes, develop few axonal sodium channel clusters (293). These data indicate that oligodendrocytes are necessary for clustering of sodium channels in vivo as in vitro. As clusters are regularly spaced even in the absence of direct axon-glial cell contact, with an average intercluster distance similar to that predicted for the Ranvier nodes in vivo, this suggests that there is an intrinsic mechanism, within the axon, that participates in the determination of spacing between nodes (reviewed in Refs. 530, 653). Glia induce ankyrin-G clustering in a pattern identical to that of sodium channel clustering; thus it is likely that cytoskeletal interactions play an important role in the induction and maintenance of sodium channel clusters (312). These data demonstrate that oligodendrocytes are specialized to induce saltatory conduction by inducing clustering of sodium channels and providing myelin insulation, and furthermore by regulation of axonal caliber and other properties (see sect. IIIG) (see discussion in Ref. 293).
E. Biochemical Aspects of Myelin Assembly and of the Node
of Ranvier
1. Specific processing of myelin proteins during synthesis by
oligodendrocytes
Preceding myelination, myelin specific genes are activated.
Immature oligodendrocytes express GalC and CNP and are clearly arborized; later, mature nonmyelinating oligodendrocytes express MBP,
PLP, and MAG (154, 399). Interestingly, in
the postnatal period, the peak of mRNA is probe dependent and not
region dependent for CNP, PLP, and MBP, suggesting a common signal
occurring simultaneously in all areas, regardless of the
caudorostral gradient of myelination in brain (292).
Although these proteins appear in oligodendrocytes regardless of the
presence of neurons, these data as well as others indicate that the
presence of neurons clearly enhances the quantity of myelin specific
proteins being synthesized (358). In oligodendrocytes in
culture, there is a spatial organization of the protein synthetic machinery in granules that may provide a vehicle for transport and
localization of specific mRNAs within the cell (4,
24). A) MBP.
The MBPs are a set of membrane proteins that function to adhere the
cytoplasmic leaflet of the myelin bilayer. Because their biophysical
properties may render MBP nonspecifically adhesive to any organelle
membranes, oligodendrocytes have developed a mechanism for the
transport of MBP mRNAs selectively to intracellular regions where MBP
proteins will be necessary for myelin compaction to occur
(123). Indeed, in situ hybridization has shown that MBP
mRNAs are first localized in the cytoplasm of oligodendrocytes, even
before myelination (589), and then dispersed in the
oligodendrocyte processes at the beginning of myelination; the myelin
sheaths stain for MBP mRNAs because the messages are in part
transported within the cytoplasmic channels that surround and
infiltrate the sheaths. Spatial segregation of MBP messages begins to
function only after oligodendrocytes have differentiated into fully
myelinating cells, cellular extensions being in place first, before the
MBP transport machinery is activated (636). Before that
period, MBP is expressed throughout the cytoplasm and surprisingly in
the nucleus. All the isoforms do not behave in the same way when
individually expressed, as has been shown transfecting individual
isoform cDNA in the shiverer oligodendrocyte devoid of functional MBP
(6); the 14- and 18.5-kDa forms have a plasma membrane
distribution in the oligodendrocyte, whereas the exon 2-containing 17- and 21.5-kDa MBPs (MBP exII) distribute diffusely through the cytoplasm and accumulate in the nuclei. The transport of MBP exII is an active
process that may suggest that these karyophilic MBPs are involved in a
regulatory function in implementing the myelination program
(447). The 14-kDa isoform that lacks exon 2 is sufficient to create myelin compaction in the CNS, as transgenic mice expressing only this form of MBP in the shiverer mutant (see sect.
IVA1A) have a compacted myelin
(299). Once the cytoplasmic extensions form, the exon 2 lacking MBPs are upregulated, and the mRNA movement mechanism is
activated. MBP is exceptionally present in the nuclei of apparently
mature oligodendrocytes (247) that may be remodeling or
remyelinating some of the myelin sheaths that they support (447). Cytoskeletal elements may be involved in dynamic
process of MBP mRNA transport (4). B) PLP.
There may be a vesicular transport of myelin PLP and sulfogalactosyl
ceramides (78). Studies of DM-20/PLP proteins show that
specific sequences of PLP gene and protein are necessary for correct
trafficking and that abnormal proteins are readily eliminated in the
endoplasmic reticulum (230). Abnormal level of misfolded
PLP proteins as seen in Pelizaeus-Merzbacher disease represent a
tremendous burden to the oligodendrocyte, as PLP mRNA represents 10%
total mRNA of the oligodendrocyte at the time of myelination (see sect.
IVA2).
2. Lipid enzyme activation
The peak of myelination is extremely precise in rat and mouse, at 18 days postnatal. The enzyme activities, which peak during that particular period, appear to be related to the myelination process. This is the case for enzymes related to lipid metabolism. Mutations in the mouse affecting the myelination process show massive reductions in these enzyme activities, in relation to the degree of reduction in myelin. These aspects were described in the 1980s (38). PAPS cerebroside-sulfotransferase, an enzyme required for the synthesis of sulfated galactosylceramide, is inducible in CNS in relation to myelination; its activity is constitutively stable in the kidney, even in dysmyelinated mutants such as jimpy (534). CGT activity also increases rapidly during myelination and decreases markedly when myelination ceases. Expression of CGT mRNA (544) correlates clearly with myelination and agrees with previously determined enzyme activities. Very-long-chain fatty acid (VLCFA) biosynthesis (C24) follows the same pattern in the endoplasmic reticulum; interestingly, although mitochondria synthesize also VLCFA, there does not seem to be a relation to myelination, in contrast to VLCFA synthesized in the microsomal fraction that comprises the endoplasmic reticulum (72). HMG-CoA reductase seems also to be activated in oligodendrocytes at the time of myelination, as has been shown using a transgenic mouse expressing the promoter of this enzyme colinked to the marker chloramphenicol acetyltransferase (320). Peroxisomal enzymes involved in plasmalogen biosynthesis are necessary for myelination; the key enzymes are acyl CoA:dihydroxyacetone phosphate acetyltransferase (DHAP-AT) and alkyl dihydroxyacetone phosphate (alkyl DHAP) synthase (545).
3. Myelin assembly by oligodendrocytes: formation of lipid and protein complexes
It has been proposed that proteins destined for the apical surface of polarized epithelial cells cocluster with glycolipid-rich microdomains during sorting and transport from the trans-Golgi network. Glycolipid-rich oligodendrocytes may adopt this mechanism for myelinogenesis. Protein-lipid complexes from oligodendrocytes and myelin were isolated utilizing detergent insolubility and two-dimensional gel electrophoresis, leading to the identification of a developmentally regulated protein, myelin vesicular protein of 17 kDa (MVP17), highly homologous to human T-cell MAL protein. (298). In relation to the processes of myelin deposition and assembly, it is interesting to note that the family of MAL-related proteins (see sect. IIIC2F), highly expressed in myelinating glial cells (362), present a lipidlike behavior and are components of detergent-insoluble myelin membranes (450). Furthermore, it was shown that rMAL, found to interact with glycosphingolipids, may lead to the formation and maintenance of stable protein-lipid microdomains in myelin and apical epithelial membranes, thus contributing to specific properties of these highly specialized plasma membranes (195). In the same context, it was discovered that, in contrast to oligodendrocyte progenitors, in maturing oligodendrocytes and myelin, GPI-anchored proteins form a complex with glycosphingolipids and cholesterol, suggesting sorting of this macromolecular complex to myelin (314). The recently described presence of caveolae, which are membrane microdomains containing high levels of GPI-anchored proteins, in oligodendrocytes as in astrocytes (93) may be relevant to the mechanisms of myelin assembly.
4. Molecular organization of the myelin membrane
Electron microscopy data visualize myelin as a series of alternating dark and less dark lines that should be protein layers, separated by unstained zones constituted by lipid hydrocarbon chains (404) (Fig. 5). In fact, the currently accepted view is that there are integral membrane proteins embedded in the lipid bilayer, although there are proteins attached to one surface or the other by weaker links. Individual components form macromolecular complexes with themselves and each other (538). Such an orderly structure could require a precise stoichiometric relationship of the individual components so that either increasing or decreasing the amount of one component could perturb the entire structure and therefore perturb myelination (see sect. IV).
The lipid compositions of the two halves of the lipid bilayer of biological membranes, including myelin, are strikingly different. The glycolipids, as in other membranes, are preferentially located at the extracellular surfaces, in the intraperiodic line. Almost all the lipid molecules that have choline in their head group (phosphatidylcholine and sphingomyelin) are in the outer half of the lipid bilayer, i.e., as the glycolipids. Almost all the phospholipid molecules that contain a terminal primary amino group (e.g., phosphatidylethanolamine, mainly plasmalogens, and phosphatidylserine) are in the inner half; they are negatively charged. This lipid asymmetry is functionally important in the compaction mechanisms of the mature myelin.
PLP and MBP are the most abundant proteins of myelin. Thus it is widely believed that the two proteins play complementary roles in myelin and are required for intra- and extracellular myelin compaction; this has been well demonstrated in the double mutant mice for PLP and MBP, viable and fertile (305, 591), which display an absence of fusion at the major dense line (typical of the homozygous shiverer mice) and a more compacted structure at the intraperiodic lines that appears as a single fused line (as in PLP mutants). PLP is an integral membrane protein with four transmembrane domains; in mutant mice that lack expression of the PLP gene, intraperiodic lines have reduced physical stability, indicating that PLP may form a stabilizing membrane junction similar to a zipper (305). It is widely accepted that the positively charged cytoplasmic proteins such as MBP in the CNS, or the cytoplasmic domain of P0 in the PNS, are responsible for compaction at the major dense line of myelin, and most likely as a result of an interaction with the acidic lipids, such as phosphatidylserine, located in the opposing membrane (113, 147).
5. Molecular organization of the node of Ranvier
Details of the molecular organization of the node of Ranvier have recently started to emerge (see Fig. 7). Spacious nodal gaps present in thick spinal axons are labeled by antibodies against HNK-1, chondroitin sulfate, and tenascin, but tiny node gaps along thin callosal axons are not labeled (56). The filamentous network subjacent to the nodal membrane contains the cytoskeletal proteins spectrin and isoforms of ankyrin (135, 322). Among the proteins binding to ankyrin at the node are the sodium channels, the Na+-K+-ATPase, specific forms of the NCAMs and the neurofascin isoform containing mucin and a third fibronectin III domain (135). Each node is flanked by paranodal regions where the axolemma is in close interaction with the membrane of the terminal loops of myelinating glial cells. Potassium-dependent channels are mainly localized in the axolemma at the level of these paranodal loops (57). Paranodin, a prominent 180-kDa transmembrane neuronal glycoprotein, was purified and cloned from adult rat brain and found in axonal membranes at their junction with myelinating glial cells, in paranodes of central and peripheral nerve fibers (382). Simultaneously, other authors isolated the same protein they called Caspr (171). Paranodin/Caspr may be a critical component of the macromolecular complex involved in the tight interactions between axons and the myelinating glial cells at the level of the paranodal region (163, 468). The glial ligand of Paranodin/Caspr has yet to be determined.
|
F. Factors Influencing Glial Cell Maturation Leading to Myelin Formation
The influence of growth factors on oligodendrocytes at different stages of their differentiation has been reported previously (see sect. IIC8).
1. Thyroid hormone
Hyperthyroidism accelerates the myelination process, and hypothyroidism decreases it (648). Nevertheless, at an advanced age, hyperthyroid animals have a myelin deficit. The differentiation of oligodendrocytes as well as the degree of myelin synthesis are increased by thyroid hormone (7). Hypothyroidism coordinately and transiently affects myelin protein gene expression in most brain regions during postnatal development (269). In culture, oligodendrocyte progenitors stop dividing and differentiate in the presence of 3,3',5-triiodothyronine (T3); although this process may occur even in the absence of this signal, thyroid hormone may be involved in regulating the timing of differentiation of this cell population (29). T3 promotes also morphological and functional maturation of postmitotic oligodendrocytes, thus the number of mature oligodendrocytes (19, 269).
The effect of T3 is mediated by the interaction of this
hormone with specific receptor isoforms (TR), three of which, only, are
functional,
1,
1, and
2.
Progenitor cells express
1, whereas mature
oligodendrocytes express
1 and
1,
although
2 may also be expressed on progenitor cells
(29). Myelin gene expression correlates with a striking
increase in
1-expression in the developing brain
(19). The expression of different receptors in relation to
the maturation state of the oligodendrocytes may mean that these
effects are independently regulated by thyroid hormone.
TR are ligand-activated transcription factors that modulate the expression of certain target genes in a developmental and tissue-specific manner. These specificities are determined by the tissue distribution of the TR isoforms, the structure of the thyroid hormone responsive element (TRE) bound by the receptor and heterodimerization partners such as retinoic acid receptor (64). Addition of glucocorticoids, thyroid hormone, or retinoic acid all increase galactocerebroside synthesis in oligodendroglia (465) and sulfolipid biosynthesis (51). Among the known target genes are MBP (182), PLP, MAG, and CNP (269).
Progress has been made in identifying some of the molecules involved in
the transcriptional regulation of myelination (265). Huo
et al. (267) have identified a nuclear protein that binds to TR isoform
1, which forms a specific complex on the
MBP-TRE. The expression of this brain nuclear factor is restricted
to the brain perinatal period when myelination is sensitive to
T3.
2. Other hormones
A) GROWTH HORMONE.
Growth hormone has an effect on proliferation and maturation of both
glial and neuronal cells (430). B) NEUROSTEROIDS.
Baulieu and co-workers (287) have shown that steroids
can be synthesized in the CNS and PNS. In the CNS, pregnenolone,
progesterone, and their sulfated metabolites are synthesized by
oligodendrocytes (287) and activate the synthesis of
specific proteins. 3. Other factors
Factors that may act within the nucleus at early stages of the
myelination program in the upregulation of transcription for myelinogenesis have been described. The DNA binding protein MyT1 (297), which binds to the promoter of the PLP gene
(265), may play a role in specification toward the glial
lineage; as do SCIP (402), cerebellum-enriched nuclear
factor 1 (CTF-NF) (274), and TR transcription factor
(182). Both CTF-NF and TR activate the MBP promoter.
The karyophilic MBPs, containing exon 2, once in the nucleus, may also
act as regulatory factors in myelination (447). G. Roles of Myelin
1. Saltatory conduction of nerve impulses
As described in section IIIB, a myelinated
fiber appears as myelinated membrane segments, termed internodes,
separated by regions of unsheathed (naked) nerve membrane (Figs. 1, 2,
3, 5, and 8). It is this disposition by segments that induces the major characteristic of the so-called "saltatory conduction" of nerve impulses in myelinated tracts. As myelin is found almost exclusively in
vertebrates, it can be considered as an essential element in the
evolution of higher nervous functions (559). The extremely dense clustering of sodium channels in the node of
Ranvier accounts for the specialization of this region of the axolemma
(see sect. IIID6). In myelinated fibers, at the
nodes of Ranvier, the sites where impulses are generated, the sodium channels are clustered at a density of some 120,000/µm2,
the highest density in the nervous system. The myelin sheath has a high
resistance and low capacitance that makes the current tend to flow down
the fiber to the next node rather than leak back across the membrane.
Therefore, the impulse may jump from node to node, and this form of
propagation is therefore called saltatory conduction (Fig.
8) (559).
2. Role of myelin on axonal development and maintenance
A) DEVELOPMENT AND REGULATION OF AXONAL CALIBER.
As early as 1951, Rushton (527) noted that the conduction
velocity in a myelinated fiber is linearly correlated with diameter and
proposed that, at a given diameter, there is a particular myelin
thickness that maximizes conduction velocity. However, today it is
still not yet fully understood how the mechanisms of morphogenesis of
the myelinated nerve fibers are regulated. Although it was first
proposed that myelination occurs only on fibers with a minimum
diameter, it has been actually shown that signals from the myelinating
glial cell, independent of myelin formation, are sufficient to induce
full axon growth, primarily by triggering local accumulation and
organization of the neurofilament network, as this can still occur in
dysmyelinated mutant mice (532). Therefore,
myelinating cells and myelin itself are important actors in the
internal organization of the axonal structure and the subsequent growth
of axon caliber (669; reviewed in Ref. 653). The final axonal caliber
is influenced by other factors, such as the neurofilaments themselves. B) MAINTENANCE AND SURVIVAL OF AXONS.
In absence of the PLP/DM-20 proteins, in the PLP-deficient mice
which make a near-normal myelin sheath (305) (see
sect. IIIG2B), morphological
abnormalities are surprisingly observed in axons, i.e., axonal
swellings and degeneration, and particularly by axonal "spheroids"
(235). The axonal spheroids contain numerous membranous bodies and mitochondria and are often located at the distal paranode, suggesting an impairment of axonal transport; these spheroids were
detected predominantly in regions of myelinated small-caliber nerve
fibers and were never observed in unmyelinated fibers. To demonstrate
that the absence of PLP and DM-20 was fully responsible of these axonal
abnormalities, PLP null mice were interbred with transgenic mice
expressing an autosomal PLP transgene (500): full
complementation was observed in offspring that were totally rescued
from the defect. To distinguish the ability of each isoform, PLP and
DM-20, to rescue a normal phenotype, PLP null mice were crossed with
the PLP or DM-20 cDNA-based transgenes (416); the presence of one or the other of these isoforms allowed a
near-complete restoration of a normal phenotype for the PLP, and at
a lesser level for the DM-20 transgene, suggesting a possible similar
role for the two isoforms in maintenance of axonal integrity. It is of
note that PLP abnormal overexpression in transgenic lines
(288, 500) causes significant axonal
degeneration with predilection for specific tracts (13)
and is toxic for myelinating oligodendrocytes and leads to different
degrees of dysmyelination or demyelination. Altogether, these data
demonstrate a pivotal role of glial-axonal communication for PLP in
maintenance of axonal integrity and function, although the molecular
mechanisms involved have yet to be determined. 3. Myelin and inhibition of axonal growth and regeneration
A major problem following mammalian CNS injury, and particularly
spinal cord traumatic insult in humans, is that lesioned axons do not
regenerate. It has been suggested that myelin and oligodendrocytes
(reviewed in Refs. 20, 61, 188, 222, 485, 546), as well as reactive
astrocytes and the molecules they secrete (reviewed in Ref. 512),
participate in inhibition of regeneration within the adult mammalian CNS. A) INHIBITORY PROPERTIES OF MYELIN FOR LATE-DEVELOPING AXONAL
TRACTS.
Oligodendrocytes and myelin may play an inhibitory role on neurite
growth, e.g., for late-developing tracts and inhibition of
plasticity in the adult brain. Because myelin formation starts at
different times in different regions and tracts of the CNS, in a
so-called "mosaic-like pattern," the inhibitory property of
myelin could serve boundary and guidance functions for late-growing fiber tracts. Oligodendrocyte-associated neurite growth inhibitors could channel late-growing CNS tracts by forming boundaries and by
exerting a "guard-rail" function (548). The different
candidate proteins for a major role in inhibition of neurite growth are described below. B) MYELIN INHIBITORY ROLES IN CNS REGENERATION.
The limited potential for axonal regrowth and regeneration of nerve
fibers in the adult CNS from higher vertebrates contrasts with recovery
that happens in the PNS of these species. It was long recognized that
the permissiveness of the environment was a determinant for CNS axonal
repair (496, 604). Later, Aguayo and
collaborators demonstrated that most CNS neurons are able to regenerate
a lesioned axon in the environment of a peripheral nerve transplant
(508), whereas peripheral nerves fail to regenerate in a
CNS glia environment (132). Recently, the use of multiple grafts of peripheral nerve tissue, bridging the lesion site and the
gray matter, was shown to permit extensive CNS axon growth and to
restore partial function to a completely transected spinal cord
(reviewed in Refs. 183, 438). Investigations of the biological mechanisms that could be responsible for this difference in neuronal regeneration between CNS and PNS tissue led to a new concept, that of a
neurite growth inhibitor (549). Central myelin and differentiated oligodendrocytes in the adult CNS were therefore recognized as responsible for inhibition of neurite outgrowth and shown
to cause growth-cone collapse in culture (21). C) MYELIN-ASSOCIATED INHIBITORY PROTEINS, NI-35 AND NI-250.
Two related protein fractions of 35 and 250 kDa (NI-35 and NI-250) were
found to contain the myelin-associated inhibitory activity. NI-35
and NI-250 are membrane-bound proteins highly enriched in mammalian
CNS myelin and oligodendrocytes, but minor in PNS myelin
(105). A monoclonal antibody (MAb IN-1) has been generated
and shown in vitro to have neutralizing properties against the
inhibitory activity of oligodendrocytes and myelin (106). In vivo, application of MAb IN-1, after the complete bilateral transection of the corticospinal tracts in spinal cord, allowed some
regeneration on a short length of a small percentage of cortical tract
axons (542). On the other hand, in a recent work
(607), IN-1 treatment after unilateral transection of the
corticospinal tract in the brain stem, above the pyramidal
decussassion, was shown to induce a significant collateral sprouting of
both intact and lesioned corticospinal and corticobulbar nerve fibers,
above and below the lesion site. This remarkable structural plasticity was associated with a functional recovery of forelimb function contralateral to the lesion (607). A similar form of
recovery, through sprouting in gray matter rather than through severed
axon regrowth in white matter, has been described in another lesion model (reviewed in Ref. 438). D) MAG, ANOTHER INHIBITORY MYELIN PROTEIN.
A well-characterized myelin protein produced by oligodendrocytes
but also by Schwann cells (albeit at 10-fold less level), MAG (see
sect. IIIC2), has been recently identified as a
major CNS inhibitory protein (376, 414), for
a number of different types of neurons. MAG is an inhibitory rather
than a nonpermissive protein; MAG is able to cause growth cone collapse
in vitro (333), and soluble extracellular domain of MAG
(dMAG), released in abundance from myelin and found in vivo
(398, 583), has been shown to inhibit axonal
regeneration in vitro (602; reviewed in Ref. 485). H. Plasticity of the Oligodendrocyte Lineage: Demyelination
and Remyelination
1. Fate of glial precursors and progenitors in the adult
CNS
In the adult, the subventricular germinative zone persists around
the brain lateral ventricles, along the striatum. These cells, although
mostly quiescent, can be amplified in vitro in the presence of
epidermal growth factor (EGF) and give rise to neurons, and to
astrocytes and oligodendrocytes, when grown in the presence of FGF2,
LIF or BDNF (339, 503), or T3
(281). The intrathecal infusion of EGF and FGF-2 activates
the mitotic and migratory potential of these cells (126).
CNS stem cells are also present in the adult spinal cord and
ventricular neuroaxis (661). Recently, a major glial cell
population, suggested to be adult oligodendrocyte progenitors, has been
described in the CNS; these cells can be identified by the expression
of two cell surface molecules, the NG2 proteoglycan and the PDGF- Recently, mouse oligodendroglial cells derived from totipotent
embryonic stem cells were transplanted in a myelin-deficient rat
model; these oligodendrocytes were able to interact with host neurons
and efficiently myelinate axons in brain and spinal cord of the mutant
animal, suggesting that similar transplantations might help patients
with Pelizaeus-Merzbacher disease or other demyelinating conditions
(80). 2. Remyelination capacities of cells of the oligodendrocyte
lineage
Plasticity of oligodendrocytes is particularly important for
remyelination, mainly after lesions of demyelination. A number of
genetic and/or inflammatory diseases may affect myelin formation (dysmyelinating diseases) or its maintenance (demyelinating diseases) (see sect. IV, A and B). The
potential of glial cells to support spontaneous remyelination, as well
as cellular or genetic therapeutic approaches aimed at myelin repair
and improvement of conduction block in lesioned myelinated tracts, has
focussed a number of studies. Very little is known about spontaneous remyelination, as only a few
early studies deal with the subject of myelin turnover. It appears that
under normal conditions, the turnover of myelin is very slow and that
each component has a different turnover rate, possibly different
according to its location in myelin and in the myelinating cell
(404). Spontaneous remyelination was observed for the first time by Bunge et
al. (83), after an experimental lesion in the cat spinal
cord. It has also been reported in other experimental models (347, 349). The ways to stimulate the
endogenous oligodendrocyte population to expand and regenerate myelin
may be an important strategy. For the moment, the growth factor
responses have not as yet been fully determined in humans, and no
myelinating cell line has as yet been obtained analogous to the CG4
cell line isolated from rodents (340). So far, no studies
have identified growth factor stimulation of division in the human
oligodendrocyte lineage. Studies determining the effect of growth
factors on remyelinating capacities in vivo are few (379,
675). In immune-mediated demyelination, related to
Theiler's virus infection, monoclonal antibodies of natural origin
(266) may stimulate remyelination through a mechanism as
yet unknown. Interestingly, inflammation seems to enhance migration of
oligodendrocyte and thus remyelination in EAE (615). Interestingly, in chronic MS (see sect. IVB1)
lesions, oligodendrocyte precursor cells are present (671,
672); however, they appear to be quiescent, not expressing
a nuclear proliferation antigen. In MS, remyelination also occurs, but
it is incomplete and poorly sustained (477,
491). After a demyelinating lesion, remyelinated myelin
never regains its normal thickness, and the normal linear relationship
between axon and sheath thickness is also never regained
(349). It is not clear whether the mechanism of
remyelination is identical to myelination. At least in part, it could
be similar to mechanisms at work in myelinogenesis; for example, it
appears that MBP transcripts containing exon 2 are widely expressed in
remyelinating oligodendrocytes in vivo and in vitro (101,
221). The molecular basis of the remyelination process has
not been studied extensively. The origin and identity of endogenous cells that affect remyelination
is still an unsolved issue. There are immature cycling cells endogenous
to white matter, which respond to experimental demyelination, by
differentiating into myelinating oligodendrocytes (216).
Proliferation of mature oligodendrocytes can also occur after a trauma
of the nervous system (348) and in an experimental model
of stab wound (8). However, no one has demonstrated that mature oligodendrocytes become involved in remyelination. Glial transplantation techniques have proven to be a useful tool for
the study of glial cell biology, as it is possible to label the
transplanted cells and follow them throughout the whole myelination
(321) and remyelination process. It is also possible to
determine the amount of myelin being formed by transplanting myelin-producing cells into the CNS of myelin-deficient
mutants. With the use of such techniques, it is also possible to
determine the influence of the in vivo environment on these capacities. The experimental conditions, myelin-deficient models, markers for
transplanted cells, and use of myelinating cell lines have been
extensively reviewed recently (156). Even adult brain
retains the potential to generate oligodendrocyte progenitors with
extensive myelination capacity (696). The potentiality for
remyelination can be exerted by many types of cells of the
oligodendrocyte lineage. Cells present in the SVZ could be able to
migrate toward a demyelinating lesion and to differentiate into
myelinating oligodendrocytes (420). It appears that
migration is reduced or very scarce under normal conditions
(196, 197), except in genetic dysmyelinating mutants (321). There seem to be signals in a demyelinated
lesion that attract myelinating cells (638). PSA-NCAM,
which is a migration-supporting signal, has been observed in areas
of demyelination (420). Inflammation may favor migration
(615). Analogous results have not been obtained by other
groups (278) in the rat without X-irradiation
(197). It is possible to enhance the proliferating
capacities of progenitor cells to be transplanted by producing
oligospheres (18, 415), or using the
oligodendrocyte progenitor cell line, i.e., the CG4 cells
(612). Nevertheless, up to now, no extensive remyelination has been obtained experimentally, although, in some cases, a functional electrophysiological recovery has been obtained (627). Remyelination by transplantation of potentially myelinating cells may
be a therapeutic approach. Although oligodendrocytes derived from fetal
human white matter implanted into the dysmyelinating rodent CNS can
synthesize myelin even after prolonged cryopreservation (554), harvesting aborted fetuses on a therapeutic scale
is unlikely to be ethically or socially acceptable (550).
Furthermore, there is a risk of immunological rejection. Thus it could
be envisaged to use tissues from the patient itself, to obtain donor
cells, such as Schwann cells (17, 260) or
olfactory glia which both can be expanded (273,
494). The ability of a transplanted cell to migrate is
obviously also of great importance in its remyelinating capacity after
a lesion (196, 197). 3. Neuron-glia interactions during demyelination and
remyelination
Recent experimental data show that axonal loss or perturbations
may be more responsible than myelin deficiency for permanent disability
(133). This has recently been observed in an experimental model: mice sensitive to Theiler's virus develop secondary
demyelination. In a transgenic mouse deficient in MHC gene class I,
Theiler's virus demyelination still occurs, but the animal does not
present any functional deficit (515). This may be as a
result of the persistence of sodium channels at the site of the Ranvier
node, implicating possibly MHC class I molecules in the development of
neurological deficits after demyelination. Loss of myelin, even from a single internode, is sufficient to block
conduction. If sufficient axons are affected in this way, severe
symptoms can arise. The loss of insulation along the axon has as
consequence that the action current is no longer focused at the very
excitable nodal membrane. The axon may adapt to its demyelinated state
over several days, by a redistribution of sodium channels. Possibly,
cell contact involving astrocytes may be required to initiate channel
rearrangement and permit restoration of nerve function
(155), although, under these conditions, conduction is
very slow and highly susceptible to external disturbances. Fast
potassium channels are located in the internodal axon membrane; being
unmasked, they may also interfere with conduction in demyelinated axons
(reviewed in Ref. 653).

View larger version (28K):
[in a new window]
Fig. 8.
Mechanisms for spread of the nerve impulse. A: continuous
conduction in an unmyelinated axon. Amplitude scale is in millivolts.
B: discontinuous (saltatory) conduction from node to node in
a myelinated axon. In the diagrams, the impulses are shown in their
spatial extent along the fiber at an instant of time. The extent of the
current is governed by the cable properties of the fiber. [From
Shepherd (559).]
receptor (reviewed in Ref. 426). They could represent a
third type of glial cells in the CNS, with still unknown functions
(reviewed in Ref. 339a).
| |
IV. EXPERIMENTAL AND HUMAN DISEASES OF MYELIN |
|---|
|
|
|---|
A. Genetic Diseases of Myelin
1. Myelin mutants
The recent characterization of a number of mutants and
determination of physical maps for mammalian genomes have greatly
improved our ability to characterize a number of animal models for
human diseases. The term myelin mutants designates animal
mutants in which myelin formation or maintenance is affected. Myelin
mutants are often named according to their phenotypes, e.g., shiverer, rumpshaker, twitcher, etc. They allow not only the identification and
cloning of genes possibly related to human diseases, but also analysis
of myelin development and biology of myelin-forming cells. They are
furthermore essential for the development of therapeutic strategies
useful for human diseases. A) MUTATIONS OF MYELIN STRUCTURAL PROTEINS.
I) PLP. Because they are recessive X-linked diseases,
the PLP mutation disorders are expressed only in males that are
hemizygous (they possess only one allele). Because they are
"mosaic" at the cellular level as a result of the random
inactivation of one of the two X-chromosomes in each cell
(355), heterozygous females present generally with a
wild-type phenotype. This group of mutants contains the higher
number of alleles within and across species. The PLP mutations occur in
different regions of the PLP protein, yet they produce qualitatively
similar phenotypes.
B) MUTATIONS IN A REGULATORY PROTEIN: THE QUAKING MOUSE. The quaking mutation comprises two classes of recessive alleles, with strikingly different phenotypes. Indeed, quaking mutations present pleiotropic effects on myelination and embryogenesis. The original "quaking viable" mutation is a spontaneous, recessive mutation, presenting a hypomyelination of both CNS and PNS, associated with a large deletion of one megabase on chromosome 17 (167). Homozygous quaking viable mice survive to adulthood and exhibit a characteristic tremor or "quaking" of the hindlimbs (562). The identification of oligodendrocytes as the affected cells, the abnormal composition and compaction of myelin, with pockets of oligodendrocyte cytoplasm, suggested that an arrest of myelin assembly is causative of the quaking viable mutation. Interestingly, myelin is not reduced in all fascicles (43). Other developmental abnormalities have also been observed, such as an increased number of noradrenergic neurons in the locus ceruleus that is likely to be involved in the convulsions of this mutant mouse (370).
A second group of recessive quaking alleles, ethylnitrosourea induced, are embryonic lethal around 9-10 embryonic days of gestation, 10 days before myelination begins; because these mutants do not present the deletion found in quaking viable, it was supposed they are due to point mutations in the quaking gene. The mouse quaking gene was identified using a positional cloning strategy by Artzt and co-workers (166). Two classes of transcripts generated by alternative splicing are expressed; class I (Qk1) is expressed in the earliest cells of the embryonic nervous system, and class II (Qk2) is expressed in the myelinated tracts of the neonatal brain. QkI transcripts implicated in embryonic developmental stages present point mutations in the ethylnitrosourea-induced qk mutants, whereas Qk2 transcripts, implicated in myelination, are truncated at their 5'-terminal end, which is coded by the part of the gene included in the deletion at the quaking locus. The loss of fertility of quaking viable affected males could be due to the expression of the quaking gene during spermatogenesis as recently demonstrated for an ortholog of the mouse quaking gene in chick spermatogenesis (386). The quaking gene products comprise a so-called K homology (KH) domain, a RNA-binding motif conserved throughout all taxonomic groups (reviewed in Ref. 697). Some of the quaking products could be located in the cytoplasm or in the nucleus of glial cells, suggesting that the quaking transcripts could combine features of RNA-binding and signal transduction proteins (166). The abnormal expression ratio and glycosylation of MAG isoforms in quaking mutants (36) could be explained by abnormal sorting, transport, or targeting of L-MAG or S-MAG (63), or alternatively, as a defect in the relative expression ratio of the two MAG isoforms, according to the putative function of the quaking proteins in regulation of alternative splicing (166). In this context, one indirect consequence of the quaking mutation might be the abnormally little L-MAG production, participating to the morphological alterations of CNS myelin in quaking mice, which could be compared with similar defects observed in the engineered L-MAG mutant mice (203) (see sect. IIIC2).C) MUTATIONS INVOLVING ENZYMES OF LIPID METABOLISM. The twitcher mouse was early recognized as an authentic model of Krabbe's disease (599). The twitcher mouse exhibits a leukodystrophy characterized by ataxia ("twitching") and abnormal periodic acid-Schiff (PAS)-positive cells, often multinucleated ("globoid cells"), in both CNS and PNS. On C57BL/6j background, death occurs at 40-45 days. Loss of myelin and accumulation of globoid cells, often clustered around blood vessels, are prominent in the white matter spinal cord and brain stem of twitcher mice. However, compacted myelin appears structurally normal, with an orderly periodicity of the dense major line and intraperiodic line. Crystalloid or slender tubular inclusions (GLD inclusions) are present in macrophages, oligodendrocytes, and astrocytes. Extensive astrocytosis is detected both in white and gray matter. Axonal loss is not prominent. The PNS is also severely affected. Infiltration of macrophages, similar to those seen in the CNS, is apparent between nerve fibers. Many nerves are demyelinated, and the presence of thinly myelinated fibers indicates remyelination. Schwann cells of myelinated fibers contain the characteristic GLD inclusions, whereas nonmyelinating Schwann cells present unusually elongated and branching processes. Both Schwann cell types possess numerous GFAP-immunoreactive processes.
Myelin and degenerating oligodendrocytes are removed and phagocytosed by globoid cells, indicating that they actively participate in the demyelinating process. As such, twitcher is a unique model of congenital demyelination. The globoid cells invading the nervous system are exogenous macrophages of mesenchymal phagocytic origin, positive for vimentin and Mac-1 but negative for GFAP. It has long been known that GalC has a specific capacity to elicit infiltration of macrophages into the brain, as shown by the production of globoid-like cells obtained by injecting cerebrosides directly into rat brain white matter. Once in the brain, macrophages are transformed to multinucleated globoid cells. The characteristic inclusions in the globoid cells appear to be GalC itself. Psychosine, the other substrate of the defective enzyme, is consistently and progressively increased in tissues of twitcher mice; the degree of psychosine accumulation correlates well with the severity of pathological lesions (see review in Ref. 595). Hematopoietic cell transplantation prolongs survival in the twitcher mouse and improves biochemical parameters, especially increasing galactocerebrosidase (GalCase) level (271). The twitcher cDNA encoding the 668 amino acids GalCase revealed a nonsense mutation at codon 339 (Trp339stop) (529). The mutation is homozygous in the twitcher and heterozygous in the carrier. A number of naturally occurring other animal mutants associated with a deficiency of GalCase have been characterized.D) MYELIN MUTANTS WITH UNKNOWN GENETIC DEFECTS. The taiep rat presents a developmental defect in CNS myelination, leading to a progressive neurological disorder (160). "Taiep" is an acronym for trembling (t), ataxia (a), immobility episodes (i), epilepsy (e), and paralysis (p). The myelin defect correlates with an abnormal and progressive accumulation of microtubules associated with endoplasmic reticulum membranes in taiep oligodendrocytes. These morphological abnormalities suggest a blockage of protein trafficking (125). Glial cell number is normal (351). Myelin yield decreases continuously from 2 wk until it reaches a stable level of ~10-15% in the affected brain and 20-25% in the spinal cord, compared with control. Thus the myelination defect in taiep has features of both hypomyelination and demyelination.
The zitter rat (501) presents two main neurological abnormalities: a spongiform encephalopathy in gray matter and a hypomyelination in the brain stem and cerebellum. Zitter oligodendrocytes contain abnormal structures associated with nuclear membranes, resembling stacks of split myelin lamellae. These abnormalities are prominent at 3 wk of age, then decrease transiently and then again increase slightly with advancing age. The spongy degeneration observed in the gray matter gradually extends to the entire CNS; however, no inflammatory nor phagocytic cell infiltrations are detected. GFAP immunoreactivity increases transiently in the vacuolated areas from 2 to 15 wk of age, then decreases, suggesting an astrocytic hypofunction in response to tissue damage. A yet unknown (see NOTE ADDED IN PROOF) genetic abnormality, probably related to cell membrane biosynthesis, produces both hypomyelination and spongy degeneration in the zitter rat (311). The hindshaker mouse shows tremors that decrease, then cease with age (301). Decreased numbers of oligodendrocytes and amount of myelin are observed in the spinal cord. Although most sheaths remain thin, there is a marked clinical improvement with time. Thus hypomyelination could result, at least in part, from a deficiency of mature oligodendrocytes able to elaborate myelin membranes or to a delayed differentiation or maturation of oligodendrocytes that are unable to synthesize sufficient myelin at the appropriate time. Spontaneous myelin mutations are extremely good tools for the study of the myelination process and its consequences; furthermore, it is possible to study the animals before the onset of the clinical disease. They are physiological models of human diseases that may be of further help for therapeutic trials.2. Leukodystrophies in humans
Inherited myelin diseases in humans, leukodystrophies, may be the result of dysmyelination, hypomyelination, or demyelination. Dysmyelination and hypomyelination are failure to myelinate occurring during fetal life or early infancy, as observed in different forms of Pelizaeus-Merzbacher disease. Demyelination, breakdown of myelin, is characteristic of metabolic leukodystrophies, such as Krabbe's disease, metachromatic leukodystrophy, ALD, Canavan disease, Alexander disease, orthochromatic leukodystrophy, or mitochondrial disorders (reviewed in Ref. 309). Dysmyelination and demyelination can be combined in some forms of leukodystrophies.
Myelin formation and maintenance require also a balance between synthesis and degradation of lipids. Although alterations of cerebroside, sulfatide, and long-chain fatty acid degradation possibly involve other cell types than oligodendrocytes, they give rise to leukodystrophies (reviewed in Ref. 309). These complex lipids and their VLCFAs are also present in the PNS. Therefore, symptoms associate both central demyelination visible by MRI and PNS demyelination with slowing of nerve conduction velocity. These leukodystrophies associate defective lysosomal enzymes or lipid transporters and accumulation of the undegraded lipid which is easily tested in fibroblast cell cultures.
In Krabbe's disease (1916), an autosomal recessive disorder, there is a defect in the lysosomal galactocerebrosidase (598), the enzyme which degrades GalC into ceramide and galactose. This disease occurs mainly during infancy, but some adult cases manifesting only as spastic paraplegia have been diagnosed (reviewed in Ref. 310). The degeneration of myelin and oligodendrocytes is due to the accumulation of psychosine, a toxic metabolite also normally degraded by this lysosomal enzyme (reviewed in Ref. 595). Exogenous macrophages, the globoid cells, invade the CNS and have given the name of globoid cell leukodystrophy to this disease. The gene is located on chromosome 14 and contains 17 exons (353, 354). There is a spontaneous mouse mutant, the twitcher mouse (see sect. IVA1), which constitutes an experimental model of Krabbe's disease (reviewed in Ref. 599).
Metachromatic leukodystrophy is also an autosomal recessive inherited lysosomal disorder. It is caused by a defect in the arylsulfatase A (ASA) gene (reviewed in Ref. 219). ASA, together with an activator (saposin B), degrades sulfogalactosylceramide into GalC and sulfate. In most of the cases, it is the deficiency of ASA that leads to the accumulation of sulfogalactosylceramide and provokes a lethal progressive demyelination. The ASA gene has been cloned; the coding sequence is divided into eight exons (315); the entire coding sequence is of 1.5 kb. The leukodystrophy generally develops during infancy, and there is a destruction of the newly formed myelin, but it can also occur later, even at adulthood (40). The phenotype of ASA-deficient mice shows morphological, biochemical, but not functional relationships to human metachromatic leukodystrophy (252), possibly in relation to other compensating metabolic pathways in the mouse.
Sphingolipid activator proteins (saposins) are necessary to the enzymatic hydrolysis of myelin galactolipids. They originate from a prosaposin gene. Targeted disruption of the mouse sphingolipid activator protein gene gives rise to a complex phenotype including a severe leukodystrophy (204).
In X-linked adrenoleukodystrophy (ALD), there is an impairment in
VLCFA
-oxidation that is normally degraded in peroxisomes. There is
an accumulation of VLCFA cholesterol esters and other lipids
mainly in white matter of the brain and in the adrenal gland. There are
two major forms (410): 1) cerebral childhood ALD (which is associated with inflammation in the brain) and multifocal demyelination and 2) adrenomyeloneuropathy which affects
mainly the spinal cord and peripheral nerves. The ALD locus has been mapped to Xq28. The gene involved is called the ALD protein (ALDP) gene
and consists of 21 kb and 10 exons. ALDP is a 75-kDa protein (411) that belongs to the ATP-binding cassette (ABC)
protein family. ALDP has been localized to the peroxisomal membrane
(411) and might be involved in the import of cofactors
necessary to VLCFA-CoA synthase activity or import of VLCFA-CoA
into the peroxisomes. In the brain, ALDP is expressed in
oligodendrocytes but also in astrocytes and microglia
(16). Mice defective in the ALDP gene have been generated
(192, 308, 342). Unexpectedly,
there are no neurological symptoms even in aged mice, although there is impaired
-oxidation of VLCFA that accumulate in CNS white matter, adrenal cortex, and testis. Therefore, the accumulation of VLCFA alone
is probably not sufficient to cause demyelination in the nervous system
(reviewed in Refs. 16, 410).
Zellweger disease is a complex peroxisomal syndrome (reviewed in Ref. 409) that also affects white matter in brain and gives rise to an accumulation of VLCFA; there is also a defect in plasmalogen biosynthesis (545), compounds known to be enriched in myelin and other abnormalities of this cerebro-hepato-renal syndrome. It is a group of genetically heterogeneous disorders that affects peroxisome peroxidation.
Another enzyme, aspartoacylase, which degrades N-acetylaspartic acid, is possibly also a myelin enzyme (284). The enzyme deficiency is the cause of Canavan's disease, which is also characterized biochemically by N-acetylaspartic aciduria. Canavan's disease gives rise to dysmyelination and spongy degeneration of the brain (reviewed in Ref. 364). Significant levels of N-acetylaspartate (NAA) are detected in cultures of immature oligodendrocytes; these metabolic abnormalities in the development of oligodendroglia may be related to the physiopathology of this disease (626). In the adult, NAA is neuronal and a useful neuronal marker in NMR spectroscopy. Recently, it has been shown that mature oligodendrocytes can express NAA in vitro (50) and possibly in vivo contribute to the NAA signals observed in spectroscopy.
Mutations in the PLP gene cause a rare leukodystrophy, the Pelizaeus-Merzbacher disease (PMD). PMD presents in several forms: connatal, infantile, and more recently a different phenotype with spastic paraplegia type 2 (SPG-2), either isolated or associated to clinical features of the classical PMD (reviewed in Refs. 422, 555). More than 30 point mutations have been found in the PLP gene from PMD and SPG-2 patients.
Another rare leukodystrophy, the 18q-syndrome, presents a deletion which includes the MBP gene (213, 309, 520).
An astrocyte pathology may also give rise to leukodystrophies such as Alexander disease. Recently, sequence analysis of DNA samples from patients representing different Alexander disease phenotypes revealed that most cases are associated with nonconservative mutations in the coding region of GFAP. Alexander disease represents the first example of a primary genetic disorder of astrocytes, one of the major cell types in the CNS (75a).
A number of leukodystrophies, most of which are genetically inherited, have also no known etiology. A new leukoencephalopathy termed "childhood ataxia with diffuse central nervous system hypomyelination" (CACH syndrome) or "leukoencephalopathy with vanishing white matter" was recently identified on clinical and neuroradiological grounds (540, 629). In addition to the cavitating white matter lesions found in this orthochromatic leukodystrophy, neuropathological data recently obtained showed that this new characterized entity is associated with an unusually increased oligodendrocyte density (521, 522).
3. Leukoencephalopathies
If the pathology of myelin or myelinating cells dominates in leukodystrophies, some genetic diseases may give rise to leukoencephalopathies in which demyelination is secondary to vascular, mitochondrial, or neuronal alterations or may be linked to a metabolic disease that may have ubiquitous signs.
White matter is vulnerable to ischemic damage (143, 186). White matter diseases can also be posttoxic, postinfectious, and postradiological.
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is an autosomal dominant cerebral arteriopathy. MRI evidences multiple subcortical infarcts, with a demyelination of white matter that can be more or less extensive (616; reviewed in Ref. 136).
MELAS means mitochondrial myopathy, encephalopathy, lactic acidosis, strokelike episodes. Most of the patients present a lactic acidosis with an increase of the lactate-to-pyruvate ratio in serum and CSF. MRI shows white matter modifications are present together with cortical atrophy (148).
Refsum disease is characterized biochemically by an accumulation of phytanic acid in tissues. This acid is only present in food (green vegetables, and also grass-eating animals) and normally degraded by phytanate oxidase (585). MRI evidences demyelination in the brain stem and the cerebellum.
4. Other metabolic diseases
It is well known that phenylketonuria can be associated with demyelination. The diet may not always be sufficient to repair cerebral alterations, especially if it is not well observed or set up too late. Abnormalities of intermediary metabolism may also cause demyelination.
Some neuronal genetic diseases can affect myelin (GM2 gangliosidoses, Wilson's disease, and degenerative diseases of CNS). Oligodendrocyte express AMPA/kainate-type receptors, and they share with neurons a high vulnerability to the AMPA/kainate receptor-mediated death, a mechanism that may contribute to white matter CNS disease (369, 373, 435).
B. Inflammatory Demyelinating Diseases
Breakdown of the blood-brain barrier is a primary event in
pathological manifestations of demyelinating disease of the CNS, such
as MS, demyelinating forms of EAE (reviewed in Ref. 663), and
virus-induced demyelination (reviewed by Ref. 184). Neural and even
nonneural activated T cells play a pivotal role in this process
(336, 665). Moreover, the opening of the
blood-brain barrier allows the entry of circulating antibodies into
the CNS, in particular demyelinating antibodies, such as anti-MOG
antibodies (214, 215, 336; see also review in Ref. 77). Access of
activated T cells to the CNS is responsible for release by inflammatory cells, macrophages, and microglia and of proinflammatory
cytokines, such as TNF-
and interferon-
(reviewed in Ref. 77).
However, the toxic action of TNF-
on oligodendrocytes
(556) remains debatable. Activated macrophages engulf
myelin debris or internalize myelin by Fc receptor and complement
receptor-mediated phagocytosis after binding to myelin-specific
antibodies (403, 628).
Other different mechanisms may be involved in the process of
demyelination. Oligodendrocytes have a high iron content, making them
especially prone to oxidative stress by reactive oxygen species (240). Neurotransmitters, especially glutamate, may also
exert a direct deleterious effect on oligodendrocytes and lead to
demyelination (369, 464; reviewed in Ref. 588). Heat shock proteins may
also be involved (77), among which
-B crystallin, which
may be a candidate encephalitogenic antigen in demyelination
(631). Matrix metalloproteinases (MMP) are a group of
zinc-dependent enzymes that can degrade extracellular matrix
components (reviewed in Ref. 687). Among other activities, they can
degrade MBP (111). MMPs are increased in active and
chronic MS (361), especially MMP-7 and MMP-9
(124). More and more, there is thought to be a viral
triggering of autoimmune diseases (664). More than one mechanism may be present in the same disease or even in the same lesion
(349).
There are many causes of demyelination in human diseases. The main causes of primary demyelination are genetic (such as in ALD, see sect. IVA2), immune mediated, viral such as HIV, and toxic (reviewed in Ref. 349); they may also be secondary to neuronal dysfunction. In some cases, white matter thinning is visualized on MRI; it is called leuko-araiosis, and it can be seen in normal, even young individuals, and more frequently in aging; its significance remains obscure. There may be a relationship between leuko-araiosis at MRI, myelin pallor, and white matter atrophy, which are as yet poorly understood (637). Diffuse myelin pallor is seen in some dementia patients (471).
1. MS
MS is a chronic and inflammatory demyelinating disease of the CNS (112). Storch and Lassmann (593) have shown that there is a profound heterogeneity of pathology and immunopathogenesis of the lesions. There is a high interindividual but a low intraindividual variety of MS lesions. The spectrum of pathology appears to be the following (344, 345): 1) primary demyelination with little oligodendrocyte damage; 2) extensive oligodendrocyte loss in the course of demyelination; 3) primary oligodendrocyte damage with secondary demyelination; and 4) extreme macrophage activation together with rather nonselective tissue damage, involving not only myelin and oligodendrocytes, but also axons and astrocytes. Axonal loss is also a prominent feature of MS and may be the pathological correlate of the irreversible neurological impairment in this disease (185, 341, 375, 621). Current evidence shows that the etiology of MS and other demyelinating diseases may involve a combination of viral and autoimmune factors.
Oligodendrocyte progenitors are present in the normal adult human CNS and in the lesions of MS but fail to repair demyelinated regions (551, 671, 672).
2. Experimental models of demyelinating diseases
There are several experimental models of demyelination: toxic, viral, and immune mediated. Among the toxic models, ethidium bromide (676) and cuprizone (59) alter mitochondrial DNA leading to abnormal respiration and necrosis (347); lysophosphatidylcholine (60) is also widely used.
A) VIRUS MODELS OF MS. The most useful virus models of MS are the experimental infections of rodents that give rise to an inflammatory demyelinating disease in the CNS. The most studied are Theiler's virus, mouse hepatitis virus, and Semliki Forest virus.
Theiler's murine encephalomyelitis virus (TMEV) is a natural pathogen of mice in which CNS infection is a rare event. To study the virus experimentally, the virus is injected into the CNS. The inflammatory response is recruited into the CNS and in some mouse strains eradicates the infection. In other mouse strains the virus persists within oligodendrocytes, albeit at low titer. Persistence gives rise to inflammation in the brain and cord and results in paralysis; susceptibility has been linked to a number of loci including MHC and TCR as well as MBP genes. In some mouse strains, infection gives rise to autoreactive T cells, demonstrating that viruses can give rise to a myelin-specific pathogenic response. Demyelination is observed with the Theiler's virus (523) in which a secondary immune-mediated disease gives rise to oligodendrocyte destruction, following a primary infection in neurons. There are susceptibility genes and resistance genes to viral persistence and demyelination (85). Like TMEV, the mouse hepatitis virus (MHV) strains JHM, A59, and MHV-4 are neurotropic and may induce CNS inflammation after either intracranial or intranasal infection. With the JHM strain virus, replication is confined to an intermediate stage between O2-A progenitors and fully differentiated oligodendrocytes, both of which are resistant to infection. Host genetics also play a role in susceptibility as seen in the resistant SJL mouse and susceptible BALB/c mice. Although in some strains virus can directly infect and destroy oligodendrocytes, this is again dependent on the host background. Infection with JHM may lead to the generation of autoreactive T cells to myelin proteins. Another experimental virus infection is Semliki Forest virus of mice. The most commonly used strains include L10, M9, and the avirulent A7 (73), which are neuroinvasive as well as neutrotropic, with the advantage being that the virus can be injected intraperitoneally and thus enable the study of the blood-brain barrier. Virus infection gives rise to large plaques of demyelination in the brain and cord. The absence of demyelination in immunocompromised athymic mice or in SCID mice in which virus persists in the brain demonstrates the role of the immune response in disease. In addition to the CNS lesions, SFV-infected animals display abnormalities in their visual evoked responses and have changes in axonal transport and optic nerve lesions. Although some studies demonstrate that SFV gives rise to autoreactive T cells (S. Amor, personal communication), others have demonstrated that similarities between the myelin protein MOG and SFV peptides are responsible for the demyelination observed in this model (396). In contrast to the experimental viral models, Visna and canine distemper are naturally occurring inflammatory diseases of sheep and dogs, respectively, and both have been studied as experimental infections from the point of view of investigating mechanisms of viral damage to myelin important for the study of MS.B) EAE. EAE, also called experimental allergic encephalomyelitis, is provoked by injection of CNS tissue, whole spinal cord, purified myelin, or myelin proteins or peptides in susceptible animals (reviewed in Ref. 73). The incubation period between sensitization and onset of the disease as well as the severity and course of the clinical disease are variable and depend on the genetic background of the animal (species and strain differences); on environmental factors, like the mode of sensitization; the dose and nature of the sensitizing antigen; or exogenous influences on immune functions, such as intercurrent infections or treatment with immunosuppressive or immunomodulatory drugs. In many cases, it is also possible to transfer EAE by sensitized T lymphocytes to a naive recipient. For a long time, MBP has been considered as the main encephalitogenic antigen (296). Later, it was recognized that PLP may lead to a very similar disease (92). Immunodominant encephalitogenic epitopes of MBP and PLP have been characterized and found to be different in various animal species and strains, in relation to MHC phenotypes (12, 304, 646; review in Ref. 268).
Many other minor myelin and myelin-associated proteins, OSP, MAG and the heat shock protein
-B-crystallin have been demonstrated to
be encephalitogenic in mice (590, 609,
658). Actually, MOG is one of the most encephalitogenic
proteins and is widely used to induce EAE. MOG by itself is able to
induce both an encephalitogenic T-cell response and an autoantibody
response in a large range of susceptible animals. MOG-induced EAE
constitute a relevant model for MS, presenting different clinical
phenotypes depending on MHC haplotype and other susceptibility genes,
as environmental factors, with both inflammation and demyelination
specifically in the CNS (1, 47,
283, 294, 335, 584,
594, 662). Interestingly, anti-MOG
antibodies have been shown to be very important in the demyelination
processes; in an experimental model in which MBP is the
encephalitogenic antigen T cell mediated. In this model there is only
inflammation, unless anti-MOG antibodies are also injected
intravenously (336), which dramatically increase the degree of demyelination. The important role of anti-MOG antibodies has been also well demonstrated in a transgenic mice engineered to
produce high titers of autoantibodies against MOG (338);
in this transgenic mouse, the presence of numerous plasma cells
secreting MOG-specific IgG antibodies accelerates and exacerbates
EAE, independently of the identity of the initial autoimmune insult
(PLP or MOG peptides). Circulating antibodies against MOG have also
been shown to facilitate MS-like lesions in a nonhuman primate, the
marmoset, and have been observed in MS (214,
215). Moreover, tolerization assays in the marmoset model
induce a lethal encephalopathy after cessation of the treatment
(214). These data suggest that such autoreactivity to MOG
may be significant in the development of MS.
Amor et al. (10) were the first to describe T-cell
encephalitogenic epitopes of MOG that induce both clinical and
histologic signs of EAE in mice. Furthermore, chronic relapsing EAE
with a delayed onset and an atypical clinical course can be induced in
PL/J mice by specific MOG peptides (294). Interestingly,
epitopes of MBP, PLP, and MOG for EAE induction in Biozzi ABH mice
share an amino acid motif (11).
One of the mechanisms participating in autoimmunity could be molecular
mimicry, due to recognition by the immune system of analogous sequences
shared by viral or bacterial proteins and myelin proteins (PLP, MBP, or
MOG) able to induce EAE (see review in Ref. 437).
C. Tumors: Oligodendrogliomas
The most common CNS gliomas traditionally are thought to arise from mature astrocytes and oligodendrocytes. Oligodendrogliomas, which appear to arise from oligodendroglial cells, have been thought for long times to be uncommon gliomas (<10% of all intracranial tumors) (254). However, reappraisal of recent data indicates that they may be more common than generally thought (193).
Recently, the possibility that gliomas may arise from a population of
glia that has properties of oligodendrocyte progenitors has been
examined. These glial cells express the NG2 chondroitin sulfate
proteoglycan and the
-receptor of PDGFR-
in vivo. NG2 and the
PDGFR-
high levels of expression have been identified in tissue from
seven of seven oligodendrogliomas, three of three pilocytic
astrocytomas, and one of five glioblastoma multiform, raising the
possibility that the NG2+/PDGF
R+ cells in the mature CNS contribute
to glial neoplasm. These data provide evidence that glial tumors arise
from glial progenitor cells. Molecules expressed by these progenitor
cells should be considered as targets for novel therapeutics
(426, 560).
| |
V. CONCLUSIONS |
|---|
|
|
|---|
The importance of glia has become more and more clear with the development of techniques of molecular biology and cell cultures. Culturing neurons and glia separately or together has contributed to the understanding of the role of oligodendrocytes in the development of neuronal pathways as well as in synaptic functions. The study of spontaneous mutations, as well as transgenic mice with overexpression or no expression of specific markers, has shown the role of specific glial components in brain constitution and function. More and more, the molecules involved, in developmental processes and in the adult, are being identified. Molecular studies of developmental mutants and human pathology have led to the identification of the involvement of glia in numerous developmental diseases.
Axonal guidance seems in many cases to involve preformed glial pathways that may remain and create glial boundaries. Myelin plays an inhibitory role to growing axons and participates in the stability of the mature, intact nervous system, by preventing random regrowth of axon sprouts once pathways have been established and myelinated. Although it may present the unwanted side effect of impairing axonal reparation after CNS injury, it gives new areas of research for brain repair (134, 607). Without glia, and especially the oligodendrocyte, nerve conduction velocity would not develop normally because these glial cells are necessary for the clustering of sodium channels at the Ranvier node essential to fast nerve conduction velocity in myelinated fibers (293). The role of the oligodendrocyte and neuronal pairing is not only essential in relation to myelin formation but also in demyelinating diseases. If neurons are needed for myelination, impaired myelin function may induce profound cytoskeletal alterations leading to axonal degeneration, as observed in myelin protein-deficient animal models (235, 686). Altogether, these data enlighten the role of myelinating glial cells-axon interactions, the "functional axon-glial unit," in the pathophysiology of myelin-related disorders. Furthermore, these studies and other works related to remyelination show the unexpected intrinsic plasticity of glial cells in the CNS, commonly recognized in neonates, but surprisingly still present in adults (reviewed in Ref. 61). Furthermore, experimental models such as EAE and studies of cellular markers in human brain seem to indicate that there are different ways of inducing demyelination, thus possibly different types of MS.
More and more these neuroglial interactions are being identified in relation to neuronal functions. By their mobility and plasticity, glial cells appear to be intrically involved in the functions of the neuronal network. As mentioned by Ullian and Barres (624), "glia are not listening to synaptic transmission but participating in the conversation as well." Synapses throughout the brain are ensheathed by glial cells. Astrocytes help to maintain synaptic functions by buffering ion concentrations, clearing released neurotransmitters, and providing metabolic substrates to synapses. Recent findings suggest that oligodendrocytes may have such a role as well.
The dysfunction of glial cells is possibly at the origin of many of the degenerative diseases of the nervous system and of the major brain tumors (glioma). Nevertheless, there are still many mysteries that are not unraveled. Although growth factors and cytokines are secreted by astrocytes and oligodendrocytes in vitro, their relevance in vivo remains to be elucidated, as neurons are also able to synthesize them. Some cytokines may be useful or harmful. Receptors for these substances have not as yet been well identified in vivo, especially in pathological states.
Although myelin repair and synaptic remodeling and regeneration can occur, many enigmas are still to search for, especially in the human in which growth factors may be different from the rodent species. Thus studies in primates, and in vivo systems, cannot be omitted at this stage, in view of therapeutic implications.
No doubt we will understand more and more the language between glial cells and neurons in normal and pathological states. Already abnormal astrocytes and oligodendrocytes appear to be involved in cognitive functions as seen in the leukodystrophies.
As mentioned by Peschanski (451), time has come for "neurogliobiology" in which neurons and glia (including microglia) in the nervous system are inseparable partners.
| |
ACKNOWLEDGMENTS |
|---|
Richard Reynolds, Jean-Léon Thomas, Constantino Sotelo, Sandra Amor, André Dautigny, and Annick Baron Van Evercooren are greatly acknowledged for their critical review of the manuscript.
The authors' research work was supported by INSERM and VML (to N. Baumann) and ARSEP, ELA, and CNRS (to D. Pham-Dinh).
| |
FOOTNOTES |
|---|
Address for reprint requests and other correspondence: N. Baumann, INSERM Unit 495, Biology of Neuron-Glia Interactions, Salpêtrière Hospital, 75651 Paris Cedex 13, France (E-mail: baumann{at}ccr.jussieu.fr).
| |
NOTE ADDED IN PROOF |
|---|
Recently, the genetic defect involved in the Zitter rat mutation has been characterized as a small deletion near a splicing site in the "attractin" gene. A mutation in attractin is also responsible for the myelin defect in a previously described mutant, the Mahogany mouse. Therefore, attractin, which plays multiple roles in regulating different physiological processes, also has a critical role in normal myelination in the CNS (318a).
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Adelmann M, Wood J, Benzel I, Fiori P, Lassmann H, Matthieu JM, Gardinier MV, Dornmair K, and Linington C. The N-terminal domain of the myelin oligodendrocyte glycoprotein (MOG) induces acute demyelinating experimental autoimmune encephalomyelitis in the Lewis rat. J Neuroimmunol 63: 17-27, 1995. |
| 2. | Agrawal HC, and Agrawal D. Proteolipid protein and DM-20 are synthesized by Schwann cells, present in myelin membrane, but they are not fatty acylated. Neurochem Res 16: 855-858, 1991. |
| 3. | Agrawal HC, Randle CL, and Agrawal D. In vivo acylation of rat brain myelin proteolipid protein. J Biol Chem 257: 4588-4592, 1982. |
| 4. | Ainger K, Avossa D, Diana AS, Barry C, Barbarese E, and Carson JH. Transport and localization elements in myelin basic protein mRNA. J Cell Biol 138: 1077-1087, 1997. |
| 5. | Allard J, Barron S, Diaz J, Lubetzki C, Zalc B, Schwartz JC, and Sokoloff P. A rat G protein-coupled receptor selectively expressed in myelin-forming cells. Eur J Neurosci 10: 1045-1053, 1998. |
| 6. | Allinquant B, Staugaitis SM, D'Urso D, and Colman DR. The ectopic expression of myelin basic protein isoforms in Shiverer oligodendrocytes: implications for myelinogenesis. J Cell Biol 113: 393-403, 1991. |
| 7. | Almazan G, Honegger P, and Matthieu JM. Triiodothreonine stimulation of oligodendroglial differentiation and maturation. A developmental study. Dev Neurosci 7: 45-54, 1985. |
| 8. | Amat JA, Farooq M, Ishiguro H, and Norton WT. Cells of the oligodendrocyte lineage proliferate following cortical stab wounds: an in vitro analysis. Glia 22: 64-71, 1998. |
| 9. | Amiguet P, Gardinier MV, Zanetta JP, and Matthieu JM. Purification and partial structural and functional characterization of mouse myelin oligodendrocyte glycoprotein (MOG). J Neurochem 58: 1676-1682, 1992. |
| 10. | Amor S, Groome N, Linington C, Morris MM, Dornmair K, Gardinier MV, Matthieu JM, and Baker D. Identification of epitopes of myelin oligodendrocyte glycoprotein for the induction of experimental allergic encephalomyelitis in SJL and Biozzi AB/H mice. J Immunol 153: 4349-4356, 1994. |
| 11. | Amor S, O'Neill JK, Morris MM, Smith RM, Wraith DC, Groome N, Travers PJ, and Baker D. Encephalitogenic epitopes of myelin basic protein, proteolipid protein, myelin oligodendrocyte glycoprotein for experimental allergic encephalomyelitis induction in Biozzi ABH (H-2Ag7) mice share an amino acid motif. J Immunol 156: 3000-3008, 1996. |
| 12. | Anderson AC, Nicholson LB, Legge KL, Turchin V, Zaghouani H, and Kuchroo VK. High frequency of autoreactive myelin proteolipid protein-specific T cells in the periphery of naive mice. Mechanisms of selection of the self-reactive repertoire. J Exp Med 191: 761-770, 2000. |
| 13. | Anderson TJ, Schneider A, Barrie JA, Klugmann M, McCulloch MC, Kirkham D, Kyriakides E, Nave KA, and Griffiths IR. Late-onset neurodegeneration in mice with increased dosage of the proteolipid protein gene. J Comp Neurol 394: 506-519, 1998. |
| 14. | Artavanis-Tsakonas S, Matsuno K, and Fortini ME. Notch signaling. Science 268: 225-232, 1995. |
| 15. | Aruga J, Okano H, and Mikoshiba K. Identification of new isoforms of mouse myelin basic protein: the existence of exon 5a. J Neurochem 56: 1222-1226, 1991. |
| 16. | Aubourg P, and Dubois-Dalcq M. X-linked adrenoleukodystrophy enigma: how does the ALD peroxisomal transporter mutation affect CNS glia? Glia 29: 186-190, 2000. |
| 17. | Avellana-Adalid V, Bachelin C, Lachapelle F, Escriou C, Ratzkin B, and Baron-Van Evercooren A. In vitro and in vivo behavior of NDF-expanded monkey Schwann cells. Eur J Neurosci 10: 291-300, 1998. |
| 18. | Avellana-Adalid V, Lachapelle F, and Baron-Van Evercooren A. Expression of rat oligodendrocyte precursors into proliferative oligospheres that retain their myelinating capacity after transplantation into the shiverer newborn brain. J Neurosci Res 45: 558-570, 1996. |
| 19. | Baas D, Bourbeau D, Sarlieve LL, Ittel ME, Dussault JH, and Puymirat J. Oligodendrocyte maturation and progenitor cell proliferation are independently regulated by thyroid hormone. Glia 19: 324-332, 1997. |
| 20. | Bandtlow CE, and Schwab ME. NI-35/250/nogo-a: a neurite growth inhibitor restricting structural plasticity and regeneration of nerve fibers in the adult vertebrate CNS. Glia 29: 175-181, 2000. |
| 21. | Bandtlow C, Zachleder E, and Schwab ME. Oligodendrocytes arrest neurite growth by contact inhibition. J Neurosci 10: 3837-3848, 1990. |
| 22. | Bansal R, Kumar M, Murrat K, Morrison RS, and Pfeiffer SE. Regulation of FGF receptors in the oligodendrocyte lineage. Mol Cell Neurosci 7: 263-275, 1996. |
| 23. | Bansal R, Warrington AE, Gard A, and Pfeiffer SE. Multiple and novel specificities of monoclonal antibodies O1, O4 and R-MAb used in the analysis of oligodendrocyte development. J Neurosci Res 24: 548-557, 1989. |
| 24. | Barbarese E, Koppel DE, Deutscher MP, Smith CL, Ainger K, Morgan F, and Carson JH. Protein translation components are colocalized in granules in oligodendrocytes. J Cell Sci 100: 2781-2790, 1995. |
| 25. | Barde YA. A crucial role for neurotrophin-3 in oligodendrocyte development. Nature 367: 371-375, 1994. |
| 26. | Baron-Van Evercooren A, Avellana-Adalid V, Ben-Younes-Chennoufi A, Gansmuller A, Nait-Ousmemar B, and Vignais L. Cell-cell interactions during the migration of myelin-forming cells transplanted in the demyelinated spinal cord. Glia 16: 147-164, 1996. |
| 27. | Barres BA. A new role for glia: generation of neurons! Cell 97: 667-670, 1999. |
| 28. | Barres BA, Hart IK, Coles HSR, Burne JF, Voyvodic JT, Richardson WD, and Raff MC. Cell death and control of cell survival in the oligodendrocyte lineage. Cell 70: 31-46, 1992. |
| 29. | Barres BA, Lazar MA, and Raff MC. A novel role for thyroid hormone, glucocorticoids and retinoic acid in timing oligodendrocyte development. Development 120: 1097-1108, 1994. |
| 30. | Barres BA, and Raff MC. Proliferation of oligodendrocytes precursor cells depends on electrical activity in axons. Nature 361: 258-260, 1993. |
| 31. | Barres BA, and Raff MC. Control of oligodendrocyte number in the developing rat optic nerve. Neuron 12: 935-942, 1994. |
| 32. | Barres BA, and Raff MC. Axonal control of oligodendrocyte development. J Cell Biol 147: 1123-1128, 1999. |
| 33. | Barres BA, Schmid R, Sendter M, and Raff MC. Multiple extracellular signals are required for long-term oligodendrocyte survival. Development 118: 283-295, 1993. |
| 34. | Bartlett WP, Li X, and Williams M. Expression of IGF1 mRNA in the murine subventricular zone during postnatal development. Mol Brain Res 12: 285-291, 1992. |
| 35. | Barton EB, Arquint M, Roder J, Dunn R, and Francke U. The myelin-associated glycoprotein gene: mapping to human chromosome 19 and mouse chromosome 7 and expression in quivering mice. Genomics 1: 107-112, 1987. |
| 36. | Bartoszewicz ZP, Noronha AB, Fujita N, Sato S, Bo L, Trapp BD, and Quarles RH. Abnormal expression and glycosylation of the large and small isoforms of myelin-associated glycoprotein in dysmyelinating quaking mutants. J Neurosci Res 41: 27-38, 1995. |
| 37. | Bartsch U, Faissner A, Trotter J, Dörries U, Bartsch S, Mohajer H, and Schachner M. Tenascin demarcates the boundary between the myelinated and non-myelinated part of the retinal ganglion cell axons in the developing and adult mouse. J Neurosci 14: 4756-4768, 1994. |
| 38. | Baumann N. (Editor). Neurological Mutations Affect Myelination. INSERM Symposium Number 14. Amsterdam: Elsevier North-Holland, 1980. |
| 39. | Baumann N, Jacque C, and Hauw JJ. Myelin in normal and diseased states. Neurol Clin 1: 701-727, 1983. |
| 40. | Baumann N, Masson M, Carreau V, Lefevre M, Herschkowitz N, and Turpin JC. Adult forms of metachromatic leukodystrophy: clinical and biochemical approach. Dev Neurosci 13: 211-215, 1991. |
| 41. | Baumann N, and Pham-Dinh D. Aspects neurobiologiques de la myéline du système nerveux central. In: Affections Démyélinisantes, Neuro-Immunologie et Clinique, edited by Bogousslavsky J. J.-M., and Léger J. L. Paris: Doin, Initiatives Santé, 1999, p. 13-22. |
| 42. | Beck KD, Powell-Braxton L, Widmer HR, Valverde J, and Hefti F. IGF-I gene disruption results in reduced brain size, CNS hypomyelination, and loss of hippocampal granule and striatal parvalbumin-containing neurons. Neuron 14: 717-730, 1995. |
| 43. | Berger B. Some ultrastructural aspects of white matter in quaking mice. Brain Res 25: 35-53, 1971. |
| 44. | Berger T, and Frotscher M. Distribution and morphological characteristics of oligodendrocytes in the rat hippocampus in situ and in vitro: an immunocytochemical study with the monoclonal Rip antibody. J Neurocytol 23: 61-74, 1994. |
| 45. | Berger T, Walz W, Schnitzer J, and Kettenmann H. GABA- and glutamate-activated currents in glial cells of the mouse corpus callosum slice. J Neurosci Res 31: 21-27, 1992. |
| 46. | Bergoffen J, Scherer SS, Wang S, Scott MO, Bone LJ, Paul DL, Chen K, Lensch MW, Chance PF, and Fischbeck KH. Connexin mutations in X-linked Charcot-Marie-Tooth disease. Science 262: 2039-2042, 1993. |
| 47. | Bernard CC, Johns TG, Slavin A, Ichikawa M, Ewing C, Liu J, and Bettadapura J. Myelin oligodendrocyte glycoprotein: a novel candidate autoantigen in multiple sclerosis. J Mol Med 75: 77-88, 1997. |
| 48. | Bernier L, Alvarez F, Norgard E, Raible M, Mentaberry DW, Schembri JG, Sabatini DD, and Colman DR. Molecular cloning of a 2',3'-cyclic nucleotide -3'-phosphodiesterase: mRNA with different 5' ends encode the same set of proteins in nervous and lymphoid tissues. J Neurosci 7: 2703-2710, 1987. |
| 49. | Bernier L, Colman DL, and D'eustachio P. Chromosomal locations of genes encoding 2',3'-cyclic nucleotide -3'-phosphodiesterase and glial fibrillary acidic protein in the mouse. J Neurosci Res 20: 497-504, 1988. |
| 50. | Bhakoo KK, and Pearce D. In vitro expression of N-acetyl aspartate by oligodendrocytes: implications for proton magnetic resonance spectroscopy signal in vivo. J Neurochem 74: 254-262, 2000. |
| 51. | Bhat NR, Rao GS, and Pieringer RA. Investigations on myelination in vitro. Regulation of sulfolipid biosynthesis by thyroid hormone in cultures of dissociated brain cells from embryonic mice. J Biol Chem 256: 1167-1171, 1981. |
| 52. | Billings-Gagliardi S, Adcock LH, and Wolf MK. Hypomyelinated mutant mice: description of jpmsd and comparison with jp and qk on their present genetic backgrounds. Brain Res 194: 325-338, 1980. |
| 53. | Billings-Gagliardi S, Kirschner DA, Nadon NL, DiBenedetto LM, Karthigasan J, Lane P, Pearsall GB, and Wolf MK. Jimpy 4J: a new X-linked mouse mutation producing severe CNS hypomyelination. Dev Neurosci 17: 300-310, 1995. |
| 54. | Birling MC, Roussel G, Nussbaum F, and Nussbaum JL. Biochemical and immunohistochemical studies with specific polyclonal antibodies directed against bovine myelin/oligodendrocyte glycoprotein. Neurochem Res 18: 937-945, 1993. |
| 55. | Birling MC, Tait S, Hardy RJ, and Brophy PJ. A novel rat tetraspan protein in cells of the oligodendrocyte lineage. J Neurochem 73: 2600-2608, 1999. |
| 56. | Bjartmar C, Karlsson B, and Hildebrand C. Cellular and extracellular components at nodes of Ranvier in rat white matter. Brain Res 667: 111-114, 1994. |
| 57. | Black JA, Kocsis JD, and Waxman SG. Ion channel organization of the myelinated fiber. Trends Neurosci 13: 48-54, 1990. |
| 58. | Black JA, and Waxman SG. The perinodal astrocyte. Glia 1: 169-183, 1988. |
| 59. | Blakemore WF. Remyelination of the superior cerebellar peduncle in the mouse following demyelination induced by feeding cuprizone. J Neurol Sci 20: 73-83, 1973. |
| 60. | Blakemore WF. Invasion of Schwann cells into the spinal cord of the rat following local injections of lysolecithin. Neuropathol Appl Neurobiol 2: 21-39, 1976. |
| 61. | Blight A. Containing plasticity: neurite inhibitory factors of myelin. Nature Neurosci 1: 87-88, 1998. |
| 62. | Bloch B, Popovici T, Levin MJ, Tuil D, and Kahn A. Transferrin gene expression visualized in oligodendrocytes of the rat brain using in situ hybridization and immunohistochemistry. Proc Natl Acad Sci USA 82: 6706-6710, 1985. |
| 63. | Bö L, Quarles RH, Fujita N, Bartoszewicz Z, Sato S, and Trapp BD. Endocytic depletion of L-MAG from CNS myelin in quaking mice. J Cell Biol 131: 1811-1820, 1995. |
| 64. | Bogazzi F, Hudson LD, and Nikodem VM. A novel heterodimerization partner of thyroid hormone receptor. J Biol Chem 269: 11683-11686, 1994. |
| 65. | Bögler O, Wren D, Barnett SC, Land H, and Noble M. Cooperation between two growth factors extended self-renewal and inhibits differentiation of oligodendrocyte-type 2 astrocytes (O-2A) progenitor cells. Proc Natl Acad Sci USA 67: 6368-6372, 1990. |
| 66. | Boison D, Bussow H, D'Urso D, Muller HW, and Stoffel W. Adhesive properties of proteolipid protein are responsible for the compaction of CNS myelin sheaths. J Neurosci 15: 5502-5513, 1995. |
| 67. | Boison D, and Stoffel W. Disruption of the compacted myelin sheath of axons of the central nervous system in proteolipid protein-deficient mice. Proc Natl Acad Sci USA 91: 11709-11713, 1994. |
| 68. | Bongarzone ER, Howard SG, Schonmann V, and Campagnoni AT. Identification of the dopamine D3 receptor in oligodendrocyte precursors: potential role in regulating differentiation and myelin formation. J Neurosci 18: 5344-5353, 1998. |
| 69. | Bosio A, Binczek E, Le Beau MM, Fernald AA, and Stoffel W. The human gene CGT encoding the UDP-galactose ceramide galactosyl transferase (cerebroside synthase): cloning, characterization, and assignment to human chromosome 4, band q26. Genomics 34: 69-75, 1996. |
| 70. | Bosio A, Binczek E, and Stoffel W. Molecular cloning and characterization of mouse CGT gene encoding UDP-galactose ceramide-galactosyltransferase (cerebroside synthetase). Genomics 35: 223-226, 1996. |
| 71. | Bosio A, Binczek E, and Stoffel W. Functional breakdown of the lipid bilayer of the myelin membrane in central and peripheral nervous system by disrupted galactocerebroside synthesis. Proc Natl Acad Sci USA 93: 13280-13285, 1996. |
| 72. | Bourre JM, Paturneau-Jouas M, Daudu O, and Baumann N. Lignoceric acid biosynthesis in the developing brain. Activities of mitochondrial acetyl-CoA-dependent synthesis and microsomal malonyl-CoA chain-elongating system in relation to myelination. Eur J Biochem 72: 41-47, 1977. |
| 73. | Bradl M, and Linington C. Animal models of demyelination. Brain Pathol 6: 303-311, 1996. |
| 74. | Braun PE, De Angelis D, Shtybel WW, and Bernier L. Isoprenoid modification permits 2',3'-cyclic nucleotide-3'phosphodiesterase to bind to membranes. J Neurosci Res 30: 540-544, 1991. |
| 75. | Braun PE, Horvath E, Yong VW, and Bernier L. Identification of GTP-binding proteins in myelin and oligodendrocyte membranes. J Neurosci Res 26: 16-23, 1990. |
| 75a. | Brenner M, Johnson AB, Boespflug-Tanguy O, Rodriguez D, Goldman JE, and Messing A. Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease. Nature Genet 27: 117-120, 2001. |
| 76. | Bronstein JM, Micevych PE, and Chen K. Oligodendrocyte-specific protein (OSP) is a major component of CNS myelin. J Neurosci Res 50: 713-720, 1997. |
| 77. | Brosnan CF, and Raine CS. Mechanisms of immune injury in multiple sclerosis. Brain Pathol 6: 243-257, 1996. |
| 78. | Brown MC, Besio Moreno M, Bongarzone ER, Cohen PD, Soto EF, and Pasquini JM. Vesicular transport of myelin proteolipid and cerebroside sulfates to the myelin membrane. J Neurosci Res 35: 402-408, 1993. |
| 79. | Brunner C, Lassmann H, Waehneldt TV, Matthieu JM, and Linington C. Differential ultrastructural localization of myelin basic protein, myelin-oligodendroglial glycoprotein, and 2',3'-cyclic nucleotide 3'-phosphodiesterase in the CNS of adult rats. J Neurochem 52: 296-304, 1989. |
| 80. | Brustle O, Jones KN, Learish RD, Karram K, Choudhary K, Wiestler OD, Duncan ID, and McKay RD. Embryonic stem cell-derived glial precursors: a source of myelinating transplants. Science 285: 754-456, 1999. |
| 81. | Bruzzone R, and Ressot C. Connexins, gap junctions and cell-cell signaling in the nervous system. Eur J Neurosci 9: 1-6, 1997. |
| 82. | Bunge MB, Bunge RP, and Pappas GD. Electron microscopic demonstration of the connections between glia and myelin sheath in the developing mammalian central nervous system. J Cell Biol 12: 448-459, 1962. |
| 83. | Bunge MB, Bunge RP, and Ris H. Ultrastructural study of remyelination in an experimental lesion in adult cat spinal cord. J Biophys Biochem Cytol 10: 67-94, 1961. |
| 84. | Bunge RP. Glial cells and the central myelin sheath. Physiol Rev 48: 197-210, 1968. |
| 85. | Bureau JF, Drescher KM, Pease LR, Vikoren T, Delcroix M, Zoecklein L, Brahic M, and Rodriguez M. Chromosome 14 contains determinants that regulate susceptibility to Theiler's virus-induced demyelination in the mouse. Genetics 148: 1941-1949, 1998. |
| 86. | Burger D, Steck AJ, Bernard CCA, and Kerlero De Rosbo N. Human myelin/oligodendrocyte glycoprotein: a new member of the L2/HNK12 family. J Neurochem 61: 1822-1827, 1993. |
| 87. | Burne JF, Staple JK, and Raff MC. Glial cells are increased proportionally in transgenic optic nerves with increased number of axons. J Neurosci 16: 2064-2073, 1996. |
| 88. | Butt AM, Duncan A, Hornby MF, Kirvell SL, Hunter A, Levine J, and Berry M. Cells expressing the NG2 antigen contact nodes of Ranvier in adult CNS white matter. Glia 26: 84-91, 1999. |
| 89. | Butt AM, Ibrahim M, Ruge FM, and Berry M. Biochemical subtypes of oligodendrocyte in the anterior medullary velum of the rat as revealed by the monoclonal antibody Rip. Glia 14: 185-197, 1995. |
| 90. | Butt AM, and Ransom B. Visualization of oligodendrocytes and astrocytes in the intact rat optic nerve by intracellular injection of Lucifer Yellow and horseradish peroxidase. Glia 2: 470-475, 1989. |
| 91. | Calver AR, Hall AC, Yu WP, Walsh FS, Heath JK, Betsholtz C, and Richardson WD. Oligodendrocyte population dynamics and the role of PDGF in vivo. Neuron 20: 869-882, 1998. |
| 92. | Cambi F, Lees MB, Williams R, and Macklin WB. Chronic EAE produced by bovine proteolipid apoprotein: immunologic studies in rabbits. Ann Neurol 13: 303-308, 1983. |
| 93. | Cameron PL, Ruffin JW, Bollag R, Rasmussen H, and Cameron RS. Identification of caveolin and caveolin-related proteins in the brain. J Neurosci 17: 9520-9535, 1997. |
| 94. | Cameron-Curry P, and Le Douarin N. Oligodendrocyte precursors originate from both the dorsal and the ventral parts of the spinal cord. Neuron 15: 1299-1310, 1995. |
| 95. | Cammer W, and Zhang H. Carbonic anhydrase in distinct precursors of astrocytes and oligodendrocytes in the forebrains of neonatal and young rats. Brain Res Dev Brain Res 67: 257-263, 1992. |
| 96. | Campagnoni AT, Campagnoni CW, Bourre JM, Jacque C, and Baumann N. Cell-free synthesis of myelin basic proteins in normal and dysmyelinating mutant mice. J Neurochem 42: 733-739, 1984. |
| 97. | Campagnoni AT, and Macklin WB. Cellular and molecular aspects of myelin protein gene expression. Mol Neurobiol 2: 41-89, 1988. |
| 98. | Campagnoni AT, Pribyl TM, Campagnoni CW, Kampf K, Amur-Umarjee S, Landry CF, Handley VW, Newman SL, Garbay B, and Kitamura K. Structure and developmental regulation of the Golli-mbp, a 105-kilobase gene that encompasses the myelin basic protein gene and is expressed in cells in the oligodendrocyte lineage in the brain. J Biol Chem 265: 4930-4938, 1993. |
| 99. | Canoll PD, Kraemer R, Teng KK, Marchionni MA, and Salzer JL. GGF/neuregulin induces a phenotypic reversion of oligodendrocytes. Mol Cell Neurosci 13: 79-94, 1999. |
| 100. | Canoll PD, Musacchio JM, Hardy R, Reynolds R, Marchionni MA, and Salzer JL. GGF neuregulin is a neuronal signal that promotes the proliferation and survival and inhibits the differentiation of oligodendrocyte progenitors. Neuron 17: 229-243, 1996. |
| 101. | Capello E, Voskuhl RR, McFarland HF, and Raine CS. Multiple sclerosis: re-expression of a developmental gene in chronic lesions correlates with remyelination. Ann Neurol 41: 797-805, 1997. |
| 102. | Carango P, Funanage VL, Quiros RE, Debruyn CS, and Marks HG. Overexpression of DM20 messenger RNA in two brothers with Pelizaeus-Merzbacher disease. Ann Neurol 38: 610-617, 1995. |
| 103. | Carenini S, Montag D, Cremer H, Schachner M, and Martini M. Absence of the myelin-associated glycoprotein (MAG) and the neural cell adhesion molecule (N-CAM) interferes with the maintenance, but not with the formation of peripheral myelin. Cell Tissue Res 287: 3-9, 1997. |
| 104. | Carnegie PR. Amino acid sequence of the encephalitogenic basic protein from human myelin. Biochem J 123: 57-67, 1971. |
| 105. | Caroni P, and Schwab ME. Two membrane protein fractions from rat central myelin with inhibitory properties for neurite growth and fibroblast spreading. J Cell Biol 106: 1281-1288, 1988. |
| 106. | Caroni P, and Schwab ME. Antibody against myelin-associated inhibitor of neurite growth neutralizes non-permissive substrate properties of CNS white matter. Neuron 1: 85-96, 1988. |
| 107. | Carson MJ, Behringer RR, Brinster RL, and McMorris FA. Insulin-like growth factor 1 increases brain growth and central nervous system myelination in transgenic mice. Neuron 10: 729-740, 1993. |
| 108. | Cellerino A, Carroll P, Thoenen H, and Barde YA. Reduced size of retinal ganglion cell axons and hypomyelination in mice lacking brain-derived neurotrophic factor. Mol Cell Neurosci 9: 397-408, 1997. |
| 109. | Cepko C. Retrovirus vectors and their applications in neurobiology. Neuron 1: 345-353, 1988. |
| 110. |
Chakraborty G,
Ziemba S,
Drivas A, and Ledeen RW.
Myelin contains neutral sphingomyelinase activity that is stimulated by tumor necrosis factor- .
J Neurosci Res
50: 466-476, 1997.
|
| 111. | Chandler S, Coates R, Gearing A, Lury J, Wells G, and Bone E. Matrix metalloproteinases degrade myelin basic protein. Neurosci Lett 201: 223-226, 1995. |
| 112. | Charcot JM. Histologie de la Sclérose en Plaque. Gazette Hôpital (Paris) 41: 554-556, 1868. |
| 113. | Cheifetz S, and Moscarello MA. Effect of bovine basic protein charge microheterogeneity on protein-induced aggregation of unilamellar vesicles containing a mixture of acidic and neutral phospholipids. Biochemistry 24: 1909-1914, 1985. |
| 114. | Chen MS, Huber AB, Van Der Haar ME, Franck M, Schnell L, Spillmann AA, Christ F, and Schwab ME. Nogo-A is a myelin-associated neurite outgrowth inhibitor and an antigen for monoclonal antibody IN-1. Nature 403: 434-439, 2000. |
| 115. | Cheng CM, Joncas G, Reinhardt RR, Farrer R, Quarles R, Janssen J, McDonald MP, Crawley JN, Powell-Braxton L, and Bondy CA. Biochemical and morphometric analyses show that myelination in the insulin-like growth factor 1 null brain is proportionate to its neuronal composition. J Neurosci 18: 5673-5681, 1998. |
| 116. | Chou DKH, Ilyas AA, Evans JE, Costello C, Quarles RH, and Jungalwala FB. Structure of sulfated glucuronyl glycolipids in the nervous system reacting with HNK-1 antibody and some IgM paraproteins in neuropathy. J Biol Chem 261: 11717-11725, 1986. |
| 117. | Cochran FB, Yu RK, and Ledeen RW. Myelin gangliosides in vertebrates. J Neurochem 39: 773-779, 1982. |
| 118. | Coetzee T, Fujita N, Dupree J, Shi R, Blight A, Suzuki K, Suzuki K, and Popko B. Myelination in the absence of galactocerebroside and sulfatide: normal structure with abnormal function and regional instability. Cell 86: 209-219, 1996. |
| 119. | Coffey JC, and McDermott KW. The regional distribution of myelin oligodendrocyte glycoprotein (MOG) in the developing rat CNS: an in vivo immunohistochemical study. J Neurocytol 26: 149-161, 1997. |
| 120. | Colello RJ, Devey LR, Imperato E, and Pott U. The chronology of oligodendrocyte differentiation in the rat optic nerve: evidence for a signaling step initiating myelination in the CNS. J Neurosci 15: 7665-7672, 1995. |
| 121. | Collinson JM, Marshall D, Gillespie CS, and Brophy PJ. Transient expression of neurofascin by oligodendrocytes at the onset of myelinogenesis: implications for mechanisms of axon-glial interaction. Glia 23: 11-23, 1998. |
| 122. | Colman DR, Doyle JP, D'urso D, Kitagawa K, Pedraza L, Yoshida M, and Fannon AM. Speculations on myelin sheath evolution. In: Glial Cell Development, edited by Jessen KR, and Richardson WD. Oxford, UK: Bios Scientific, 1996, p. 85-100. |
| 123. | Colman DR, Kreibich G, Frey AB, and Sabatini DD. Synthesis and incorporation of myelin polypeptides into CNS myelin. J Cell Biol 95: 598-608, 1982. |
| 124. | Cossins JA, Clements JM, Ford J, Miller KM, Pigott R, Vos W, Van Der Valk P, and De Groot CJA. Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions. Acta Neuropathol 94: 590-598, 1997. |
| 125. | Couve E, Cabello JF, Krsulovic J, and Roncagliolo M. Binding of microtubules to transitional elements in oligodendrocytes of the myelin mutant taiep rat. J Neurosci Res 47: 573-581, 1997. |
| 126. | Craig C, Tropepe V, Morshead CM, Reynolds BA, Weiss S, and Van Der Kooy D. In vivo growth factor expansion of endogenous subependymal neural precursor cell populations in the adult mouse brain. J Neurosci 16: 2649-2658, 1996. |
| 127. | Curtis R, Cohen J, Fok-Seang J, Hanley MR, Gregson NA, Reynolds R, and Wilkin GP. Development of macroglial cells in rat cerebellum. I. Use of antibodies to follow early in vivo development and migration of oligodendrocytes. J Neurocytol 17: 43-54, 1988. |
| 128. | Dahl D. The vimentin-GFA protein transition in rat neuroglia cytoskeleton occurs at the time of myelination. J Neurosci Res 6: 741-748, 1981. |
| 129. | D'amelio F, Eng LF, and Gibbs MA. Glutamine synthetase immunoreactivity is present in oligodendroglia of various regions of the central nervous system. Glia 3: 335-341, 1990. |
| 130. | Daubas PM, Pham-Dinh D, and Dautigny A. Structure and polymorphism of the mouse myelin/oligodendrocyte glycoprotein. Genomics 23: 36-41, 1994. |
| 131. | Dautigny A, Mattei MG, Morello D, Alliel PM, Pham-Dinh D, Amar L, Arnaud D, Simon D, Mattei JF, Guenet JL, Jolles P, and Avner P. The structural gene coding for myelin-associated proteolipid protein is mutated in jimpy mice. Nature 321: 867-875, 1986. |
| 132. | David S, and Aguayo A. Axonal elongation into peripheral nervous system "bridges" after central nervous system injury in adult rats. Science 214: 931-933, 1981. |
| 133. | Davie CA, Barker GJ, Webb S, Tofts PS, Az. Thompson J, Harding AE, McDonald WI, and Miller DH. Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. Brain 118: 1583-1592, 1995. |
| 134. | Davies SJ, Fitch MT, Memberg SP, Hall AK, Raisman G, and Silver J. Regeneration of adult axons in white matter tracts of the central nervous system. Nature 390: 680-683, 1997. |
| 135. | Davis JO, Lambert S, and Bennett V. Molecular composition of the node of Ranvier; identification of ankyrin-binding cell adhesion molecules neurofascin (mucin+/third FNIII domain) and NrCAM at nodal axon segments. J Biol Chem 135: 1365-1368, 1996. |
| 136. | Davous P. Cadasil: a review with proposed diagnostic criteria. Eur J Neurol 5: 219-233, 1998. |
| 136a. | Dawson MR, Levine JM, and Reynolds R. NG2-expressing cells in the central nervous system: are they oligodendroglial progenitors? J Neurosci Res 61: 471-479, 2000. |
| 137. | De Ferra F, Engh H, Hudson L, Kamholz J, Puckett C, Molineaux S, and Lazzarini RA. Alternative splicing accounts for the four forms of myelin basic protein. Cell 43: 721-727, 1985. |
| 138. | Della Gaspera B, Pham-Dinh D, Roussel G, Nussbaum J-L, and Dautigny D. Membrane topology of the myelin/oligodendrocyte glycoprotein. Eur J Biochem 258: 478-484, 1998. |
| 139. | Demerens C, Stankof B, Logak M, Anglade P, Allinquant B, Couraud F, Zalc B, and Lubetzki C. Induction of myelination in the central nervous system by electrical activity. Proc Natl Acad Sci USA 93: 9887-9892, 1996. |
| 140. | Dermietzel R, Farooq M, Kessler JA, Althaus H, Hertzberg EL, and Spray DC. Oligodendrocytes express gap junction proteins connexin32 and connexin45. Glia 20: 101-114, 1997. |
| 141. | Dermietzel R, and Spray DC. Gap junctions in the brain: where, what type, how many and why? Trends Neurosci 16: 186-192, 1993. |
| 142. | D'eustachio P, Colman DR, and Salzer JL. Chromosomal location of the mouse gene that encodes the myelin-associated glycoproteins. J Neurochem 50: 589-593, 1988. |
| 143. | Dewar D, Yam P, and McCulloch J. Drug development for stroke: importance of protecting cerebral white matter. Eur J Pharmacol 375: 41-50, 1999. |
| 144. | Dickinson PJ, Fanarraga ML, Griffiths IR, Barrie JM, Kyriakides E, and Montague P. Oligodendrocyte progenitors in the embryonic spinal cord express DM-20. Neuropathol Appl Neurobiol 22: 188-198, 1996. |
| 145. | Dickinson PJ, Griffiths IR, Barrie JM, Kyriakides E, Pollock GF, and Barnett SC. Expression of the dm-20 isoform of the plp gene in olfactory nerve ensheathing cells: evidence from developmental studies. J Neurocytol 26: 181-189, 1997. |
| 146. | Diehl HJ, Schaich M, Budzinski RM, and Stoffel W. Individual exons encode the integral membrane domains of human myelin proteolipid proteins. Proc Natl Acad Sci USA 83: 9807-9811, 1986. |
| 147. | Ding Y, and Brunden KR. The cytoplasmic domain of myelin glycoprotein P0 interacts with negatively charged phospholipid bilayers. J Biol Chem 269: 10764-10770, 1994. |
| 148. | Di Trapani G, Gregori B, Servidei S, Ricci E, Sabatelli M, and Tonali P. Mitochondrial encephalopathy, lactic acidosis and stroke-like episodes (MELAS). Clin Neuropathol 16: 195-200, 1997. |
| 149. | Doetsch F, Garcia-Verdugo JM, and Alvarez-Buylla A. Cellular composition and three-dimensional organization of the subventricular germinal zone in the adult mammalian brain. J Neurosci 17: 5046-5061, 1997. |
| 150. | Doolittle DP, Baumann N, and Chernoff G. Allelism of two myelin deficiency mutations in the mouse. J Hered 72: 285, 1981. |
| 151. | Doolittle DP, and Schweikart KM. Myelin deficient, a new neurological mutant in the mouse. J Hered 68: 331-332, 1977. |
| 152. | Douglas AJ, Fox MF, Abbott CM, Hinks LJ, Sharpe G, Povey S, and Thompson RJ. Structure and chromosomal localization of 2'3'-cyclic nucleotide-3'-phosphodiesterase gene. Ann Hum Genet 56: 243-254, 1992. |
| 153. | Dubois C, Manuguerra JC, Hauttecoeur B, and Maze J. Monoclonal antibody A2B5, which detects cell surface antigens, binds to ganglioside GT3 [II3 (NeuAc)3LacCer] and to its 9-O-acetylated derivative. J Biol Chem 265: 2797-2803, 1990. |
| 154. | Dubois-Dalcq M, Behar T, Hudson L, and Lazzarini RA. Emergence of three myelin proteins in oligodendrocytes cultured without neurons. J Cell Biol 102: 384-392, 1986. |
| 155. | Dugandzija-Novakovic S, Koszowski AG, Levinson SR, and Shrager P. Clustering of Na+ channels and node of Ranvier formation in remyelinating axons. J Neurosci 15: 492-503, 1995. |
| 156. | Duncan ID. Glial cell transplantation and remyelination of the central nervous system. Neuropathol Appl Neurobiol 22: 87-100, 1996. |
| 157. | Duncan ID, Hammang JP, Goda S, and Quarles RH. Myelination in the jimpy mouse in the absence of proteolipid protein. Glia 2: 148-154, 1989. |
| 158. | Duncan ID, Hammang JP, and Trapp BD. Abnormal compact myelin in the myelin-deficient rat: absence of proteolipid protein correlates with a defect in the intra-period line. Proc Natl Acad Sci USA 84: 6287-6291, 1987. |
| 159. | Duncan ID, and Hoffman RL. Schwann cell invasion of the central nervous system of the myelin mutants. J Anat 190: 35-49, 1997. |
| 160. | Duncan ID, Lunn KF, Holmgren B, Urba-Holmgren R, and Brignolo-Holmes L. The taiep rat: a myelin mutant with an associated oligodendrocyte microtubular defect. J Neurocytol 21: 870-884, 1992. |
| 161. | Duncan ID, Nadon NL, Hoffman RL, Lunn KF, Csiza C, and Wells MR. Oligodendrocyte survival and function in the long-lived strain of the myelin deficient rat. J Neurocytol 24: 745-762, 1995. |
| 162. | Dupouey P, Jacque C, Bourre JM, Cesselin F, Privat A, and Baumann N. Immunochemical studies of myelin basic protein in shiverer mouse devoid of major dense line of myelin. Neurosci Lett 12: 113-118, 1979. |
| 163. | Dupree JL, Coetzee T, Blight A, Suzuki K, and Popko B. Myelin galactolipids are essential for proper node of Ranvier formation in the CNS. J Neurosci 18: 1642-1649, 1998. |
| 164. | Dyer CA, and Benjamins JA. Antibody to galactocerebroside alters organization of oligodendroglial membrane sheets in culture. J Neurosci 8: 4307-4318, 1988. |
| 165. | Dyer CA, Hickey WF, and Geisert EE. Myelin/oligodendrocyte specific protein: a novel surface membrane protein that associates with microtubules. J Neurosci Res 28: 607-613, 1991. |
| 166. | Ebersole TA, Chen Q, Justice MJ, and Artzt K. The quaking gene product necessary in embryogenesis and myelination combines features of RNA binding and signal transduction proteins. Nat Genet 12: 260-265, 1996. |
| 167. | Ebersole T, Rho O, and Artzt K. The proximal end of mouse chromosome 17: new molecular markers identify a deletion associated with quakingviable. Genetics 131: 183-190, 1992. |
| 168. | Eccleston PA, and Silberberg DH. Fibroblast growth factor is a mitogen for oligodendrocytes in vitro. Brain Res 210: 315-318, 1984. |
| 169. | Edwards AM, Arquint M, Braun PE, Roder JC, Dunn RJ, Pawson T, and Bell JC. Myelin-associated glycoprotein, a cell adhesion molecule of oligodendrocytes, is phosphorylated in brain. Mol Cell Biol 8: 2655-2658, 1988. |
| 170. | Eicher EM, and Hoppe PC. Use of chimeras to transmit lethal genes in the mouse and to demonstrate allelism of the two X-linked male lethal genes jp and msd. J Exp Zool 183: 181-184, 1973. |
| 171. | Einheber S, Zanazzi G, Ching W, Scherer S, Milner TA, Peles E, and Salzer JL. The axonal membrane protein Caspr, a homologue of neurexin IV, is a component of the septate-like paranodal junctions that assemble during myelination. J Cell Biol 139: 1495-1506, 1997. |
| 172. | Eisenbarth GS, Walsh FS, and Nirenberg M. Monoclonal antibody to a plasma membrane antigen of neurons. Proc Natl Acad Sci USA 76: 4913-4917, 1979. |
| 173. | Ellison J, and de Vellis J. Platelet-derived growth factor receptor is expressed by cells in the early oligodendrocyte lineage. J Neurosci Res 37: 116-128, 1994. |
| 174. | Ellison J, and De Vellis J. Amoeboid microglia expressing GD3 ganglioside are concentrated in areas of oligodendrogliogenesis during development of the rat corpus callosum. Glia 14: 123-132, 1995. |
| 175. | Ernfors P, Lonnerberg P, Ayer-Lelievre C, and Persson P. Developmental and regional expression of basic fibroblast growth factor mRNA in the rat central nervous system. J Neurosci Res 27: 10-15, 1990. |
| 176. | Espinosa de los Monteros A, Pena LA, and de Vellis J. Does transferrin have a special role in the nervous system? J Neurosci Res 24: 125-136, 1989. |
| 177. | Espinosa de los Monteros A, Zhang M, and De Vellis J. O2A progenitor cells transplanted into the neonatal rat brain develop into oligodendrocytes but not astrocytes. Proc Natl Acad Sci USA 90: 50-54, 1993. |
| 178. | Eylar EH, Brostoff S, Hashim G, Caccam J, and Burnett P. Basic protein of the myelin membrane, the complete amino acid sequence. J Biol Chem 246: 5770-5784, 1971. |
| 179. | Fanarraga ML, Griffiths IR, McCulloch MC, Barrie JA, Kennedy PG, and Brophy PJ. Rumpshaker: an X-linked mutation causing hypomyelination: developmental differences in myelination and glial cells between the optic nerve and spinal cord. Glia 5: 161-170, 1992. |
| 180. | Farkas-Bargeton E, Robain O, and Mandel P. Abnormal glial maturation in the white matter in Jimpy mice. An optical study. Acta Neuropathol 21: 272-281, 1972. |
| 181. | Farrer RG, and Quarles RH. GT3 and its O-acetylated derivative are the principal A2B5-reactive gangliosides in cultured O2A lineage cells and are down-regulated along with O-acetyl GD3 during differentiation to oligodendrocytes. J Neurosci Res 57: 371-380, 1999. |
| 182. | Farsetti A, Mitsubashi T, Desvergne B, Robbins J, and Nikodem VM. Molecular basis of thyroid hormone regulation of myelin basic protein gene expression in rodent brain. J Biol Chem 266: 23226-23232, 1991. |
| 183. | Fawcett JW, and Geller HM. Regeneration in the CNS: optimism mounts. Trends Neurosci 21: 179-180, 1998. |
| 184. | Fazakerley JK, and Buchmeier MJ. Pathogenesis of virus-induced demyelination. Adv Virus Res 42: 249-324, 1993. |
| 185. | Ferguson B, Matyszak MK, Esiri MM, and Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain 120: 393-399, 1997. |
| 186. | Fern R, and Moller T. Rapid ischemic cell death in immature oligodendrocytes: a fatal glutamate release feedback loop. J Neurosci 20: 34-42, 2000. |
| 187. | Ffrench-Constant C, Miller RH, Burne JF, and Raff MC. Evidence that migratory oligodendrocyte-type-2 astrocyte (O-2A) progenitor cells are kept out of the rat retina by a barrier at the eye-end of the optic nerve. J Neurocytol 17: 13-25, 1988. |
| 188. | Filbin MT. The muddle with MAG. Mol Cell Neurosci 8: 84-92, 1996. |
| 189. | Fischer G, and Kettenmann H. Cultured astrocytes form a syncytium after maturation. Exp Cell Res 159: 273-279, 1985. |
| 190. | Folch J, and Lees MB. Proteolipids, a new type of tissue lipoproteins, their isolation from brain. J Biol Chem 191: 807-817, 1951. |
| 191. | Foran DR, and Peterson AC. Myelin acquisition in the central nervous system of the mouse revealed by an MBP-Lac Z transgene. J Neurosci 12: 4890-4897, 1992. |
| 192. | Forss-Peter S, Werner H, Berger J, Lassmann H, Molzer B, Schwab MK, Bernheimer H, Zimmermann F, and Nave KA. Targeted inactivation of the X-linked adrenoleukodystrophy gene in mice. J Neurosci 50: 829-843, 1997. |
| 193. | Fortin D, Cairncross JG, and Hammond RR. Oligodendroglioma: an appraisal of recent data pertaining diagnosis and treatment. Neurosurgery 45: 1279-1291, 1999. |
| 194. | Frail DE, Webster HD, and Braun PE. Developmental expression of the myelin-associated glycoprotein in the peripheral nervous system is different from that in the central nervous system. J Neurochem 45: 1308-1310, 1985. |
| 195. | Frank M, Van Der Haar ME, Schaeren-Wiemers N, and Schwab ME. rMAL is a glycosphingolipid-associated protein of myelin and apical membranes of epithelial cells in kidney and stomach. J Neurosci 18: 4901-4913, 1998. |
| 196. | Franklin RJM, and Blakemore WF. Glial cell transplantation and plasticity in the O-2A lineage: implications for CNS repair. Trends Neurosci 18: 151-156, 1995. |
| 197. | Franklin RJM, and Blakemore WF. Transplanting oligodendrocyte progenitors into the adult CNS. J Anat 190: 23-33, 1997. |
| 198. | Fredman P, Magnani JL, Nirenberg M, and Ginsburg V. Monoclonal antibody A2B5 reacts with many gangliosides in neuronal tissue. Arch Biochem Biophys 233: 661-666, 1984. |
| 199. | Friedman B, Hockfield S, Black J, Woodruf KA, and Waxman SG. In situ demonstration of mature oligodendrocytes and their processes: an immunocytochemical study with a new monoclonal antibody, Rip. Glia 2: 380-390, 1989. |
| 200. | Frost E, Kiernan BW, Faissner A, and Ffrench-Constant C. Regulation of oligodendrocyte precursor migration by extracellular matrix: evidence for substrate-specific inhibition of migration by tenascin-C. Dev Neurosci 18: 266-273, 1996. |
| 201. | Fruttiger M, Karlsson L, Hall AC, Abramsson A, Calver AR, Bostrom H, Willetts K, Bertold CH, Heath JK, Betsholtz C, and Richardson WD. Defective oligodendrocyte development and severe hypomyelination in PDGF-A knock-out mice. Development 126: 457-467, 1999. |
| 202. | Fruttiger M, Montag D, Schachner M, and Martini R. Crucial role for the myelin-associated glycoprotein in the maintenance of axon-myelin integrity. Eur J Neurosci 7: 511-515, 1995. |
| 203. | Fujita N, Kemper A, Dupree J, Nakayasu H, Bartsch U, Schachner M, Maeda N, Suzuki K, and Popko B. The cytoplasmic domain of the large myelin-associated glycoprotein isoform is needed for proper CNS but not peripheral nervous system myelination. J Neurosci 18: 1970-1978, 1998. |
| 204. | Fujita N, Suzuki K, Vanier MT, Popko B, Maeda N, Klein A, Henseler M, Sandhoff K, Nakayasu H, and Suzuki K. Targeted disruption of the mouse sphingolipid activator protein gene: a complex phenotype, including severe leukodystrophy and wide-spread storage of multiple sphingolipids. Hum Mol Genet 5: 711-725, 1996. |
| 205. | Fulcrand J, and Privat A. Neuroglial reactions secondary to Wallerian degeneration in the optic nerve of the postnatal rat: ultrastructural and quantitative study. J Comp Neurol 176: 189-224, 1977. |
| 206. | Gallo V, and Armstrong RC. Developmental and growth factor-induced regulation of nestin in oligodendrocyte lineage cells. J Neurosci 15: 394-406, 1995. |
| 207. | Gallo V, Zhou JM, McBain CJ, Wright PW, Knutson PL, and Armstrong RC. Oligodendrocyte progenitor cell proliferation and lineage progression are regulated by glutamate receptor-mediated K+ channel block. J Neurosci 16: 2659-2670, 1996. |
| 208. | Gao FB, Apperly J, and Raff M. Cell-intrinsic timers and thyroid hormone regulate the probability of cell-cycle withdrawal and differentiation of oligodendrocyte precursor cells. Dev Biol 197: 54-66, 1998. |
| 209. | Garbern JY, Cambi F, Tang XM, Sima AAF, Vallat JM, Bosch EP, Lewis R, Shy M, Sohl J, Kraft G, Chen KL, Joshi I, Leonard DGB, Johnson W, Raskind W, Dlouhy SR, Pratt V, Hodes ME, Bird T, and Kamholz J. Proteolipid protein is necessary in peripheral as well as central myelin. Neuron 19: 205-218, 1997. |
| 210. | Gard AL, Burrell MR, Pfeiffer SE, Rudge JS, and Williams WC II. Astroglial control of oligodendrocyte survival mediated by PDGF and leukemia inhibitory factor-like protein. Development 121: 2187-2197, 1995. |
| 211. | Gard AL, and Pfeiffer S. Glial cell mitogens bFGF and PDGF differentially regulate development of O4+GalC- oligodendrocyte progenitors. Dev Biol 159: 618-630, 1993. |
| 212. | Gardinier MV, Imaged P, Linington C, and Matthieu JM. Myelin-oligodendrocyte glycoprotein is a unique member of the immunoglobulin superfamily. J Neurosci Res 33: 177-187, 1992. |
| 213. | Gay CT, Hardies LJ, Rauch RA, Lancaster JL, Plaetke R, DuPont BR, Cody JD, Cornell JE, Herndon RC, Ghidoni PD, Schiff JM, Kaye CI, Leach RJ, and Fox PT. Magnetic resonance imaging demonstrates incomplete myelination in 18q-syndrome: evidence for myelin basic protein haploinsufficiency. Am J Med Genet 74: 422-431, 1997. |
| 214. | Genain CP, Abel K, Belmar N, Villinger F, Rosenberg DP, Linington C, Raine CS, and Hauser SL. Late complications of immune deviation therapy in a nonhuman primate. Science 274: 2054-2057, 1996. |
| 215. | Genain CP, Cannella B, Hauser SL, and Raine CS. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med 5: 170-175, 1999. |
| 216. | Gensert JM, and Goldman JE. Endogenous progenitors remyelinate demyelinated axons in the adult CNS. Neuron 19: 197-203, 1997. |
| 217. | Ghandour MS, Langley OK, Vincendon G, Gombos G, Filippi D, Limozin N, Dalmasso C, and Laurent G. Immunochemical and immunohistochemical study of carbonic anhydrase II in adult rat cerebellum. A marker for oligodendrocytes. Neuroscience 5: 559-571, 1980. |
| 218. | Giaume C, and Venance L. Gap junctions in brain glial cells and development. Perspect Dev Neurobiol 2: 335-345, 1995. |
| 219. | Gieselmann V, Zlotogora J, Harris A, Wenger D, and Morris CP. Molecular genetics of metachromatic leukodystrophy. Hum Mutat 4: 233-243, 1994. |
| 220. | Gillen C, Gleichmann R, Greiner-Petter R, Zoidl G, Kupfer S, Bosse F, Auer J, and Muller HW. Full-length cloning, expression and cellular localization of rat plasmolipin mRNA, a proteolipid of PNS and CNS. Eur J Neurosci 8: 405-414, 1996. |
| 221. | Gogate N, Verma L, Zhou JM, Milward E, Rusten R, O'connor M, Kufta C, Kim J, Hudson L, and Dubois-Dalcq M. Plasticity in the human oligodendrocyte lineage. J Neurosci 14: 4571-4587, 1994. |
| 222. | Goldberg JL, and Barres BA. Nogo in nerve regeneration. Nature 403: 369-370, 2000. |
| 223. | Goldman JE, and Reynolds R. A reappraisal of ganglioside GD3 expression in the CNS. Glia 16: 291-295, 1996. |
| 224. | Goujet-Zalc C, Babinet C, Monge M, Timsit S, Cabon F, Gansmuller A, Miura M, Sanchez M, Pournin S, and Mikoshiba K. The proximal region of the MBP gene promoter is sufficient to induce oligodendroglial-specific expression in transgenic mice. Eur J Neurosci 5: 624-632, 1993. |
| 225. | Gould RM, Byrd AL, and Barbarese E. The number of Schmidt-Lanterman incisures is more than doubled in shiverer PNS myelin sheaths. J Neurocytol 24: 85-98, 1995. |
| 226. | Gout O, Gansmuller A, Baumann N, and Gumpel M. Remyelination by transplanted oligodendrocytes of a demyelinated lesion in the spinal cord of the adult shiverer model. Neurosci Lett 89: 195-199, 1988. |
| 227. | Gow A, Friedrich VL, and Lazzarini RA. Myelin basic protein gene contains separate enhancers for oligodendrocyte and Schwann cell expression. J Cell Biol 119: 605-616, 1992. |
| 228. | Gow A, Friedrich VL, and Lazzarini RA. Intracellular transport and sorting of the oligodendrocyte transmembrane proteolipid protein. J Neurosci Res 37: 563-573, 1994. |
| 229. | Gow A, Gragerov A, Gard A, Colman DR, and Lazzarini RA. Conservation of topology, but not conformation, of the proteolipid proteins of the myelin sheath. J Neurosci 17: 181-189, 1997. |
| 230. | Gow A, and Lazzarini RA. A cellular mechanism governing the severity of Pelizaeus-Merzbacher disease. Nature Genet 13: 422-428, 1996. |
| 231. | Gow A, Southwood CM, Li JS, Pariali M, Riordan GP, Brodie SE, Danias J, Bronstein JM, Kachar B, and Lazzarini RA. CNS myelin and Sertoli cell tight junction strands are absent in Osp/claudin-11 null mice. Cell 99: 649-659, 1999. |
| 232. | Grandpre T, Nakamura F, Vartanian T, and Strittmatter SM. Identification of the Nogo inhibitor of axon regeneration as a reticulon protein. Nature 403: 439-444, 2000. |
| 233. | Gravel M, Peterson J, Yong VW, Kottis V, Trapp B, and Braun PE. Overexpression of 2'3'-cyclic nucleotide 3'phosphodiesterase in transgenic mice alters oligodendrocyte development and produces aberrant myelination. Mol Cell Neurosci 6: 453-466, 1996. |
| 234. | Griffiths IR, Duncan ID, and McCulloch M. Shaking pups: a disorder of central myelination in the spaniel dog. II. Ultrastructural observations on the white matter of the cervical spinal cord. J Neurocytol 10: 847-858, 1981. |
| 235. | Griffiths IR, Klugmann M, Anderson T, Yool D, Thomson C, Schwab MH, Schneider A, Zimmermann F, McCulloch M, Nadon N, and Nave KA. Axonal swellings and degeneration in mice lacking the major proteolipid of myelin. Science 280: 1610-1613, 1998. |
| 236. | Griffiths IR, Scott I, McCulloch MC, Barrie JA, McPhilemy K, and Cattanach BM. Rumpshaker mouse: a new X-linked mutation affecting myelination: evidence for a defect in PLP expression. J Neurocytol 19: 273-283, 1990. |
| 237. | Grima B, Zelenika D, Javoy-Agid F, and Pessac B. Identification of new human myelin basic protein transcripts in the immune and central nervous systems. Neurobiol Dis 1: 61-66, 1994. |
| 238. | Grima B, Zelenika D, and Pessac B. A novel transcript overlapping the myelin basic protein gene. J Neurochem 59: 2318-2323, 1992. |
| 239. | Grinspan J, and Franceschini B. Platelet-derived growth factor is a survival factor for PSA-NCAM+ oligodendrocyte pre-progenitor cells. J Neurosci Res 41: 540-545, 1995. |
| 240. | Griot C, Burge T, Vandevelde M, and Peterhans E. Antibody-induced generation of reactive oxygen radicals by brain macrophages in canine distemper encephalitis: a mechanism for bystander demyelination. Acta Neuropathol 78: 396-403, 1989. |
| 241. | Gross RE, Mehler MF, Mabie PC, Zang Z, Santschi L, and Kessler JA. Bone morphogenetic proteins promote astroglial lineage commitment by mammalian subventricular zone progenitor cells. Neuron 17: 595-606, 1996. |
| 242. | Gyllesten L, Malmfors T, and Norrlin-Gretve ML. Developmental and functional alterations in the fiber composition of the optic nerve in visually deprived mice. J Comp Neurol 128: 413-418, 1966. |
| 243. | Habib AA, Marton LS, Allwart B, Gulcher JR, Mikol DD, Hognason T, Chattopadhyay N, and Stefansson K. Expression of the oligodendrocyte-myelin glycoprotein by neurons in the mouse central nervous system. J Neurochem 70: 1704-1711, 1998. |
| 244. | Hajihosseini M, Tham TN, and Dubois-Dalcq M. Origin of oligodendrocytes within the human spinal cord. J Neurosci 16: 7981-7994, 1996. |
| 245. | Hardy RJ. Dorsoventral patterning and oligodendroglial specification in the developing central nervous system. J Neurosci Res 50: 139-145, 1997. |
| 246. | Hardy RJ, and Friedrich VL. Progressive remodeling of the oligodendrocyte process arbor during myelinogenesis. Dev Neurosci 18: 243-254, 1996. |
| 247. | Hardy RJ, Lazzarini RA, Colman DR, and Friedrich VL. Cytoplasmic and nuclear localization of myelin basic proteins reveals heterogeneity among oligodendrocytes. J Neurosci Res 46: 246-257, 1996. |
| 248. | Hardy R, and Reynolds R. Proliferation and differentiation potential of rat forebrain oligodendroglial progenitors both in vitro and in vivo. Development 111: 1061-1080, 1991. |
| 249. | Hardy R, and Reynolds R. Neuron-oligodendroglial interactions during central nervous system development. J Neurosci Res 36: 121-126, 1993. |
| 250. | Hart IK, Richardson WD, Bolsover SR, and Raff MC. PDGF and intracellular signaling in the timing of oligodendrocyte differentiation. J Cell Biol 109: 3411-3417, 1989. |
| 251. | Head MW, Corbin E, and Goldman JE. Overexpression and abnormal modification of the stress proteins alpha B-crystallin and HSP27 in Alexander disease. Am J Pathol 143: 1743-1753, 1993. |
| 252. | Hess B, Saftig P, Hartmann D, Coenen R, Lüllmann-Rauch R, Goebel H, Evers M, Von Figura K, D'hooge R, Nagels G, DeDeyn P, Peters C, and Gieselmann V. Phenotype of arylsulfatase A-deficient mice: relationships to human metachromatic leukodystrophy. Proc Natl Acad Sci USA 93: 14821-14826, 1996. |
| 253. | Hildebrand C, Remahl S, Persson H, and Bjartmar C. Myelinated nerve fibers in the CNS. Prog Neurobiol 40: 319-384, 1993. |
| 254. | Hill JR, Kuriyama N, Kuriyama H, and Israel MA. Molecular genetics of brain tumors. Arch Neurol 56: 439-441, 1999. |
| 255. | Hilton AA, Slavin AJ, Hilton DJ, and Bernard CCA. Characterization of cDNA and genomic clones encoding human myelin oligodendrocyte glycoprotein. J Neurochem 65: 309-318, 1995. |
| 256. | Hirano A, and Dembitzer HM. Further studies on the transverse bands. J Neurocytol 11: 851-856, 1982. |
| 257. | Hockfield S, and McKay RDG. Identification of major cell classes in the developing mammalian nervous system. J Neurosci 5: 3310-3328, 1985. |
| 258. | Holz A, Frank M, Copeland NG, Gilbert DJ, Jenkins NA, and Schwab ME. Chromosomal localization of the myelin-associated oligodendrocytic basic protein and expression in the genetically linked neurological mouse mutants Ducky and Tippy. J Neurochem 69: 1801-1809, 1997. |
| 259. | Holz A, and Schwab ME. Developmental expression of the myelin gene MOBP in the rat nervous system. J Neurocytol 6: 467-477, 1997. |
| 260. | Honmou O, Felts PA, Waxman SG, and Kocsis JD. Restoration of normal conduction properties in demyelinated spinal cord axons in the adult rat by transplantation of exogenous Schwann cells. J Neurosci 16: 3199-3208, 1996. |
| 261. | Hosoya T, Takizawa K, Nitta K, and Hotta Y. Glial cells missing: a binary switch between neuronal and glial determination in Drosophila. Cell 82: 1025-1036, 1995. |
| 262. | Howard S, Landry CF, Fisher R, Bezouglaia O, Handley V, and Campagnoni AT. The postnatal localization and morphogenesis of cells expressing the dopaminergic D2 receptor gene in rat brain: expression in non-neuronal cells. J Comp Neurol 391: 87-98, 1998. |
| 263. | Hsieh ST, Kidd GJ, Crawford TO, Yu Z, Trapp BD, Cleveland DW, and Griffin JW. Regional modulation of neurofilament organization by myelination in normal axons. J Neurosci 14: 6392-6401, 1994. |
| 264. | Huber LA, Madison DL, Simons K, and Pfeiffer SE. Myelin membrane biogenesis by oligodendrocytes. Developmental regulation of low molecular weight GTP-binding proteins. FEBS Lett 347: 273-278, 1994. |
| 265. | Hudson LD, Ko N, and Kim JG. Control of myelin gene expression. In: Glial Cell Development, edited by Jessen K, and Richardson W. Oxford, UK: Bios Scientific, 1994, p. 101-122. |
| 266. | Hunter SF, Miller DJ, and Rodriguez M. Monoclonal remyelination-promoting natural autoantibody SCH 94.03: pharmacokinetics and in vivo targets within demyelinated spinal cord in a mouse model of multiple sclerosis. J Neurol Sci 150: 103-113, 1997. |
| 267. | Huo B, Dozin B, and Nikodem VM. Identification of a nuclear protein from rat developing brain as heterodimerization partner with thyroid hormone receptor beta. Endocrinology 138: 3283-3289, 1997. |
| 268. | Husaby ES, and Goverman J. Tolerating the nervous system: a delicate balance. J Exp Med 191: 757-760, 2000. |
| 269. | Ibarrola N, and Rodriguez-Pena A. Hypothyroidism coordinately and transiently affects myelin protein gene expression in most rat regions during postnatal development. Brain Res 752: 285-293, 1997. |
| 270. | Ichimura T, and Ellisman MH. Three-dimensional fine structure of cytoskeletal-membrane interactions at nodes of Ranvier. J Neurocytol 20: 667-681, 1991. |
| 271. | Ichioka T, Kishimoto Y, Brennan S, Santos GW, and Yeager AM. Hematopoietic cell transplantation in murine globoid cell leukodystrophy-the twitcher mouse-: effects on levels of galactosylceramidase, psychosine, and galactocerebrosides. Proc Natl Acad Sci USA 84: 4259-4263, 1987. |
| 272. | Ikenaka K, Kagawa T, and Mikoshiba K. Selective expression of DM-20 and alternatively spliced myelin proteolipid protein gene product, in developing nervous system and in nonglial cells. J Neurochem 58: 2248-2453, 1992. |
| 273. | Imaizumi T, Lankford KL, Waxman SG, Greer CA, and Kocsis JD. Transplanted olfactory ensheathing cells remyelinate and enhance axonal conduction in the demyelinated dorsal columns of the rat spinal cord. J Neurosci 18: 6176-6185, 1998. |
| 274. | Inoue T, Tamura T, Furuichi T, and Mikoshiba K. Isolation of complementary DNAs encoding a cerebellum-enriched nuclear factor I family that activates transcription from the mouse myelin basic protein promoter. J Biol Chem 265: 19065-19070, 1990. |
| 275. | Iwaki T, Kume-Iwaki A, Liem RK, and Goldman JE. Alpha B-crystallin is expressed in non-lenticular tissues and accumulates in Alexander's disease brain. Cell 57: 71-78, 1989. |
| 276. | Jacque C, Bourre JM, Moreno P, and Baumann N. Composition en acides gras de lipides totaux et des cérébrosides chez les souris normales et quaking en fonction de l'âge. Biochimie 53: 1121-1124, 1971. |
| 277. | Jacque C, Lachapelle F, Collier P, Raoul M, and Baumann N. Accumulation of GFA, the monomeric precursor of the gliofilaments, during development in normal mice and dysmyelinating mutants. J Neurosci Res 5: 379-385, 1980. |
| 278. | Jeffery ND, and Blakemore WF. Remyelination of mouse spinal cord axons demyelinated by local injection of lysolecithin. J Neurocytol 24: 775-781, 1995. |
| 279. | Jensen AB, and Raff MC. Continuous observation of multipotential retinal progenitor cells in clonal density culture. Dev Biol 188: 267-279, 1997. |
| 280. | Johansson CB, Momma S, Clarke DL, Risling M, Lendahl U, and Frisen J. Identification of a neural stem cell in the adult mammalian central nervous system. Cell 96: 25-34, 1999. |
| 281. | Johe KK, Hazel TG, Muller T, Dugich-Djordjevic MM, and McKay RDG. Single factors direct differentiation of stem cells from the fetal and adult central nervous system. Genes Dev 10: 3129-3140, 1996. |
| 282. | Johns TG, and Bernard CC. Binding of complement component C1q to myelin oligodendrocyte glycoprotein: a novel mechanism for regulating CNS inflammation. Mol Immunol 34: 33-38, 1997. |
| 283. | Johns TG, Kerlero de Rosbo N, Menon KK, Abo S, Gonzales MF, and Bernard CC. Myelin oligodendrocyte glycoprotein induces a demyelinating encephalomyelitis resembling multiple sclerosis. J Immunol 154: 5536-5541, 1995. |
| 284. | Johnson AR, Kaul R, Casanova J, and Matalon R. Aspartoacylase, the deficient enzyme in spongy degeneration (Canavan disease) is a myelin-associated enzyme. J Neuropathol Exp Neurol 48: 349, 1989. |
| 285. | Jones BW, Fetter RD, Tear G, and Goodman CS. Glial cells missing: a genetic switch that controls glial versus neuronal fate. Cell 82: 1013-1023, 1995. |
| 286. | Jung M, Sommer I, Schachner M, and Nave KA. Monoclonal antibody O10 defines a conformationaly sensitive cell-surface epitope of proteolipid protein (PLP): evidence that PLP misfolding underlies dysmyelination in mutant mice. J Neurosci 16: 7920-7929, 1996. |
| 287. | Jung-Testas I, Schumacher M, Robel P, and Baulieu EE. Action of steroid hormones and growth factors on glial cells of the central and peripheral nervous system. J Steroid Biochem Mol Biol 48: 145-154, 1994. |
| 288. | Kagawa T, Ikenaka K, Inoue Y, Kuriyama S, Tsujii T, Nakao J, Nakajima K, Aruga J, Okano H, and Mikoshiba K. Glial cell degeneration and hypomyelination caused by overexpression of myelin proteolipid protein gene. Neuron 13: 427-442, 1994. |
| 289. | Kahn MA, Kumar S, Liebl D, Chang R, Parada LF, and De Vellis J. Mice lacking NT-3, and its receptor TrkC, exhibit profound deficiencies in CNS glial cells. Glia 26: 153-165, 1999. |
| 290. | Kalwy S, Marty MC, Bausero P, and Pessac B. Myelin basic protein-related proteins in mouse brain and immune tissues. J Neurochem 70: 435-438, 1998. |
| 291. | Kamholz J, Toffeneti J, and Lazzarini RA. Organization and expression of the human myelin basic protein gene. J Neurosci Res 21: 62-70, 1988. |
| 292. | Kanfer J, Parenty M, Goujet-Zalc C, Monge M, Bernier L, Campagnoni AT, Dautigny A, and Zalc B. Developmental expression of myelin proteolipid, basic protein and 2',3'-cyclic nucleotide 3'-phosphodiesterase transcripts in different rat brain regions. J Mol Neurosci 1: 39-46, 1989. |
| 293. | Kaplan MR, Meyer-Franke A, Lambert S, Bennett V, Duncan ID, Levinson SR, and Barres BA. Induction of sodium channels by oligodendrocytes. Nature 386: 724-728, 1997. |
| 294. | Kerlero De Rosbo N, Mendel I, and Ben-Nun A. Chronic relapsing experimental autoimmune encephalomyelitis with a delayed onset and an atypical course, induced on PL/J mice by myelin oligodendrocyte glycoprotein (MOG)-derived peptide. Preliminary analysis of MOG T cell epitopes. Eur J Immunol 25: 985-993, 1995. |
| 295. | Kidd GJ, Hauer PE, and Trapp BD. Axons modulate myelin protein messenger RNA levels during central nervous system myelination in vivo. J Neurosci Res 26: 409-418, 1990. |
| 296. | Kies MW, Murphy JB, and Alvord EC. Fractionation of guinea-pig proteins with encephalitogenic activity (Abstract). Federation Proc 19: 207, 1965. |
| 297. | Kim JG, and Hudson LD. Novel member of the zinc finger superfamily: a C2-HC finger that recognizes a glia-specific gene. Mol Cell Biol 12: 5632-5639, 1992. |
| 298. | Kim T, Fiedler K, Madison DL, Krueger WH, and Pfeiffer SE. Cloning and characterization of MVP17: a developmentally regulated myelin protein in oligodendrocytes. J Neurosci Res 42: 413-422, 1995. |
| 299. | Kimura M, Sato M, Akatsuka A, Nozawa-Kimura S, Takahashi R, Yokoyama M, Nomura T, and Katsuki M. Restoration of myelin formation by a single type of myelin basic protein in transgenic Shiverer mouse. Proc Natl Acad Sci USA 86: 5661-5665, 1989. |
| 300. | Kimura M, Sato M, Akatsuka A, Saito S, Ando K, Yokoyama M, and Katsuki M. Overexpression of a minor component of myelin basic protein isoform (172 kDa) can restore myelinogenesis in transgenic shiverer mice. Brain Res 785: 245-252, 1998. |
| 301. | King H, McCulloch MC, Barrie JA, Kyriakides E, Beechey CV, Cattanach BM, and Griffiths IR. Hindshaker, a novel myelin mutant showing hypomyelination preferentially affecting the spinal cord. J Neurocytol 26: 557-566, 1997. |
| 302. | Kirschner DA, and Ganser A. Compact myelin exists in the absence of basic protein in the shiverer mutant mouse. Nature 283: 207-210, 1980. |
| 303. | Kitagawa K, Sinoway MP, Yang C, Gould RM, and Colman DR. A proteolipid protein gene family: expression in sharks and rays and possible evolution from an ancestral gene encoding a pore-forming polypeptide. Neuron 11: 433-448, 1993. |
| 304. | Klein L, Klugmann M, Nave KA, and Kyewski B. Shaping of the autoreactive T-cell repertoire by a splice variant of self protein expressed in thymic epithelial cells. Nat Med 6: 56-61, 2000. |
| 305. | Klugmann M, Schwab MH, Pulhofer A, Schneider A, Zimmermann F, Griffiths IR, and Nave KA. Assembly of CNS myelin in the absence of proteolipid protein. Neuron 18: 59-70, 1997. |
| 306. | Knapp PE, Maderspach K, and Hauser KF. Endogenous opioid system in developing normal and Jimpy oligodendrocytes: mu and kappa opioid receptors mediate differential mitogenic and growth responses. Glia 22: 189-201, 2000. |
| 307. | Knapp PE, Skoff RP, and Redstone DW. Oligodendroglial cell death in jimpy mice: an explanation for the myelin deficit. J Neurosci 6: 2813-2822, 1986. |
| 308. | Kobayashi T, Shinnoh N, Kondo A, and Yamada T. Adrenoleukodystrophy protein-deficient mice represent abnormality of very long chain fatty acid metabolism. Biochem Biophys Res Commun 232: 631-636, 1997. |
| 309. | Kolodny EH. Dysmyelinating and demyelinating conditions in infancy. Curr Opin Neurol Neurosurg 6: 379-386, 1993. |
| 310. | Kolodny EH. Globoid leukodystrophy. Handb Clin Neurol 22: 187-210, 1996. |
| 311. | Kondo A, Sendoh S, Miyata K, and Takamatsu J. Spongy degeneration in the zitter rat: ultrastructural and immunohistochemical studies. J Neurocytol 24: 533-544, 1995. |
| 312. | Kordeli E, Lambert S, Bennett V, and Ankyrin G. A new ankyrin gene with neural-specific isoforms localized at the axonal initial segment and node of Ranvier. J Biol Chem 270: 2352-2359, 1995. |
| 313. | Kotani M, Kawashima I, Ozawa H, Terashima T, and Tai T. Differential distribution of major gangliosides in rat central nervous system detected by specific monoclonal antibodies. Glycobiology 3: 137-146, 1993. |
| 314. | Kramer EM, Koch T, Niehaus A, and Trotter J. Oligodendrocytes direct glycosyl phosphatidylinositol-anchored proteins to the myelin sheath in glycosphingolipid-rich complexes. J Biol Chem 272: 8937-8945, 1997. |
| 315. | Kreysing J, von Figura K, and Gieselmann V. Structure of the arylsulfatase A gene. Eur J Biochem 191: 627-631, 1990. |
| 316. | Kroepfl JF, Viise LR, Charron AJ, Linington C, and Gardinier MV. Investigation of myelin/oligodendrocyte glycoprotein membrane topology. J Neurochem 67: 2219-2222, 1996. |
| 317. | Kumar S, and de Vellis J. Neurotrophin activates signal transduction in oligodendroglial cells: expression of functional TrkC receptor isoforms. J Neurosci Res 44: 490-498, 1996. |
| 318. | Kunzelmann P, Blumcke I, Traub O, Dermietzel R, and Willecke K. Coexpression of connexin45 and -32 in oligodendrocytes of rat brain. J Neurocytol 26: 17-22, 1997. |
| 318a. | Kuramoto T, Kitada K, Inui T, Sasaki Y, Ito K, Hase T, Kawagachi S, Ogawa Y, Nakao K, Barsh GS, Nagao M, Ushijima T, and Serikawa T. Attractin/Mahogany/Zitter plays a critical role in myelination of the central nervous system. Proc Natl Acad Sci USA 98: 559-564, 2000. |
| 319. | Kurihara T, Monoh K, Sakimura K, and Takahashi Y. Alternative splicing of mouse brain 2',3' cyclic nucleotide-3'-phosphodiesterase mRNA. Biochem Biophys Res Commun 152: 837-842, 1990. |
| 320. | Lachapelle F, Duhamel-Clerin E, Gansmuller A, Baron-Van Evercooren A, Villarroya H, and Gumpel M. Transplanted transgenically-marked oligodendrocytes survive, migrate and myelinate in the normal mouse brain as they do in the shiverer mouse brain. Eur J Neurosci 6: 814-824, 1994. |
| 321. | Lachapelle F, Gumpel M, Baulac M, Jacque C, Duc P, and Baumann N. Transplantation of CNS fragments into the brain of shiverer mutant mice: extensive myelination by implanted oligodendrocytes. I. Immunohistochemical studies. Dev Neurosci 6: 325-334, 1983. |
| 322. | Lambert S, Davis JQ, and Bennett V. Morphogenesis of the node of Ranvier: co-clusters of ankyrin and ankyrin-binding integral proteins define early developmental intermediates. J Neurosci 17: 7025-7036, 1997. |
| 323. | Lassmann H, Bartsch U, Montag D, and Schachman M. Dying-back oligodendrogliopathy: a late sequel of myelin-associated glycoprotein deficiency. Glia 19: 104-110, 1997. |
| 323a. | Laywell ED, Rakic P, Kukekov VG, Holland EC, and Steindler DA. Identification of a multipotent astrocytic stem cell in the immature and adult mouse brain. Proc Natl Acad Sci USA 97: 13883-13888, 2000. |
| 324. | Lebar R, Boutry JM, Vincent C, Robineaux R, and Voisin GA. Studies on autoimmune encephalomyelitis in the guinea pig. II. An in vitro investigation on the nature, properties, and specificity of the serum-demyelinating factor. J Immunol 116: 1439-1446, 1976. |
| 325. | Lebar R, Lubetzki C, Vincent C, Lombrail C, and Boutry JM. The M2 antigen of central nervous system myelin, a glycoprotein present in oligodendrocyte membrane. Clin Exp Immunol 66: 423-443, 1986. |
| 326. | Lees MB, Chao B, Lin LH, Samiullah M, and Laursen R. Amino acid sequence of bovine white matter proteolipid. Arch Biochem Biophys 226: 643-656, 1983. |
| 327. | Lendahl U, Zimmerman LB, and McKay RD. CNS stem cells express a new class of intermediate filament protein. Cell 60: 585-595, 1990. |
| 328. | Levine JM, Stincone F, and Lee YS. Development and differentiation of glial precursor cells in the rat cerebellum. Glia 7: 307-321, 1993. |
| 329. | Levison SW, and Goldman JE. Both oligodendrocytes and astrocytes develop from progenitors in the subventricular zone of postnatal rat brain. Neuron 10: 201-212, 1993. |
| 330. | Li C, Trapp B, Ludwin S, Peterson A, and Roder J. Myelin associated glycoprotein modulates glia-axon contact in vivo. J Neurosci Res 51: 210-217, 1998. |
| 331. | Li C, Tropak MB, Gerlai R, Clapoff S, Abramow-Newerly W, Trapp B, Peterson A, and Roder J. Myelination in the absence of myelin-associated glycoprotein. Nature 369: 747-750, 1994. |
| 332. | Li J, Hertzberg EL, and Nagy JI. Connexin32 in oligodendrocytes and association with myelinated fibers in mouse and rat brain. J Comp Neurol 379: 571-591, 1997. |
| 333. | Li M, Shibata A, Li C, Braun PE, McKerracher L, Roder J, Kater SB, and David S. Myelin-associated glycoprotein inhibits neurite/axon growth and causes growth cone collapse. J Neurosci Res 46: 404-414, 1996. |
| 334. | Liedtke W, Edelmann W, Bieri PL, Chiu FC, and Cowan NJ. GFAP is necessary for the integrity of CNS white matter architecture and long-term maintenance of myelination. Neuron 17: 607-615, 1996. |
| 335. | Linington C, Berger T, Perry L, Weerth S, Hinze-Selch D, Zhang Y, Lu HC, Lassmann H, and Wekerle H. T cells specific for the myelin oligodendrocyte glycoprotein (MOG) mediate an unusual autoimmune inflammatory response in the central nervous system. Eur J Immunol 23: 1364-1372, 1993. |
| 336. | Linington C, Bradl M, Lassmann H, Brunner C, and Vass K. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am J Pathol 130: 443-454, 1988. |
| 337. | Linington Webb CM, and Woodhams PL. A novel myelin-associated glycoprotein defined by a mouse monoclonal antibody. J Neuroimmunol 6: 387-396, 1984. |
| 338. | Litzenburger T, Fassler R, Bauer J, Lassmann H, Linington C, Wekerle H, and Iglesias A. B lymphocytes producing demyelinating autoantibodies: development and function in gene-targeted transgenic mice. J Exp Med 188: 169-180, 1998. |
| 339. | Lois C, and Alvarez-Buylla A. Proliferating subventricular zone cells in the adult mammalian forebrain can differentiate into neurons and glia. Proc Natl Acad Sci USA 90: 2074-2077, 1993. |
| 339a. | Lo Turco JJ. Neural circuits in the 21st century: synaptic networks of neurons and glia. Proc Natl Acad Sci USA 97: 8196-8197, 2000. |
| 340. | Louis JC, Magal EE, Muir D, Manthorpe M, and Varon S. Cg-4, a new bipotential glial cell line from rat brain, is capable of differentiating in vitro into either mature oligodendrocytes or type-2 astrocytes. J Neurosci Res 31: 193-204, 1992. |
| 341. | Lovas G, Szilagyi N, Majtenyi K, Palkovits M, and Komoly S. Axonal changes in chronic demyelinated cervical spinal cord plaques. Brain 123: 308-317, 2000. |
| 342. | Lu JF, Lawler AM, Watkins PA, Powers JM, Moser AB, Moser HW, and Smith KD. A mouse model for X-linked adrenoleukodystrophy. Proc Natl Acad Sci USA 94: 9366-9371, 1997. |
| 343. | Lubetzki C, Demerens C, Anglade PA, Villarroya H, Frankfurter A, Lee MY, and Zalc B. Even in culture, oligodendrocytes myelinate solely axons. Proc Natl Acad Sci USA 90: 6820-6824, 1993. |
| 344. | Lubetzki C, Demerens C, and Zalc B. Signaux axonaux et myélinogenèse dans le système nerveux central. Médecine/Sciences 13: 1097-1105, 1997. |
| 345. | Lucchinetti CF, Bruck W, Parisi J, Scheithauer B, Rodriguez M, and Lassmann H. A quantitative analysis of oligodendrocytes in multiple sclerosis lesions: a study of 113 cases. Brain 122: 2279-2295, 2000. |
| 346. | Lucchinetti CF, Bruck W, Rodriguez M, and Lassmann H. Distinct patterns of multiple sclerosis pathology indicates heterogeneity in pathogenesis. Brain Pathol 6: 259-274, 1996. |
| 347. | Ludwin SK. Central nervous system demyelination and remyelination in the mouse. An ultrastructural study of cuprizone toxicity. Lab Invest 39: 597-612, 1978. |
| 348. | Ludwin SK. Proliferation of mature oligodendrocytes after trauma of the central nervous system. Nature 308: 274-275, 1984. |
| 349. | Ludwin SK. The pathobiology of the oligodendrocyte. J Neuropathol Exp Neurol 56: 111-124, 1997. |
| 350. | Lunn KF, Baas PW, and Duncan ID. Microtubule organization and stability in the oligodendrocyte. J Neurosci 17: 4921-4932, 1997. |
| 351. | Lunn KF, Clayton MK, and Duncan ID. The temporal progression of the myelination defect in the taiep rat. J Neurocytol 26: 267-281, 1997. |
| 352. | Luskin MB, Pearlman AL, and Sanes JR. Cell lineage in the cerebral cortex of the mouse studied in vivo and in vitro with a recombinant retrovirus. Neuron 1: 635-647, 1988. |
| 353. | Luzi P, Rafi MA, and Wenger DA. Structure and organization of the human galactocerebrosidase (GALC) gene. Genomics 26: 407-409, 1995. |
| 354. | Luzi P, Rafi MA, and Wenger DA. Characterization of the large deletion in the GALC gene found in patients with Krabbe disease. Hum Mol Genet 4: 2335-2338, 1995. |
| 355. | Lyon MF. X chromosome inactivation and the location and expression of X-linked genes. Am J Hum Genet 42: 8-16, 1988. |
| 356. | Macklin WB, Campagnoni CW, Deininger PL, and Gardinier MV. Structure and expression of the mouse myelin proteolipid protein gene. J Neurosci Res 18: 383-394, 1987. |
| 357. |
Macklin WB,
Gardinier KD,
King MV, and Kampf K.
An AG GG transition at a splice site in the myelin proteolipid protein gene in jimpy mice results in the removal of an exon.
FEBS Lett
223: 417-421, 1987.
|
| 358. | Macklin WB, Weill CL, and Deininger PL. Expression of myelin proteolipid and basic protein mRNAs in cultured cells. J Neurosci Res 6: 203-217, 1986. |
| 359. | Madison DL, Krueger WH, Cheng D, Trapp BD, and Pfeiffer SE. SNARE complex proteins, including the cognate pair VAMP-2 and syntaxin-4, are expressed in cultured oligodendrocytes. J Neurochem 72: 988-998, 1999. |
| 360. | Madison DL, Kruger WH, Kim T, and Pfeiffer SE. Differential expression of rab3 isoforms in oligodendrocytes and astrocytes. J Neurosci Res 45: 258-268, 1996. |
| 361. | Maeda A, and Sobel RA. Matrix metalloproteinases in the normal human nervous system, microglial nodules, and multiple sclerosis lesions. J Neuropathol Exp Neurol 55: 300-309, 1996. |
| 362. | Magyar JP, Ebensperger C, Schaeren-Wiemers N, and Suter U. Myelin and lymphocyte protein (MAL/MVP17/VIP17) and plasmolipin are members of an extended gene family. Gene 189: 269-275, 1997. |
| 363. | Martini R, Mohajeri MH, Kasper S, Giese KP, and Schachner M. Mice doubly deficient in the genes for P0 and myelin basic protein show that both proteins contribute to the formation of the major dense line in peripheral nerve myelin. J Neurosci 15: 4488-4495, 1995. |
| 364. | Matalon R, Kaul R, and Michals K. Canavan's disease: from spongy degeneration to molecular analysis. J Pediatr 127: 511-517, 1995. |
| 365. | Mathisen PM, Pease S, Garvey J, Hood L, and Readhead C. Identification of an embryonic isoform of myelin basic protein that is expressed widely in the mouse embryo. Proc Natl Acad Sci USA 90: 10125-10129, 1993. |
| 366. | Matsuda Y, Koito H, and Yamamoto H. Induction of myelin-associated glycoprotein expression through neuron-oligodendrocyte contact. Dev Brain Res 100: 110-116, 1997. |
| 367. | Mattei MG, Alliel PM, Dautigny A, Passage E, Pham-Dinh D, Mattei JF, and Jolles P. The gene encoding for the major brain proteolipid protein (PLP) maps on the q-22 band of the human X-chromosome. Hum Genet 72: 352-353, 1986. |
| 368. | Matthieu JM, and Amiguet P. Myelin/oligodendrocyte glycoprotein expression during development in normal and myelin-deficient mice. Dev Neurosci 12: 293-302, 1990. |
| 369. | Matute C. Characteristics of acute and chronic kainate excitotoxic damage to the optic nerve. Proc Natl Acad Sci USA 95: 10229-10234, 1998. |
| 370. | Maurin Y, Berger B, Le Saux F, Gay M, and Baumann N. Increased number of locus cerulaeus noradrenergic neurons in the convulsive mutant quaking mouse. Neurosci Lett 57: 313-318, 1985. |
| 371. | Mayer M, Bögler O, and Noble M. The inhibition of oligodendrocyte differentiation of O-2A progenitors caused by fibroblast growth factor is overridden by astrocytes. Glia 8: 12-19, 1993. |
| 372. | Mccallion AS, Guenet J, Montague P, Griffiths IR, Savioz A, and Davies RW. The mouse gene (Mobp) encoding myelin-associated oligodendrocytic basic protein maps to distal chromosome 9. Mamm Genome 7: 847-849, 1996. |
| 373. | McDonald JW, Althomsons SP, Hyrc KL, Choi DW, and Goldberg MP. Oligodendrocytes from forebrain are highly vulnerable to AMPA/kainate receptor-mediated excitotoxicity. Nature Med 4: 291-297, 1998. |
| 374. | McGarry RC, Helfand SL, Quarles RH, and Roder JC. Recognition of myelin-associated glycoprotein by the monoclonal antibody HNK-1. Nature 306: 376-378, 1983. |
| 375. | Mcgavern DB, Murray PD, Rivera-Quinones C, Schmelzer JD, Low PA, and Rodriguez M. Axonal loss results in spinal cord atrophy, electrophysiological abnormalities and neurological deficits following demyelination in a chronic inflammatory model of multiple sclerosis. Brain 123: 519-531, 2000. |
| 376. | McKerracher L, David S, Jackson DL, Kottis V, Dunn RJ, and Braun PE. Identification of myelin-associated glycoprotein as a major myelin-derived inhibitor of neurite outgrowth. Neuron 13: 805-811, 1994. |
| 377. | McKinnon RD, Matsui T, Dubois-Dalcq M, and Aronson SA. FGF modulates the PDGF-driven pathway of oligodendrocyte development. Neuron 5: 603-614, 1990. |
| 378. | McMorris A, and Dubois-Dalcq M. Insulin-like growth factor 1 promotes cell proliferation and oligodendroglial commitment in rat glial progenitor cells developing in vitro. J Neurosci Res 21: 199-209, 1988. |
| 379. | McMorris FA, and McKinnon RD. Regulation of oligodendrocyte development and CNS myelination by growth factors: prospects for therapy of demyelinating diseases. Brain Pathol 6: 313-329, 1996. |
| 380. | McTigue DM, Horner PJ, Stokes BT, and Gage FH. Neurotrophin-3 and brain-derived neurotrophic factor induce oligodendrocyte proliferation and myelination of regenerating axons in the contused adult rat spinal cord. J Neurosci 18: 5354-5365, 1998. |
| 381. | Meier C, and Bischoff A. Oligodendroglial cell development in jimpy mice and controls. An electron-microscopic study in the optic nerve. J Neurol Sci 26: 517-528, 1975. |
| 382. | Menegoz M, Gaspar P, Le Bert M, Galvez T, Burgaya F, Palfrey C, Ezan P, Arnos F, and Girault JA. Paranodin, a glycoprotein of neuronal paranodal membranes. Neuron 19: 319-331, 1997. |
| 383. | Messing A, Head MW, Galles K, Galbreath EJ, Goldman JE, and Brenner M. Fatal encephalopathy with astrocyte inclusions in GFAP transgenic mice. Am J Pathol 152: 391-398, 1998. |
| 384. | Meyer-Franke A, and Barres B. Myelination without myelin-associated glycoprotein. Curr Biol 4: 847-850, 1994. |
| 385. | Meyer-Franke A, Shen S, and Barres BA. Astrocytes induce oligodendrocyte processes to align with and adhere to axons. Mol Cell Neurosci 14: 385-397, 1999. |
| 386. | Mezquita J, Pau M, and Mezquita C. Four isoforms of the signal-transduction and RNA-binding protein QKI expressed during chicken spermatogenesis. Mol Reprod Dev 50: 70-78, 1998. |
| 387. | Miescher GC, Lutzelschwab R, Erne B, Ferracin F, Huber S, and Steck AJ. Reciprocal expression of myelin-associated glycoprotein splice variants in the adult human peripheral and central nervous systems. Brain Res 52: 299-306, 1997. |
| 388. | Mikol DD, Gulcher JR, and Stefansson K. The oligodendrocyte-myelin glycoprotein belongs to a distinct family of proteins and contains the HNK-1 carbohydrate. J Cell Biol 110: 471-479, 1990. |
| 389. | Mikoshiba K, Aruga J, and Okano H. Molecular biology of myelin basic protein: gene rearrangement and expression of anti-sense RNA in myelin-deficient mutants. Comp Biochem Physiol 98: 51-61, 1991. |
| 390. | Mikoshiba K, Kohsaka S, Takamatsu K, and Tsukada Y. Neurochemical and morphological studies on the myelin of peripheral nervous system from Shiverer mutant mice: absence of basic proteins common to central nervous system. Brain Res 204: 455-460, 1980. |
| 391. | Mikoshiba K, Yokoyama M, Takamatsu K, Tsukada Y, and Nomura T. Chimeric analysis of the pathogenesis of dysmyelination of shiverer mutant mice. Presence of patches of MBP-positive and negative sites in white matter indicating the absence of humoral factors for dysmyelination. Dev Neurosci 5: 520-524, 1982. |
| 392. | Miller RH. Oligodendrocyte origins. Trends Neurosci 19: 92-96, 1996. |
| 393. | Milner R, Anderson HJ, Rippon RF, McKay JS, Franklin RJ, Marchionni MA, Reynolds R, and Ffrench-Constant C. Contrasting effects of mitogenic growth factors on oligodendrocyte precursor cell migration. Glia 19: 85-90, 1997. |
| 394. | Milner R, Edwards G, Streuli C, and Ffrench-Constant C. A role in migration for the alpha V beta 1 integrin expressed on oligodendrocyte precursors. J Neurosci 16: 7240-7252, 1996. |
| 395. | Minuk J, and Braun PE. Differential intracellular sorting of the myelin-associated glycoprotein isoforms. J Neurosci Res 44: 411-420, 1996. |
| 396. | Mokhtarian F, Zhang Z, Shi Y, Gonzales E, and Sobel RA. Molecular mimicry between a viral peptide and a myelin oligodendrocyte glycoprotein peptide induces autoimmune demyelinating disease in mice. J Neuroimmunol 95: 43-54, 1999. |
| 397. | Molineaux SM, Engh H, DeFerra F, Hudson L, and Lazzarini RA. Recombination within the myelin basic protein gene created the dysmyelinating shiverer mouse mutation. Proc Natl Acad Sci USA 83: 7542-7546, 1986. |
| 398. | Moller JR. Rapid conversion of myelin-associated glycoprotein to a soluble derivative in primates. Brain Res 741: 27-31, 1996. |
| 399. | Monge M, Kadiiski D, Jacque CM, and Zalc B. Oligodendroglial expression and deposition of four myelin constituents in the myelin sheath during development. An in vivo study. Dev Neurosci 8: 222-226, 1986. |
| 400. | Montag D, Giese KP, Bartsch U, Martini R, Lang Y, Bluthman H, Karthigasan J, Kirschner DA, Wintergerst ES, Nave KA, Zielasek J, Toyka KV, Lipp HP, and Schachner M. Mice deficient for the myelin-associated glycoprotein show subtle abnormalities in myelin. Neuron 13: 229-246, 1994. |
| 401. | Montague P, Dickinson PJ, McCallion AS, Stewart GJ, Savioz A, Davies RW, Kennedy PGE, and Griffiths IR. Developmental expression of the Mobp gene. J Neurosci Res 49: 133-143, 1997. |
| 402. | Monuki ES, Kuhn R, Weinmaster G, Trapp BD, and Lemke G. Expression and activity of the POU transcription factor SCIP. Science 249: 1300-1303, 1990. |
| 403. | Moore GR, and Raine CS. Immunogold localization and analysis of IgG during immune-mediated demyelination. Lab Invest 59: 641-648, 1988. |
| 404. | Morell P, Quarles RH, and Norton WT. Myelin formation, structure and biochemistry. In: Basic Neurochemistry, edited by Siegel GJ, Agranoff BW, Albers RW, and Molinoff PB. New York: Raven, 1994, p. 117-143. |
| 405. | Morello D, Dautigny A, Pham-Dinh D, and Jolles P. Myelin proteolipid protein (PLP and DM20) transcripts are deleted in jimpy mice. EMBO J 5: 3489-3493, 1986. |
| 406. | Mori S, and Leblond CP. Electron microscopic identification of three classes of oligodendrocytes and a preliminary study of their proliferative activity in the corpus callosum of young rats. J Comp Neurol 139: 1-30, 1970. |
| 407. | Moriguchi A, Ikenaka K, Furuichi T, Okano H, Iwasaki Y, Mikoshiba K, and Moser H. The fifth exon of the myelin proteolipid protein-coding gene is not utilized in the brain of jimpy mutant mice. Gene 55: 333-337, 1987. |
| 408. | Morita K, Sasaki H, Fujimoto K, Furuse M, and Tsukita S. Claudin-11/OSP-based tight junctions of myelin sheaths in brain and Sertoli cells in testis. J Cell Biol 145: 579-588, 1999. |
| 409. | Moser HW. Peroxisomal disorders. Semin Pediatr Neurol 3: 298-304, 1996. |
| 410. | Moser HW. Adrenoleukodystrophy: phenotype, genetics, pathogenesis and therapy. Brain 120: 1485-1508, 1997. |
| 411. | Mosser J, Lutz Y, Stoeckel ME, Sarde CO, Kretz C, Douar AM, Aubourg P, and Mandel JL. The gene responsible for adrenoleukodystrophy encodes a peroxisomal membrane protein. Hum Mol Genet 3: 265-271, 1994. |
| 412. | Mudhar HS, Pollock RA, Wang C, Stiles CD, and Richardson WD. PDGF and its receptors in the developing rodent retina and optic nerve. Development 118: 539-552, 1993. |
| 413. | Mugnaini E. Cell junctions of astrocytes, ependyma, and related cells in the mammalian central nervous system, with emphasis on the hypothesis of a generalized functional syncytium of supporting cells. In: Astrocytes, edited by Federoff S, and Vernadakis A. New York: Academic, 1986, vol. I, p. 329-371. |
| 414. | Mukhopadhyay G, Doherty P, Walsh FS, Crocker PR, and Filbin MT. A novel role for myelin-associated glycoprotein as an inhibitor of axonal regeneration. Neuron 13: 757-767, 1994. |
| 415. | Murray K, and Dubois-Dalcq M. Emergence of oligodendrocytes from human neural spheres. J Neurosci Res 50: 145-156, 1997. |
| 416. | Nadon NL, Arnheiter H, and Hudson LD. A combination of PLP and DM20 transgenes promotes partial myelination in the jimpy mouse. J Neurochem 63: 822-833, 1994. |
| 417. | Nadon NL, Duncan ID, and Hudson LD. A point mutation in the proteolipid protein gene of the "shaking pup" interrupts oligodendrocyte development. Development 110: 529-537, 1990. |
| 418. | Naef R, and Suter U. Many facets of the peripheral myelin protein PMP22 in myelination and disease. Microsc Res Technol 41: 359-371, 1998. |
| 419. | Nagy JI, Ochalski PA, Li J, and Hertzberg EL. Evidence for the co-localization of another connexin with connexin-43 at astrocytic gap junctions in rat brain. Neuroscience 78: 533-548, 1997. |
| 420. | Nait-Oumesmar B, Vignais L, Duhamel-Clerin E, Avellana-Adalid V, Rougon G, and Baron-Van Evercooren A. Expression of the highly polysialylated neural cell adhesion molecule during postnatal myelination and following chemically induced demyelination of the adult mouse spinal cord. Eur J Neurosci 7: 480-491, 1995. |
| 421. | Nakajima K, Ikenaka K, Kagawa T, Aruga J, Nakao J, Nakahira K, Shiota C, Kim SU, and Mikoshiba K. Novel isoforms of mouse myelin basic protein predominantly expressed in embryonic stage. J Neurochem 60: 1554-1563, 1993. |
| 422. | Nave KA, and Boespflug-Tanguy O. X-linked developmental defects of myelination: from mouse mutants to human genetic diseases. Neuroscientist 2: 33-43, 1996. |
| 423. | Nave KA, Lai C, Bloom FE, and Milner RJ. Splice site selection in the proteolipid protein (PLP) gene transcript and primary structure of the DM-20 protein of the central nervous system myelin. Proc Natl Acad Sci USA 84: 5665-5669, 1986. |
| 424. | Newman SL, Kitamura K, and Campagnoni AT. Identification of a fifth form of myelin basic protein in mouse. Proc Natl Acad Sci USA 84: 886-890, 1987. |
| 425. | Newman S, Saito M, and Yu RK. Biochemistry of myelin proteins and enzymes. In: Neuroglia, edited by Kettenmann H, and Ransom BR. New York: Oxford Univ. Press, 1995, p. 535-554. |
| 426. | Nishiyama A, Chang A, and Trapp BD. NG2+ glial cells: a novel glial cell population in the adult brain. J Neuropathol Exp Neurol 58: 1113-1124, 1999. |
| 427. |
Nishiyama A,
Lin XH,
Giese N,
Heldin CH, and Stallcup WB.
Co-localization of NG2 proteoglycan and PDGF -receptor on O-2A progenitor cells in the developing rat brain.
J Neurosci Res
43: 299-314, 1996.
|
| 428. | Nixon RA. Increased axonal proteolysis in myelin-deficient mutant mice. Science 215: 999-1001, 1982. |
| 429. | Noebels JL, Marcom PK, and Jalilian-Tehrani MH. Sodium channel density in hypomyelinated brain increased by myelin basic protein gene deletion. Nature 352: 431-434, 1991. |
| 430. | Noguchi T. Effects of growth hormone on cerebral development: morphological studies. Horm Res 45: 5-17, 1996. |
| 431. | Norton WT, and Poduslo S. Myelination in rat brain: method of myelin isolation. J Neurochem 21: 749-757, 1973. |
| 432. | Norton WT, and Poduslo S. Myelination in rat brain: changes in myelin composition during brain maturation. J Neurochem 21: 759-773, 1973. |
| 433. | O'Connor LT, Goetz BD, Kwiecien JM, Delaney KH, Fletch AL, and Duncan ID. Insertion of a retrotransposon in Mbp disrupts mRNA splicing and myelination in a new mutant rat. J Neurosci 19: 3404-3413, 1999. |
| 434. | Oh LYS, Larsen PH, Krekoski CA, Edwards DE, Donovan F, Werb Z, and Lee VW. Matrix metalloproteinase-9/Gelatinase B is required for process outgrowth by oligodendrocytes. J Neurosci 19: 8464-8475, 1999. |
| 435. | Oka A, Belliveau MJ, Rosenberg PA, and Volpe JJ. Vulnerability of oligodendroglia to glutamate: pharmacology, mechanisms and prevention. J Neurosci 13: 1441-1453, 1993. |
| 436. | Okano H, Miura M, Moriguchi A, Ikenaka K, Tsukada Y, and Mikoshiba K. Inefficient transcription of the myelin basic protein gene possibly causes hypomyelination in myelin-deficient mutant mice. J Neurochem 48: 470-476, 1987. |
| 437. | Oldstone MBA. Molecular mimicry and immune-mediated diseases. FASEB J 12: 1255-1265, 1998. |
| 438. | Olson L. Regeneration in the adult central nervous system: experimental repair strategies. Nat Med 3: 1329-1339, 1997. |
| 439. | O'Neill RC, Minuk J, Cox ME, Braun PE, and Gravel M. CNP2 mRNA directs synthesis of both CNP1 and CNP2 polypeptides. J Neurosci Res 50: 248-257, 1997. |
| 440. | Ono K, Yasui Y, Rutishauser U, and Miller RH. Focal ventricular origin and migration of oligodendrocyte precursors into the chick optic nerve. Neuron 19: 283-292, 1997. |
| 441. | Orentas DM, Hayes JE, Dyer KL, and Miller RH. Sonic hedgehog signaling is required during the appearance of spinal cord oligodendrocyte precursors. Development 126: 2419-2429, 1999. |
| 442. | Orentas DM, and Miller RH. The origin of spinal cord oligodendrocytes is dependent on local influences from the notochord. Dev Biol 177: 43-53, 1996. |
| 443. | Osterhout DJ, Wolven A, Wolf RM, Resh MD, and Chao MV. Morphological differentiation of oligodendrocytes requires activation of fyn tyrosine kinase. J Cell Biol 145: 1209-1218, 1999. |
| 444. | Otero GC, and Merrill JE. Response of human oligodendrocytes to interleukin-2. Brain Behav Immun 11: 24-38, 1997. |
| 445. | Parmantier E, Braun C, Thomas JL, Peyron F, Martinez S, and Zalc B. PMP-22 expression in the central nervous system of the embryonic mouse defines potential transverse segments and longitudinal columns. J Comp Neurol 378: 159-172, 1997. |
| 446. | Parmantier E, Cabon F, Braun C, D'urso D, Muller HW, and Zalc B. Peripheral myelin protein PMP-22 is expressed in rat and mouse brain and spinal cord motoneurons. Eur J Neurosci 7: 1080-1088, 1995. |
| 447. | Pedraza L, Fidler L, Staugaitis SM, and Colman DR. The active transport of myelin basic protein into the nucleus suggests a regulatory role in myelination. Neuron 18: 579-589, 1997. |
| 448. | Pedraza L, Owens GC, Green LA, and Salzer JL. The myelin-associated glycoproteins: membrane disposition, evidence of a novel disulfide linkage between immunoglobulin-like domains, and posttranslational palmitylation. J Cell Biol 111: 2651-2661, 1990. |
| 449. | Penfield W. Neuroglia: normal and pathological. In: Cytology and Cellular Pathology in the Nervous System, edited by Penfield W. New York: Hoeber, 1932, vol. 2, p. 421-479. |
| 450. | Perez P, Puertollano R, and Alonso MA. Structural and biochemical similarities reveal a family of proteins related to the MAL proteolipid, a component of detergent-insoluble microdomains. Biochem Biophys Res Commun 232: 618-621, 1997. |
| 451. | Peschanski M. Le temps venu de la " Neurogliobiologie." Médecine/Sciences 7: 766-767, 1991. |
| 452. | Peters A. Observations on the connections between myelin sheaths and glial cells of the optic nerve of young rats. J Anat 98: 125-134, 1964. |
| 453. | Peters A, Palay S, and Webster H de F.. The Fine Structure of the Nervous System: the Neuron and the Supporting Cells. Oxford, UK: Oxford Univ. Press, 1991. |
| 454. | Peyron F, Timsit S, Thomas JL, Kagawa T, Ikenaka K, and Zalc B. In situ expression of PLP/DM-20, MBP, and CNP during embryonic and postnatal development of the jimpy mutant and of transgenic mice overexpressing PLP. J Neurosci Res 50: 190-201, 1997. |
| 455. | Pfeiffer SE, Warrington AE, and Bansal R. The oligodendrocyte and its many cellular processes. Trends Cell Biol 3: 191-197, 1993. |
| 456. | Pfrieger FW, and Barres BA. What the fly's glia tell the fly's brain. Cell 83: 671-674, 1995. |
| 457. | Pham-Dinh D. Les cellules gliales. In: Physiologie du Neurone, edited by Tritsch D, Chesnoy-Marchais D, and Feltz A. Doin, France: Initiatives Santé, 1998, p. 31-90. |
| 458. | Pham-Dinh D, Birling MC, Roussel G, Dautigny A, and Nussbaum JL. Proteolipid DM-20 predominates over PLP in peripheral nervous system. Neuroreport 2: 89-92, 1991. |
| 459. | Pham-Dinh D, Della Gaspera B, Kerlero De Rosbo N, and Dautigny A. Human myelin/oligodendrocyte glycoprotein gene: alternative splicing generates multiple isoforms. Genomics 29: 345-352, 1995. |
| 460. | Pham-Dinh D, Jones E, Pitiot G, Daubas P, Mallet J, Le Paslier D, Fischer Lindahl K, and Dautigny A. Physical mapping of human and mouse MOG gene at the distal end of MHC class Ib region. Immunogenetics 42: 386-391, 1995. |
| 461. | Pham-Dinh D, Mattei MG, Nussbaum JL, Roussel G, Pontarotti P, Roeckel N, Mather IH, Arzt K, Lindahl KF, and Dautigny A. Myelin/oligodendrocyte glycoprotein is a member of a subset of the immunoglobulin superfamily encoded within the major histocompatibility complex. Proc Natl Acad Sci USA 90: 7990-7994, 1993. |
| 462. | Phillips JSR. Jimpy: a new totally sex-linked gene in the house mouse. Arch Indukt Abstammungs-Verebungsl 86: 322, 1954. |
| 463. | Pieringer J, Rao GS, Mandel P, and Pieringer RA. The association of the sulphogalactosylglycerolipid of rat brain with myelination. Biochem J 166: 421-428, 1977. |
| 464. | Pitt D, Werner P, and Raine CS. Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med 6: 67-70, 2000. |
| 465. | Poduslo SE, Miller K, and Pak CH. Induction of cerebroside synthesis in oligodendroglia. Neurochem Res 15: 739-742, 1990. |
| 466. | Poltorak M, Sadoul R, Keilhauer G, Landa C, Fahrig T, and Schachner M. Myelin-associated glycoprotein, a member of the L2-HNK1 family of neural cell adhesion molecules, is involved in neuron-oligodendrocyte and oligodendrocyte-oligodendrocyte interaction. J Cell Biol 105: 1893-1899, 1987. |
| 467. | Poncet C, Soula C, Trousse F, Kan P, Hirsinger E, Pourquier O, Duprat AM, and Cochard P. Induction of oligodendrocyte progenitors in the trunk neural tube by ventralizing signals: effects of notochord and floor plate grafts, and of sonic hedgehog. Mech Dev 60: 13-32, 1996. |
| 468. | Popko B. Myelin galactolipids: mediators of axon-glial interactions? Glia 29: 149-153, 2000. |
| 469. | Popko B, Puckett C, Lai E, Shine HD, Readhead C, Takahashi N, Hunt SW, Sidman RL, and Hood L. Myelin deficient mice: expression of myelin basic protein and generation of mice with varying levels of myelin. Cell 48: 713-721, 1987. |
| 470. | Popot JL, Pham-Dinh D, and Dautigny A. Major myelin proteolipid: the 4-alpha-helix topology. J Membr Biol 120: 233-246, 1991. |
| 471. | Power C, Kong PA, Crawford TO, Wesselingh S, Glass JD, McArthur JC, and Trapp BD. Cerebral white matter changes in acquired immunodeficiency syndrome dementia: alterations of the blood-brain barrier. Ann Neurol 34: 339-350, 1993. |
| 472. | Pribyl TM, Campagnoni CW, Kampf K, Ellison JA, Landry CF, Kashima T, McMahon J, and Campagnoni AT. Expression of the myelin basic protein gene locus in neurons and oligodendrocytes in the human fetal central nervous system. J Comp Neurol 374: 342-353, 1996. |
| 473. | Pribyl TM, Campagnoni CW, Kampf K, Handley VW, and Campagnoni AT. The major myelin protein genes are expressed in the human thymus. J Neurosci Res 45: 812-819, 1996. |
| 474. | Pribyl TM, Campagnoni CW, Kampf K, Kashima T, Handley VW, McMahon J, and Campagnoni AT. The human myelin basic protein gene is included within a 179-kilobase transcription unit: expression in the immune and central nervous systems. Proc Natl Acad Sci USA 90: 10695-10699, 1993. |
| 475. | Price J. Glial cell lineage and development. Curr Opin Neurobiol 4: 680-686, 1994. |
| 476. | Price J, and Thurlow L. Cell lineage in the rat cerebral cortex: a study using retroviral-mediated gene transfer. Development 104: 173-182, 1988. |
| 477. | Prineas JW, Barnard RO, Kwon EE, Sharer LR, and Cho ES. Multiple sclerosis: remyelination of nascent lesions. Ann Neurol 33: 137-151, 1993. |
| 478. | Pringle NP, and Richardson WD. A singularity of PDGF alpha-receptor expression in the dorso-ventral axis of the neural tube may define the origin of the oligodendrocyte lineage. Development 117: 525-533, 1993. |
| 479. | Pringle NP, Yu WP, Guthrie S, Roelink H, Lumsden A, Peterson AC, and Richardson WD. Determination of neuroepithelial fate: induction of the oligodendrocyte lineage by ventral midline cells and sonic hedgehog. Dev Biol 177: 30-42, 1996. |
| 480. | Privat A, Jacque C, Bourre JM, Dupouey P, and Baumann N. Absence of the major dense line in myelin of the mutant mouse shiverer. Neurosci Lett 12: 107-112, 1979. |
| 481. | Privat A, Valat J, and Fulcrand J. Proliferation of neuroglial cell lines in the degenerating optic nerve of young rats. A radioautographic study. J Neuropathol Exp Neurol 40: 46-80, 1981. |
| 482. | Puckett C, Hudson L, Ono K, Friedrich V, Benecke J, Dubois-Dalcq M, and Lazzarini RA. Myelin specific proteolipid protein is expressed in myelinating Schwann cells but is not incorporated into the myelin sheaths. J Neurosci Res 18: 511-518, 1987. |
| 483. | Pukel CS, Lloyd KO, Travasso LR, Dippold WG, Oettgen HF, and Old LJ. GD3, a prominent ganglioside of human melanoma. J Exp Med 155: 1133-1147, 1982. |
| 484. | Qian X, Davis AA, Goderie SK, and Temple S. FGF2 concentration regulates the generation of neurons and glia from multipotential cortical stem cells. Neuron 18: 81-93, 1997. |
| 485. | Qiu J, Cai D, and Filbin MT. Glial inhibition of nerve regeneration in the mature mammalian CNS. Glia 29: 166-174, 2000. |
| 486. | Quarles RH. Glycoprotein of myelin sheaths. J Mol Neurosci 8: 1-12, 1997. |
| 487. | Quarles RH, McIntyre LJ, and Pasnak CF. Lectin-binding proteins in central-nervous-system myelin. Binding of glycoproteins in purified myelin to immobilized lectins. Biochem J 183: 213-221, 1979. |
| 488. | Raff MC, Fields KL, Hakamori S, Mirsky R, Pruss RM, and Winter J. Cell-type-specific markers for distinguishing and studying neurons and the major classes of glial cells in culture. Brain Res 174: 283-308, 1979. |
| 489. | Raff MC, Lillien LE, Richardson WD, Burne JF, and Noble MD. Platelet-derived growth factor from astrocytes drives the clock that times oligodendrocyte development in culture. Nature 333: 562-565, 1988. |
| 490. | Raff MC, Mirsky R, Fields KL, Lisak RP, Dorfman SH, Silberberg DH, Gregson NA, Leibowitz S, and Kennedy MC. Galactocerebroside is a specific cell-surface antigenic marker for oligodendrocytes in culture. Nature 274: 813-816, 1978. |
| 491. | Raine CS, and Wu E. Multiple sclerosis: remyelination in acute lesions. J Neuropathol Exp Neurol 52: 199-204, 1993. |
| 492. | Raisman G. Transplantation of Schwann cells into the CNS: potential for repair of tract lesions. In: Glial Cell Development, Basic Principles and Clinical Relevance, edited by Jessen KR, and Richardson WD. Oxford, UK: Bios Scientific, 1995, p. 221-228. |
| 493. | Rakic P. Radial cells: scaffolding for brain construction. In: Neuroglia, edited by Kettenmann H, and Ransom BR. Oxford, UK: Oxford Univ. Press, 1995, p. 746-762. |
| 494. | Ramon-Cueto A, Plant GW, Avila J, and Bunge MB. Long-distance axonal regeneration in the transected adult rat spinal cord is promoted by olfactory ensheathing glia transplants. J Neurosci 18: 3803-3815, 1998. |
| 495. | Ramon y Cajal S. Contribucion al conocimiento de la neuroglia del cerebro humano. Trab Lab Invest Biol (Madrid) 11: 255-315, 1913. |
| 496. | Ramon y Cajal S. In: Degeneration and Regeneration of the Nervous System, edited by May RM. London: Oxford Univ. Press, 1928. |
| 497. | Ranscht B, Clapshaw PA, Price J, Noble M, and Seifert W. Development of oligodendrocytes and Schwann cells studied with a monoclonal antibody against galactocerebroside. Proc Natl Acad Sci USA 79: 2709-2713, 1982. |
| 498. | Rash JE, Duffy HS, Dudek FE, Bilhartz BL, Whalen LR, and Yasumura T. Grid-mapped freeze-fracture analysis of gap junctions in gray and white matter of adult rat central nervous system, with evidence for a "panglial syncytium" that is not coupled to neurons. J Comp Neurol 388: 265-292, 1997. |
| 499. | Readhead C, Popko B, Takahashi N, Shine HD, Saavedra RA, Sidman RL, and Hood L. Expression of a myelin basic protein gene in transgenic shiverer mice: correction of the dysmyelinating phenotype. Cell 48: 703-712, 1987. |
| 500. | Readhead C, Schneider A, Griffiths I, and Nave KA. Premature arrest of myelin formation in transgenic mice with increased proteolipid protein gene dosage. Neuron 12: 583-595, 1994. |
| 501. | Rehm S, Mehraein P, Anzil AP, and Deerberg F. A new rat mutant with defective overhairs and spongy degeneration of the central nervous system: clinical and pathologic studies. Lab Anim Sci 32: 70-73, 1982. |
| 502. | Rettig WJ, and Old LJ. Immunogenetics of human cell surface differentiation. Annu Rev Immunol 7: 481-511, 1989. |
| 503. | Reynolds BA, and Weiss S. Generation of neurons and astrocytes from isolated cells of the adult mammalian nervous system. Science 255: 1707-1710, 1992. |
| 504. | Reynolds R, and Hardy R. Oligodendroglial progenitors labeled with the O4 antibody persist in the adult rat cerebral cortex in vivo. J Neurosci Res 47: 455-470, 1997. |
| 505. | Reynolds R, and Wilkin GP. Development of macroglial cells in rat cerebellum. II. An in situ immunohistochemical study of oligodendroglial lineage from precursor to mature myelinating cell. Development 102: 409-425, 1988. |
| 506. | Reynolds R, and Wilkin GP. Expression of GD3 by developing Purkinje cells. J Neurosci Res 20: 311-319, 1988. |
| 507. | Reynolds R, and Wilkin GP. Oligodendroglial progenitor cells but not oligodendroglia divide during normal development of the rat. J Neurocytol 20: 216-224, 1991. |
| 508. | Richardson PM, McGuiness UM, and Aguayo AJ. Axons from CNS neurons regenerate into PNS grafts. Nature 284: 264-265, 1980. |
| 509. | Richardson WD, Pringle N, Mosley MJ, Westermark B, and Dubois-Dalcq M. A role for platelet-derived growth factor in normal gliogenesis in the central nervous system. Cell 53: 309-319, 1988. |
| 510. | Richardson WD, Smith HK, Sun T, Pringle NP, Hall A, and Woodruff R. Oligodendrocyte lineage and the motor neuron connexion. Glia 29: 136-142, 2000. |
| 511. | Rickmann M, and Wolff JR. S100 immunoreactivity in a subpopulation of oligodendrocytes and Ranvier's node of adult rat brain. Neurosci Lett 186: 13-16, 1995. |
| 512. | Ridet JI, Malhotra SK, Privat A, and Gage FG. Reactive astrocytes: cellular and molecular cues to biological function. Trends Neurosci 20: 570-577, 1997. |
| 513. | Rio Hortega DP. Histogenesis y evolucion normal; exodo y distribucion regional de la microglia. Memor Real Soc Esp Hist Nat 11: 213-268, 1921. |
| 514. | Rio Hortega DP. Tercera aportacion al conocimiento morfologico e interpretacion funcional de la oligodendroglia. Memor Real Soc Esp Hist Nat 14: 5-122, 1928. |
| 515. | Rivera-Quinones C, McGavern D, Schmeldzer JD, Hunter SF, Low PA, and Rodriguez M. Absence of neurological deficits following extensive demyelination in a class-I deficient murine model of multiple sclerosis. Nature Med 4: 187-193, 1998. |
| 516. | Roach A, Boylan K, Horvath S, Prusiner SB, and Hood LE. Characterization of cloned cDNA representing rat myelin basic protein: absence of expression in brain of shiverer mutant mice. Cell 34: 799-806, 1983. |
| 517. | Roach A, Takahashi N, Pravtcheva D, Ruddle F, and Hood LE. Chromosomal mapping of mouse myelin basic protein gene and structure and transcription of the partially deleted gene in shiverer mutant mouse. Cell 42: 149-155, 1985. |
| 518. | Robain O. The jimpy mouse. Acta Zool Pathol 68: 68-92, 1977. |
| 519. | Robinson SR, Hampson EC, Munro MN, and Vaney DI. Unidirectional coupling of gap junctions between neuroglia. Science 262: 1072-1074, 1993. |
| 520. | Rodichok L, and Miller G. A study of evoked potentials in the 18q-syndrome which includes the absence of the gene locus for myelin basic protein. Neuropediatrics 23: 218-220, 1992. |
| 521. | Rodriguez D, and Gelot A. Phenotypique variation in leukoencephalopathy with vanishing white matter. Neurology 53: 1373-1374, 2000. |
| 522. | Rodriguez D, Gelot A, della Gaspera B, Robain O, Ponsot G, SarliEve LL, Folhen M, Pompidou A, Dautigny A, Aubourg P, and Pham-Dinh D. Neuropathological and biochemical study of two cases of "CACH" (Childhood Ataxia with diffuse Central nervous system Hypomyelination) syndrome. Acta Neuropathol 97: 469-480, 1999. |
| 523. | Rodriguez M, Leibowitz JL, and Lampert PW. Persistent infection of oligodendrocytes in Theiler's virus-induced encephalomyelitis. Ann Neurol 13: 426-433, 1983. |
| 524. | Rosenfeld J, and Freidrich VL. Axonal swellings in jimpy mice: does lack of myelin cause neuronal abnormalities? Neuroscience 10: 959-966, 1983. |
| 525. | Roth MP, Malfroy L, Offer C, Sevin J, Enault G, Borot N, Pontarotti P, and Coppin H. The human myelin oligodendrocyte glycoprotein (MOG) gene: complete nucleotide sequence and structural characterization. Genomics 28: 241-250, 1995. |
| 526. | Roussel G, Neskovic NM, Trifilieff E, Artault JC, and Nussbaum JL. Arrest of proteolipid transport through the Golgi apparatus in Jimpy brain. J Neurocytol 16: 195-204, 1987. |
| 527. | Rushton WAH. A theory of the effects of fibre size in medullated nerve. J Physiol (Lond) 115: 112-122, 1951. |
| 528. | Rutishauser U, and Landmesser L. Polysialic acid in the vertebrate nervous system: a promoter of plasticity in cell-cell interactions. Trends Neurosci 19: 422-427, 1996. |
| 529. | Sakai N, Inui K, Tatsumi N, Fukushima H, Nishigaki T, Taniike M, Nishimoto J, Tsukamoto H, Yanagihara I, Ozono K, and Okada S. Molecular cloning and expression of cDNA for murine galactocerebrosidase and mutation analysis of the twitcher mouse, a model of Krabbe's disease. J Neurochem 66: 1118-1124, 1996. |
| 530. | Salzer JL. Clustering sodium channels at the node of Ranvier: close encounters of the axon-glia kind. Neuron 18: 843-846, 1997. |
| 531. | Salzer JL, Holmes WP, and Colman DR. The amino acid sequences of the myelin-associated glycoproteins: homology to the superimmunoglobulin gene superfamily. J Cell Biol 104: 957-965, 1987. |
| 532. | Sanchez I, Hassinger L, Paskevich PA, Shine HD, and Nixon RA. Oligodendroglia regulate the regional expansion of axon caliber and local accumulation of neurofilaments during development independently of myelin formation. J Neurosci 16: 5095-5105, 1996. |
| 533. | Sarlieve LL, Fabre M, Susz J, and Matthieu JM. Investigations on myelination in vitro. IV. "Myelin-like" or premyelin structures in cultures of dissociated brain cells from 14- to 15-day-old embryonic mice. J Neurosci Res 10: 191-210, 1983. |
| 534. | Sarlieve LL, Neskovic NM, and Mandel P. Paps-cerebroside sulfotransferase activity in the brain and kidney of neurological mutants. FEBS Lett 19: 91-95, 1971. |
| 535. |
Saxe DF,
Takahashi N,
Hood L, and Simon MI.
Localization of the human myelin basic protein gene (MBP) to region 18q-22 qter by in situ hybridization.
Cytogenet Cell Genet
39: 246-249, 1985.
|
| 536. | Schaeren-Wiemers N, Valenzuela DM, Frank M, and Schwab ME. Characterization of a rat gene, rMAL, encoding a protein with four hydrophobic domains in central and peripheral myelin. J Neurosci 8: 5753-5764, 1995. |
| 537. | Schaeren-Wiemers N, Van Der Bijl P, and Schwab ME. The UDP-galactose:ceramide galactosyltransferase: expression pattern in oligodendrocytes and Schwann cells during myelination and substrate preference for hydroxyceramide. J Neurochem 65: 2267-2278, 1995. |
| 538. | Scherer SS. Molecular genetics of demyelination: new wrinkles on an old membrane. Neuron 18: 13-16, 1997. |
| 539. | Scherer SS, Deschenes SM, Xu YT, Grinspan JB, Fischbeck KH, and Paul DL. Connexin32 is a myelin-related protein in the PNS and CNS. J Neurosci 15: 8281-8294, 1995. |
| 540. | Schiffmann R, Moller JR, Trapp BD, Shih HH, Farrer RG, Katz DA, Alger JR, Parker CC, Hauer PE, Kaneski CR, Heiss JD, Heiss EM, Kaye EM, Quarles RH, Brady RO, and Barton NW. Childhood ataxia with diffuse central nervous system hypomyelination. Ann Neurol 35: 331-340, 1994. |
| 541. | Schmidt-Schultz T, and Althaus HH. Monogalactosyl diglyceride, a marker for myelination, activates oligodendroglial protein kinase C. J Neurochem 62: 1578-1585, 1994. |
| 542. | Schnell L, and Schwab ME. Sprouting and regeneration of lesioned corticospinal tract fibres in the adult spinal cord. Eur J Neurosci 5: 1156-1171, 1993. |
| 543. | Schroeder F, Jolly CA, Cho TH, and Frolov A. Fatty acid binding protein isoforms: structure and function. Chem Phys Lipids 92: 1-25, 1998. |
| 544. | Schulte S, and Stoffel W. Ceramide UDP galactosyltransferase from myelinating rat brain: purification, cloning and expression. Proc Natl Acad Sci USA 90: 10265-10269, 1993. |
| 545. | Schutgens RBH, Schrakamp G, Wanders RJA, Heymans HSA, Moser HW, Moser AB, Tager JM, Bosch HVD, and Aubourg P. The cerebro-hepato-renal (Zellweger) syndrome: prenatal detection based on impaired biosynthesis of plasmalogens. Prenat Diagn 5: 337-541, 1985. |
| 546. | Schwab ME, and Bartoldi D. Degeneration and regeneration of axons in the lesioned spinal cord. Physiol Rev 76: 319-370, 1996. |
| 547. | Schwab ME, and Schnell L. Region-specific appearance of myelin constituents in the developing rat spinal cord. J Neurocytol 18: 183-190, 1989. |
| 548. | Schwab ME, and Schnell L. Channeling of developing rat corticospinal tract axons by myelin-associated neurite growth inhibitors. J Neurosci 11: 709-721, 1991. |
| 549. | Schwab ME, and Thoenen H. Dissociated neurons regenerate into sciatic but not optic nerve explants in culture irrespective of neurotrophic factors. J Neurosci 5: 2415-2423, 1985. |
| 550. | Scolding N. Strategies for repair and remyelination in demyelinating diseases. Curr Opin Neurol 10: 193-200, 1997. |
| 551. | Scolding N, Franklin R, Stevens S, Heldin CH, Compston A, and Newcombe J. Oligodendrocyte progenitors are present in the normal adult human CNS and in the lesions of multiple sclerosis. Brain 121: 2221-2228, 1998. |
| 552. | Scolding NJ, Frith S, Linington C, Morgan BP, Campbell AK, and Compston DAS. Myelin-oligodendrocyte glycoprotein is a surface marker of oligodendrocyte maturation. J Neuroimmunol 22: 169-176, 1989. |
| 553. | Scott-Drew S, and Frebcg-Constant C. Expression and function of thrombospondin-1 in myelinating glial cells of the central nervous system. J Neurosci Res 50: 202-214, 1997. |
| 554. | Seilhean D, Gansmuller A, Baron-Van Evercooren A, Gumpel M, and Lachapelle F. Myelination by transplanted human and mouse central nervous system tissue after long-term cryopreservation. Acta Neuropathol 91: 82-88, 1996. |
| 555. | Seitelberger F. Neuropathology and genetics of Pelizaeus- Merzbacher disease. Brain Pathol 5: 267-273, 1995. |
| 556. | Selmaj KW, and Raine CS. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 23: 339-346, 1988. |
| 557. | Sgroi D, Varki A, Braesch-Andersen S, and Stamenkovic I. CD22, a B cell-specific immunoglobulin superfamily member, is a sialic acid-binding lectin. J Biol Chem 268: 7011-7018, 1993. |
| 558. | Shen XY, Billings-Gagliardi S, Sidman RL, and Wolf MK. Myelin deficient (shambled) mutant allele: morphological comparison with shiverer (shi) allele on a B6C3 mouse stock. Brain Res 360: 235-247, 1985. |
| 559. | Shepherd GM. Neurobiology (2nd ed.). New York: Oxford Univ. Press, 1988. |
| 560. | Shoshan Y, Nishiyama A, Chang A, Mork S, Barnett GH, Cowell JK, Trapp BD, and Staugaitis SM. Expression of oligodendrocyte progenitor cell antigens by gliomas: implications for the histogenesis of brain tumors. Proc Natl Acad Sci USA 96: 10361-10366, 1999. |
| 561. | Shrager P, and Novakovic SD. Control of myelination, axonal growth, and synapse formation in spinal cord explants by ion channels and electrical activity. Brain Res 88: 68-78, 1995. |
| 562. | Sidman RL, Dickie MM, and Appel SH. Mutant mice (quaking and jimpy) with deficient myelination on the central nervous system. Science 144: 309-311, 1964. |
| 563. | Sjöstrand F. SEM study of the retinal rods in the guinea-pig eye. J Cell Comp Physiol 33: 383-398, 1949. |
| 564. | Skoff RP. Increased proliferation of oligodendrocytes in the hypomyelinated mouse mutant-jimpy. Brain Res 248: 19-31, 1982. |
| 565. | Skoff RP. Gliogenesis in rat optic nerve: astrocytes are generated in a single wave before oligodendrocytes. Dev Biol 139: 149-168, 1990. |
| 566. | Skoff RP, and Ghandour MS. Oligodendrocytes in female carriers of the jimpy gene make more myelin than normal oligodendrocytes. J Comp Neurol 355: 124-133, 1995. |
| 567. | Skoff RP, Price DL, and Stocks A. Electron microscopic autoradiographic studies of gliogenesis in rat optic nerve. I. Cell proliferation. J Comp Neurol 169: 291-312, 1976. |
| 568. | Small RK, Riddle P, and Noble M. Evidence for migration of oligodendrocyte-type-2 astrocyte progenitor cells into the developing rat optic nerve. Nature 328: 155-157, 1987. |
| 569. | Snipes GJ, Suter U, and Shooter EM. Human peripheral myelin protein-22 carries the L2/HNK-1 carbohydrate adhesion epitope. J Neurochem 61: 1961-1964, 1993. |
| 570. | Solly SK, Thomas JL, Monge M, Demerens C, Lubetzki C, Gardinier MV, Matthieu JM, and Zalc B. Myelin/oligodendrocyte glycoprotein (MOG) expression is associated with myelin deposition. Glia 18: 39-48, 1996. |
| 571. | Sommer I, and Schachner M. Monoclonal antibodies (01 to 04) to oligodendrocyte cell surfaces: an immunocytological study in the central nervous system. Dev Biol 83: 311-327, 1981. |
| 572. | Sontheimer H, Trotter J, Schachner M, and Kettenmann H. Channel expression correlates with differentiation stage during the development of oligodendrocytes from their precursor cells in culture. Neuron 2: 1135-1145, 1989. |
| 573. | Sotelo C, Alvaredo-Mallart RM, Frain M, and Vernet M. Molecular plasticity of adult Bergmann fibers is associated with radial migration of grafted Purkinje cells. J Neurosci 14: 124-133, 1994. |
| 574. | Sotelo C, and Angaut P. The fine structure of the cerebellar central nuclei in the cat. I. Neurons and neuroglial cells. Exp Brain Res 16: 410-430, 1973. |
| 575. | Sparkes RS, Mohandas T, Heinzmann C, Roth HJ, Klisak I, and Campagnoni AT. Assignment of the myelin basic protein gene to human chromosome 18q22-qter. Hum Genet 75: 147-150, 1987. |
| 576. | Spassky N, Goujet-Zalc C, Parmantier E, Olivier C, Martinez S, Ivanova A, Ikenaka K, Macklin W, Cerruti I, Zalc B, and Thomas JL. Multiple restricted origins of oligodendrocytes. J Neurosci 18: 8331-8343, 1998. |
| 577. | Spassky N, Olivier C, Perez-Villegas E, Goujet-Zalc C, Martinez S, Thomas JL, and Zalc B. Single or multiple oligodendroglial lineages: a controversy. Glia 29: 143-148, 2000. |
| 578. | Spillmann AA, Bandtlow CE, Lottspeich F, Keller F, and Schwab ME. Identification and characterization of a bovine neurite growth inhibitor (bNI-220). J Biol Chem 18: 1753-1762, 1998. |
| 579. | Sprinkle TJ. 2',3'-Cyclic nucleotide-3-phosphodiesterase, an oligodendrocyte-Schwann cell and myelin-associated enzyme of the nervous system. Crit Rev Neurobiol 4: 235-301, 1989. |
| 580. | Sprinkle TJ, Wells MR, Garver FA, and Smith DB. Studies on the Wolfgram high molecular weight CNS proteins: relationship to 2',3'-cyclic nucleotide-3-phosphodiesterase. J Neurochem 35: 1200-1208, 1980. |
| 581. | Starr R, Attema B, De Vries GH, and Monteiro MJ. Neurofilament phosphorylation is modulated by myelination. J Neurosci Res 44: 328-337, 1996. |
| 582. | Staugaitis SM, Smith PR, and Colman DR. Expression of myelin basic proteins isoforms in nonglial cell lines. J Cell Biol 110: 1719-1727, 1990. |
| 583. | Stebbins JW, Jaffe H, Fales HM, and Moller JR. Determination of a native proteolytic site in myelin-associated glycoprotein. Biochemistry 36: 2221-2226, 1997. |
| 584. | Stefferl A, Brehm U, Storch M, Lambracht-Washington D, Bourquin C, Wonigeit K, Lassmann H, and Linington C. Myelin oligodendrocyte glycoprotein induces experimental autoimmune encephalomyelitis in the "resistant" Brown Norway rat: disease susceptibility is determined by MHC and MHC-linked effects on the B cell response. J Immunol 163: 40-49, 1999. |
| 585. | Steinberg D. Elucidation of the metabolic error in Refsum's disease: strategy and tactics. Adv Neurol 21: 113-124, 1978. |
| 586. | Steinhauser C, and Gallo V. News on glutamate receptors in glial cells. Trends Neurosci 19: 339-345, 1996. |
| 587. | Steinman L. Connections between the immune system and the nervous system. Proc Natl Acad Sci USA 90: 7912-7914, 1993. |
| 588. | Steinman L. Multiple approaches to multiple sclerosis. Nature Med 6: 15-16, 2000. |
| 589. | Sternberger NH, Itoyama Y, Kies M, and Webster H de F. Myelin basic protein demonstrated immunocytochemically in oligodendroglia prior to myelin formation. Proc Natl Acad Sci USA 75: 2521-2524, 1978. |
| 590. | Stevens DB, Chen K, Seitz RS, Sercarz EE, and Bronstein JM. Oligodendrocyte-specific protein peptides induce experimental autoimmune encephalomyelitis in SJL/J mice. J Immunol 162: 7501-7509, 1999. |
| 591. | Stoffel W, Boison D, and Bussow H. Functional analysis in vivo of the double mutant mouse deficient both proteolipid protein (PLP) and myelin basic protein (MBP) in the central nervous system. Cell Tissue Res 289: 195-206, 1997. |
| 592. | Stoffel W, Schroeder W, Hillen H, and Deutzmann R. Analysis of the primary structure of the strongly hydrophobic brain myelin proteolipid apoprotein (lipophilin). Isolation and aminoacid sequence determination of proteolytic fragments. Hoppe-Seyler's Z Physiol Chem 363: 1117-1131, 1982. |
| 593. | Storch M, and Lassmann H. Pathology and pathogenesis of demyelinating diseases. Curr Opin Neurol 10: 186-192, 1997. |
| 594. | Storch MK, Stefferl A, Brehm U, Weissert R, Wallstrom E, Kerschensteiner M, Olsson T, Linington C, and Lassmann H. Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol 8: 681-694, 1998. |
| 595. | Suzuki K. Twenty five years of the "psychosine hypothesis": a personal perspective of its history and present status. Neurochem Res 23: 251-259, 1998. |
| 596. | Suzuki M, and Raisman G. The glial framework of central white matter tracts: segmented rows of contiguous interfascicular oligodendrocytes and solitary astrocytes give rise to a continuous meshwork of transverse and longitudinal processes in the adult rat fimbria. Glia 6: 222-235, 1992. |
| 597. | Suzuki M, and Raisman G. Multifocal pattern of postnatal development of the macroglial framework of the rat fimbria. Glia 12: 294-308, 1994. |
| 598. | Suzuki M, and Suzuki K. Krabbe's globoid cell leukodystrophy: deficiency of glactocerebrosidase in serum, leukocytes, and fibroblasts. Science 171: 73-75, 1971. |
| 599. | Suzuki M, and Suzuki K. The twitcher mouse: a model for Krabbe disease and for experimental therapies. Brain Pathol 5: 249-258, 1995. |
| 600. | Takahashi N, Roach A, Teplow DB, Prusiner SB, and Hood L. Cloning and characterization of the myelin basic protein gene from mouse: one gene can encode both 14kd and 18.5kd MBPs by alternate use of exons. Cell 42: 139-148, 1985. |
| 601. | Tang S, Shen YJ, DeBellard ME, Mukhopadhyay G, Salzer JL, Crocker PR, and Filbin MT. Myelin-associated glycoprotein interacts with neurons via a sialic acid binding site at ARG118 and a distinct neurite inhibition site. J Cell Biol 138: 1355-1366, 1997. |
| 602. | Tang S, Woodhall RW, Shen YJ, DeBellard ME, Safell JL, Doherty P, Walsh FS, and Filbin MT. Soluble myelin-associated glycoprotein (MAG) found in vivo inhibits axonal regeneration. Mol Cell Neurosci 9: 333-346, 1997. |
| 603. | Tauber H, Waehneldt TV, and Neuhoff V. Myelination in rabbit optic nerves is accelerated by artificial eye opening. Neurosci Lett 16: 235-238, 1980. |
| 604. | Tello F. La influencia del neurotropismo en la regeneraçion de los centros nerviosos. Trab Lab Invest Biol 9: 123-159, 1911. |
| 605. | Temple S, and Raff M. Clonal analysis of oligodendrocyte development in culture: evidence for a developmental clock that counts cell divisions. Cell 44: 773-779, 1986. |
| 606. | Tetzloff SU, and Bizzozero OA. Palmitoylation of proteolipid protein from rat brain myelin using endogenously generated 18:0-fatty acids. J Biol Chem 273: 279-285, 1998. |
| 607. | Thallmair M, Metz GAS, Z'graggen WJ, Raineteau O, Kartje GL, and Schwab ME. Neurite growth inhibitors restrict plasticity and functional recovery following corticospinal tract lesions. Nature Neurosci 1: 124-131, 1998. |
| 608. | Theret N, Boulenguer P, Fournet B, Fruchart JC, Bourre JM, and Delbart C. Acylgalactosylceramides in developing dysmyelinating mutant mice. J Neurochem 50: 883-888, 1988. |
| 609. | Thoua NM, van Noort JM, Baker D, Bose A, van Sechel AC, van Stipdonk MJB, Travers PJ, and Amor S. Encephalitogenic and immunogenic potential of the stress protein B-crystallin in Biozzi ABH (H-2Ag7) mice. J Neuroimmunol 104: 47-57, 2000. |
| 610. | Timsit S, Bally-Cuif L, Colman D, and Zalc B. Dm-20 mRNA is expressed during the embryonic development of the nervous system in the mouse. J Neurochem 58: 1172-1175, 1992. |
| 611. | Timsit S, Martinez S, Allinquant B, Peyron F, Puelles L, and Zalc B. Oligodendrocytes originate from a restricted zone of the embryonic ventral neural tube defined by DM-20 mRNA. J Neurosci 15: 1012-1024, 1995. |
| 612. | Tontsch U, Archer DR, Dubois-Dalcq M, and Duncan ID. Transplantation of an oligodendrocyte cell line leading to extensive myelination. Proc Natl Acad Sci USA 91: 11616-11620, 1994. |
| 613. | Tosic M, Dolivo M, Amiguet P, Domanska-Janik K, and Matthieu JM. Paralytic tremor (pt) rabbit: a sex-linked mutation affecting proteolipid protein-gene expression. Brain Res 625: 307-312, 1993. |
| 614. | Tosic M, Matthey B, Gow A, Lazzarini RA, and Matthieu JM. Intracellular transport of the DM-20 bearing shaking pup (shp) mutation and its possible phenotypic consequences. J Neurosci Res 50: 844-852, 1997. |
| 615. | Tourbah A, Linnington C, Bachelin C, Avellana-Adalid V, Wekerle H, and Baron-Van Evercooren A. Inflammation promotes survival and migration of the CG4 oligodendrocyte progenitors transplanted in the spinal cord of both inflammatory and demyelinated EAE rats. J Neurosci Res 50: 1-9, 1997. |
| 616. | Tournier-Lasserve E, Iba-Zizen MT, Romero N, and Bousser N. Autosomal dominant syndrome with stroke-like episodes and leukoencephalopathy. Stroke 22: 1297-1302, 1991. |
| 617. | Trapp BD, Andrews SB, Cootauco C, and Quarles R. The myelin-associated glycoprotein is enriched in multivesicular bodies and periaxonal membranes of actively myelinating oligodendrocytes. J Cell Biol 109: 2417-2426, 1989. |
| 618. | Trapp BD, Bernier L, Andrews SB, and Colman DR. Cellular and subcellular distribution of 2',3'-cyclic nucleotide 3'-phosphodiesterase and its mRNA in the rat central nervous system. J Neurochem 51: 859-868, 1988. |
| 619. | Trapp BD, Itoyama Y, MacIntosh TD, and Quarles RH. P2 protein in oligodendrocytes and myelin of the rabbit central nervous system. J Neurochem 40: 47-54, 1983. |
| 620. | Trapp BD, Nishiyama A, Cheng D, and Macklin W. Differentiation and death of premyelinating oligodendrocytes in developing rodent brain. J Cell Biol 137: 459-468, 1997. |
| 621. | Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, and Bö L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338: 278-285, 1998. |
| 622. | Trapp BD, and Quarles RH. Presence of the myelin-associated glycoprotein correlates with alterations in the periodicity of peripheral myelin. J Cell Biol 92: 877-882, 1982. |
| 623. | Uhm JH, Dooley NP, Oh LYS, and Yong VW. Oligodendrocytes utilize a matrix metalloproteinase, MMP-9, to extend processes along an astrocyte extracellular matrix. Glia 22: 53-63, 1998. |
| 624. | Ullian EM, and Barres BA. The Schwann song of the glia-less synapse. Neuron 21: 651-652, 1998. |
| 625. | Umemori H, Sato S, Yagi T, Aizawa S, and Yamamoto T. Initial events of myelination involve Fyn tyrosine kinase signaling. Nature 367: 572-576, 1994. |
| 626. | Urenjak J, Williams SR, Gadian DG, and Noble M. Specific expression of N-acetylaspartate in neurons, oligodendrocytes-type-2 astrocyte progenitors and immature oligodendrocytes in vitro. J Neurochem 59: 55-61, 1992. |
| 627. | Utzschneider DA, Archer DR, Kocsis JD, Waxman SG, and Duncan ID. Transplantation of glial cells enhances action potential conduction of amyelinated spinal cord in the myelin-deficient rat. Proc Natl Acad Sci USA 91: 53-57, 1994. |
| 628. | Van der Goes A, Kortekaas M, Hoekstra K, Dijkstra CD, and Amor S. The role of anti-myelin (auto)-antibodies in the phagocytosis of myelin by macrophages. J Neuroimmunol 101: 61-67, 1999. |
| 629. | van der Knaap MS, Barth PG, Gabre'ls FJM, Franzoni E, Begeer JH, Stroink H, Rotteveel JJ, and Walk J. A new leukoencephalopathy with vanishing white matter. Neurology 48: 845-855, 1997. |
| 630. | Van Der Knaap MS, and Valk J. Myelination and retarded myelination. In: Magnetic Resonance of Myelin, Myelination and Myelin Disorders. Berlin: Springer, 1995, p. 31-57. |
| 631. | Van Noort JM, Van Sechel AC, Bajramovic J, El Ouagmiri M, Polman CH, Lassmann H, and Ravid R. A novel candidate autoantigen in multiple sclerosis: alpha B-crystallin, a small heat shock protein. Nature 375: 798-801, 1995. |
| 632. | Vartanian T, Fischbach G, and Miller R. Failure of spinal cord oligodendrocyte development in mice lacking neuregulin. Proc Natl Acad Sci USA 96: 731-735, 1999. |
| 633. | Vaysse PJ, and Goldman JE. A clonal analysis of glial lineages in neonatal forebrain development in vitro. Neuron 5: 227-235, 1990. |
| 634. | Venance L, Cordier J, Monge M, Zalc B, Glowinski J, and Giaume C. Homotypic and heterotypic coupling mediated by gap junctions during glial cell differentiation in vitro. Eur J Neurosci 7: 451-461, 1995. |
| 635. | Venance L, Stella N, Glowinski J, and Giaume C. Mechanism involved in initiation and propagation of receptor-induced intercellular calcium signaling in cultured rat astrocytes. J Neurosci 17: 1981-1992, 1997. |
| 636. | Verity AN, and Campagnoni AT. Regional expression of myelin protein genes in the developing mouse brain. J Neurosci Res 21: 238-248, 1988. |
| 637. | Verny M, Duyckaerts C, Pierot L, and Hauw JJ. Leuko-araiosis. Dev Neurosci 13: 245-250, 1991. |
| 638. | Vignais L, Nait Oumesmar B, Mellouk F, Gout O, Labourdette G, Baron-Van Evercooren A, and Gumpel M. Transplantation of oligodendrocyte precursors in the adult demyelinated spinal cord: migration and remyelination. Int J Dev Neurosci 11: 603-612, 1993. |
| 639. | Virchow R. Ueber das granulirte Aussehen der Wandungen der Gehirnventrikel. Allg Z Psychiat 3: 242-250, 1846. |
| 640. | Virchow R. Ueber das ausgebreitete Vorkommen einer dem Nervenmark analogen substanz in den tierischen Geweben. Virchows Arch Pathol Anat 6: 562, 1854. |
| 641. | Viskochil D, Cawthon R, O'Connell P, Xu GF, Stevens J, Culver M, Carey J, and White R. The gene encoding the oligodendrocyte-myelin glycoprotein is embedded within the neurofibromatosis type 1 gene. Mol Cell Biol 11: 906-912, 1991. |
| 642. | Vogel US, and Thompson RJ. Molecular structure, localization and possible functions of the myelin-associated enzyme 2'3'-cyclic nucleotide-3'-phosphodiesterase. J Neurochem 50: 1667-1677, 1988. |
| 643. | Voshol H, Van Zuylen CW, Orberger G, Vliegenthart JF, and Schachner M. Structure of the HNK-1 carbohydrate epitope on bovine peripheral nerve myelin glycoprotein P0. J Biol Chem 271: 22957-22960, 1996. |
| 644. | Vouyiouklis DA, and Brophy PJ. Microtubule-associated proteins in developing oligodendrocytes: transient expression of a MAP2c isoform in oligodendrocyte precursors. J Neurosci Res 42: 803-817, 1995. |
| 645. | Waehneldt TV. Phylogeny of myelin proteins. Ann NY Acad Sci 605: 15-28, 1990. |
| 646. | Waldner H, Whitters JM, Sobel RA, Collins M, and Kuchroo VK. Fulminant spontaneous autoimmunity of the central nervous system in mice transgenic for the myelin proteolipid protein-specific T cell receptor. Proc Natl Acad Sci USA 97: 3413-3417, 2000. |
| 647. | Walsh MJ, and Murray JM. Dual implication of 2',3'-cyclic nucleotide 3' phosphodiesterase as major autoantigen and C3 complement-binding protein in the pathogenesis of multiple sclerosis. J Clin Invest 101: 1923-1931, 1998. |
| 648. | Walters SN, and Morell P. Effects of altered thyroid states on myelinogenesis. J Neurochem 36: 1792-1801, 1981. |
| 649. | Wang C, Rougon G, and Kiss |